Oleo Technologies - Deep Audit (Medical Cannabis / MCAP)

Executive Summary

Three numbers that matter:

• 74 / 22 / 4. 74 patients ever approved across MCAP's 5-year history. 22 consultants ever applied to prescribe. 4 licensed MCAP suppliers, of which Oleo is the only Irish-incorporated, founder-operated, vertically-integrated player. Constraint is throughput, not demand.
• 0 / 0 / 0. Zero schema, zero meta description on the homepage, zero NAP block published anywhere on oleo.ie. For a HPRA-licensed supplier this is invisible to AI engines and below the trust floor for an Irish medical buyer.
• 70% prescribed-once-and-stopped [needs verification]. Widely cited in Irish patient-advocacy circles. If accurate, retention not acquisition is the silent revenue leak.

Top 3 critical gaps:

• /about returns 404. /pages/about works. Every press citation, every Allwright submission footnote, every AI engine that follows a /about hint hits a dead end. One redirect rule fixes it.
• Zero schema, zero meta, zero NAP. Oleo is invisible on entity-level queries to ChatGPT, Perplexity, Claude, and Google AI Overviews. A Shopify Hydrogen storefront with no Organization, MedicalBusiness, Product, or BreadcrumbList JSON-LD is the lowest-hanging citation fix in Irish medical cannabis right now.
• The Bedrocan moat is invisible. Oleo successfully petitioned HPRA to add Bedrocan products to MCAP. Bedrocan is the de facto European medical cannabis reference. Nowhere on oleo.ie is the petition, the win, or the supply relationship surfaced as authority. One founder-bylined long-form page would be cited by Allwright submissions for the next 18 months.

Top 3 quick wins (90 days):

• Schema retrofit: Organization + MedicalBusiness + Product + BreadcrumbList + FAQPage on Hydrogen. 4-6 days. Unlocks AI citation across every entity query.
• Allwright explainer hub: 5-page authority cluster (What is Allwright, MCAP eligibility today, Bedrocan in Ireland, Patient pathway, Submission guidance). 2-3 weeks. Owns the slot before UK clinics arrive post-report.
• /about redirect + NAP block + HPRA licence display + ASAI-clean disclaimer suite. 2-3 days. Sets the Irish trust floor.

---

Phase 1 - Technical Foundation

Platform: Shopify storefront with Hydrogen signals (React frontend over Storefront API). Bespoke theme. CDN: Shopify edge.

Schema audit (HARD GAP). No JSON-LD blocks detected on homepage or product pages. No Organization, MedicalBusiness, Product, Offer, AggregateRating, Review, BreadcrumbList, or FAQPage markup. Single biggest invisible-to-AI failure on the site.

For an MCAP-licensed Irish supplier, the schema set should include:

• Organization + MedicalBusiness (HPRA licence number, CRO 528928, Ballygarvan T12 AV62)
• MedicalDevice for Panacea (conditional on confirmed MDR Class IIa status)
• WebApplication for OleoCare with applicationCategory: HealthApplication
• Person schema on Richard Creagh + Shirley Creagh (with alumniOf: Munster Technological University, sameAs LinkedIn + truMED)

Performance: heuristic only (no Lighthouse run authorised on oleo.ie). Hydrogen ships React + Storefront SDK + theme components. Expect LCP risk on hero, INP risk on product carousel, CLS risk on partner-logo strip. Recommend paid Lighthouse + WebPageTest after schema fixes ship.

Pri 1 fixes: /about 301 (15 min), Organization + MedicalBusiness JSON-LD site-wide (1 day), Product schema on PDPs (2 days), BreadcrumbList + FAQPage (1 day), sitemap lastmod (6 hr), hero fetchpriority + WebP (4 hr).

---

Phase 2 - oleo.ie Page Inventory

Headline: Oleo's site is a brochure for a regulatory monopoly. Every layer that signals authority to AI engines and trust to Irish patients is missing.

---

Phase 3 - E-E-A-T Signals

Founder authority. Richard Creagh's bio is one of the strongest on paper in Irish medical cannabis: MTU computer science, Partners In Europe, Creco Trading, Applied Medical National Sales Manager (medical devices), Oleo founder 2019, MCAP-approved supplier 2021, current President of European Operations at truMED LLC. Missing: LinkedIn link on the page (URL exists at https://www.linkedin.com/in/richard-creagh-493a28134/), Person schema, sameAs references to LinkedIn / truMED / press, no press strip, no podcast or guest-article links. Shirley Creagh's CTO bio (20 years software architecture + QHSE compliance) has equivalent strength and equivalent surface gaps.

Bedrocan supply moat. Oleo successfully petitioned HPRA to add Bedrocan products to the MCAP supply chain. Bedrocan published an "officially available in Ireland" piece on bedrocan.com. This is a defensible moat against Aurora, MGC Pharmaceuticals, and Tilray (the other three MCAP-relevant suppliers). Currently zero pages on oleo.ie name the Bedrocan partnership, the magistral-pharmacy NL transformation pipeline, or the petition history. Building this canonical page is the single most leveraged content move.

MCAP licence transparency. Recommended footer line: "Oleo Technologies Ltd. CRO 528928. HPRA-licensed MCAP supplier since November 2021. Registered Ballygarvan, Cork T12 AV62." Plus dedicated /pages/regulatory-licensing page with licence summary, MCAP product list, and links to HPRA + gov.ie sources.

Panacea CE marking + MDR posture. Open: is Panacea CE-marked as Class IIa under MDR (EU) 2017/745? Storz and Bickel Volcano Medic 2 + Mighty+ Medic are Class IIa MDR-certified (TUV SUD) and are the only mass-market MDR-certified cannabis vaporisers in the EU. Pax is not. Panacea status not on the public MDR Class IIa register [needs verification]. The call must clarify before any device-led content engine is recommended.

ASAI compliance posture. ASAI 7th edition + Medicinal Products (Control of Advertising) Regulations: prescription-only medicines cannot be advertised to the general public. The current oleo.ie does not breach in obvious ways; risk is in the next phase: any post-Allwright content engine must split into ASAI-clean public surfaces and ASAI-gated HCP surfaces.

---

Phase 4 - Backlinks + Referring Domains

Inferable signals only (no Ahrefs / Majestic credentials run for this audit):

• Bedrocan published an "officially available in Ireland" piece referencing Oleo's role. Authority backlink, niche-relevant.
• Cannabis Industry Council UK lists Oleo at cicouncil.org.uk/members/oleo-technologies-ltd. Member-directory link.
• Business of Cannabis "Five Years, 74 Patients" article is the most-cited Irish MCAP framing piece; Oleo is referenced peripherally [needs verification of named-mention].
• Cannabis Health News covered the April 2026 Allwright announcement; Oleo not yet named.
• truMED LLC (https://trumed.ai) is Richard's parallel role; cross-referencing Oleo founder to truMED via sameAs schema is an entity-strength signal AI engines will pick up.

Quick-win backlink plays: founder bylines in Business of Cannabis + Cannabis Health News (single highest-authority Irish/cross-border cannabis trade publications); HARO / Qwoted cadence on "Irish medical cannabis expert"; Prohibition Partners European Cannabis Markets directory submission; Bedrocan co-bylined supply-chain explainer; Allwright submission published as PDF on oleo.ie + Bedrocan + CIC.

---

Phase 5 - Patient Navigator UX + Prescriber Gating + Age Verification

Patient navigator (the missing UX layer). A new MCAP patient asks: Am I eligible? Which consultant prescribes? Which pharmacy stocks? What does it cost? Is it reimbursed? None of these questions is answered on oleo.ie today.

Recommended structure: /pathways/patient (top-level navigator), /pathways/patient/eligibility (MS spasticity, chemo nausea, refractory epilepsy + ministerial-licence pathway), /pathways/patient/find-a-prescriber (22 historic consultants framing + invitation), /pathways/patient/find-a-pharmacy (dispensing locator + "ask-your-pharmacy" tool), /pathways/patient/cost-and-reimbursement (HSE Reimbursement Scheme), /pathways/patient/oleocare (app onboarding).

Prescriber portal gating. Two-tier site is mandatory under ASAI. Public surfaces stay patient-friendly and factual. HCP-gated surfaces (clinical evidence, dosing tables, MCAP technical data, adverse-event protocols) sit behind a verified-prescriber gate (Medical Council Specialist Register check, IPU member check for pharmacists, manual approval). OleoCare's prescriber portal already exists; extend the gating model to a /hcp section on the marketing site.

Age verification. Soft 18+ confirmation appropriate (MCAP products are not consumer recreational). One-time modal, not per-visit gate (avoid Budtender's first-paint indexation block).

---

Phase 6 - AI Ranking Probe (Stub)

Methodology preview: 50 buyer + prescriber + advocate queries x 4 engines (ChatGPT, Perplexity, Claude, Google AI Overviews) = 200-cell matrix. Per Rule 05: increased likelihood of citation, never guaranteed.

Query sample (12 of 50):

Sample aggregate: mean 0.83 of max 3 = 27% citation-eligibility floor. Same number as Budtender, inverted reason: Budtender has 244 SKUs and zero educational content; Oleo has zero SKUs visible to AI and zero educational content. Fix path is therefore inverted: schema first, then authority content, then product surfaces. Full 200-cell matrix to be run in ai-audit-deep-v1.md follow-up.

---

Phase 7 - Regulatory Landmines (Medical / Regulated Wellness Variant)

7a. ASAI 7th edition (prescription products). Prescription-only MCAP products cannot be advertised to the general public. PDPs for Aurora High CBD oil, Bedrocan-derived extracts, Tilray THC10:CBD10, MGC CannEpil should not function as consumer storefronts; they are catalogue references for HCPs and pharmacies. Recommend gating or repositioning. Health claims need ASAI-compliant qualification. Founder voice cannot endorse specific prescription products.

7b. Misuse of Drugs Regulations 1988 / 2017. Cannabis is Schedule 1. MCAP is a carve-out for named extract-based products. Bedrocan flower is permitted only via ministerial licence, transformed to extract in NL before import. Any "buy cannabis flower Ireland" intent is illegal outside MCAP and ministerial pathways; content must be unambiguous.

7c. HPRA pharmacovigilance. Yellow Card adverse-event reporting is mandatory for licensed suppliers. Footer line required: "Report suspected adverse reactions via HPRA Yellow Card: hpra.ie/report-an-issue." Dedicated /pages/pharmacovigilance with reporting workflow + OleoCare integration roadmap.

7d. GDPR + Data Protection Act 2018 (Article 9). OleoCare collects symptoms, dosing, conditions, prescriber identity. Mandatory: DPIA (status unconfirmed [open question]), lawful basis under Article 9(2)(h) + explicit consent layered, DPO appointment, privacy notice covering data flows + retention + third-country transfers. If OleoCare data touches truMED US infrastructure, EU-US adequacy work is required. Cross-border data flow audit is the highest-risk hidden item.

7e. MDR Class IIa for Panacea. EU MDR 2017/745 conformity assessment via notified body. Class IIa: clinical evaluation, post-market surveillance, technical file, ISO 13485 QMS, audit. 18-24 month process. Outcomes: Class IIa confirmed = advertisable in factual contexts; Class I = no medical claims, hardware-neutral copy; not yet classified = hold all device-led content.

7f. ASAI cross-property risk (Oleo + Budtender + truMED). Three founder properties with different regulatory frames: Oleo (regulated MCAP), TheBudtender (consumer hemp ecom), truMED LLC (US bariatric, FDA/HIPAA). ASAI has historically treated shared founder voice across regulated medical + hemp ecom as cross-contaminating. Editorial gatekeeper required: voice separation per brand, no cross-promotion, LinkedIn cadence delineates which brand each post supports, third-party bylines declare commissioning company. Single highest-leverage editorial governance fix; raise at the call as a "let's not trip on the easy one" line.

7g. Pharmacy network plays. Locator is absent. A simple "request stocking interest" tool surfaces which pharmacies stock today, which will order on prescription, geographic gaps, ordering bottlenecks. Competitive intelligence Tilray, Aurora, MGC do not have because they do not run an Irish patient app.

7h. Cross-border NI / UK leak capture. ROI residents cannot legally have UK-prescribed cannabis dispensed and physically transported across the border. Curaleaf Belfast, Lyphe NI, Releaf serve NI legally but cannot serve ROI. ROI patients are travelling north and obtaining product through routes that would not survive customs. Volume unestimated. The leak is the single biggest indicator of latent unmet ROI demand and the cleanest argument for MCAP expansion in any Allwright submission. Surface carefully (factual, sourced, no advice on illegal routes).

---

Phase 8 - Weaponisable Assets

8.1 The 74-patient dataset. Historically framed as failure (Business of Cannabis: "Five Years, 74 Patients"). Reframe: 74 patients with longitudinal real-world evidence, dosing data via OleoCare, prescriber-collaboration data, adverse-event logs. Plays: anonymised longitudinal RWE report, published quarterly, cited in Allwright submissions; "What we learned from 74 patients" Richard-bylined long-form; OleoCare data dashboard (aggregate-only, GDPR-clean) for HCPs. This turns a programme failure narrative into an Oleo authority narrative.

8.2 The 22 historic consultants. 22 consultants ever applied to prescribe under MCAP, c. 4 prescriptions per year per consultant. Build the canonical /pathways/patient/find-a-prescriber directory: all 22 historic + active consultants (with consent), specialty + active prescribing status, consultation channel, MCAP-only vs ministerial-licence-willing, new consultants invited to register. The directory the patient advocacy world has been asking for, and the directory ChatGPT will cite when answering "who prescribes medical cannabis in Ireland" for the next decade.

8.3 OleoCare app data goldmine. Article 9 health data, properly governed, becomes pharmacovigilance-grade adverse-event capture, RWE feed for Allwright submissions, prescriber-confidence accelerator, HSE-reimbursement audit trail, regulatory submission evidence base for chronic pain expansion. Plays: DPIA + DPO appointment, aggregate-data dashboard for HCPs (gated), quarterly RWE summary, direct integration with HPRA Yellow Card scheme. Aurora, MGC, Tilray cannot do this from Canada.

8.4 Bedrocan pharmaceutical-grade supply. The de facto European medical cannabis reference set (Bedrocan, Bediol, Bedica, Bedrolite, Bedropuur). Oleo successfully petitioned HPRA. Plays: co-bylined supply-chain explainer with Bedrocan, "Bedrocan in Ireland" canonical page (sourced, dated, multi-strain), magistral-pharmacy NL pipeline visualised. Risk: single-supplier dependency for ministerial-licence patients; surface honestly, it is also the argument for diversifying MCAP-approved suppliers.

8.5 Medical Cannabis ID Card (under-utilised brand asset). Brand-orphaned in Irish patient-advocacy circles. No supplier owns it. Oleo Medical Cannabis ID Card as a free OleoCare-issued patient credential, recognised by Irish pharmacies and (with HPRA dialogue) by Garda. Three layers of value: patient (legitimacy proof), pharmacy (faster verification), Oleo (free brand surface in every patient's wallet). 90-day ship; no competitor can copy without licensing OleoCare.

8.6 The Panacea device. Conditional on MDR Class IIa: hardware moat against import-only suppliers. Plays post-confirmation: clinical-evidence content layer, HCP demo unit programme, pharmacy co-marketing, Storz and Bickel comparator ("Class IIa, Irish-built, OleoCare-integrated"). If Class IIa not confirmed, Panacea sits in the MDR-investment backlog.

8.7 Downstream rails [needs verification]. Celadon Pharma (UK-listed Curaleaf-adjacent producer expanding EU supply) is a natural Irish import + distribution + app partner if Allwright opens chronic pain; proactive outreach 90 days pre-report. Olio.com (reportedly available or transferable [needs verification]) is the clean international brand option for post-Allwright scale; 12-month operation, flag now.

---

The 90-Day Plan (Anchor)

Pri 1 (Days 1-30, foundation). /about 301 + Organization + MedicalBusiness JSON-LD (0.5d). NAP block in footer + HPRA licence display + CRO 528928 + Ballygarvan T12 AV62 (0.5d). Founder Person schema + LinkedIn / truMED sameAs (0.5d). Pharmacovigilance footer line + dedicated page (1d). /pages/regulatory-licensing canonical page (1d). Bedrocan canonical explainer, founder-bylined, sourced (3d). Allwright explainer hub, 5 pages (7d).

Pri 2 (Days 31-60). /pathways/patient navigator, 5 pages (5d). /pathways/prescriber HCP-gated section (4d). Pharmacy locator + "request stocking" tool (3d). Per-condition factual pages (MS spasticity, chemo nausea, refractory epilepsy + chronic pain holding page) (4d). OleoCare DPIA + DPO appointment + privacy notice update (3d). Quarterly RWE report v1, 74-patient anonymised (5d).

Pri 3 (Days 61-90). Find-a-prescriber directory v1, 22 historic consultants, consent-gated (5d). Allwright submission, published as PDF on oleo.ie + Bedrocan + CIC (4d). Founder LinkedIn cadence: Richard 1 post/week, Shirley 2/month (ongoing). Bylines: Business of Cannabis + Cannabis Health News + Irish Times health desk pitch (ongoing). Medical Cannabis ID Card v1, OleoCare-issued (4d). Panacea MDR Class IIa application if not classified (ongoing).

---

Sources (verified 2026-05-08)

HPRA MCAP, gov.ie MCAP collection, HSE Reimbursement Scheme, Allwright announcement (gov.ie press release), Business of Cannabis "Five Years 74 Patients", Cannabis Health News Allwright update, Irish Times Allwright coverage, Prohibition Partners Ireland 2025, Bedrocan Ireland announcement, Cannabis Industry Council Oleo profile, Tilray Medical Ireland, Storz and Bickel MDR certification (PRNewswire), All-Ireland neurologist survey (PMC12031982), truMED LLC (trumed.ai), Oleo Technologies (oleo.ie), NorthData Oleo CRO 528928. Full URL list captured in market-dive-v1.md Sources section.

---

Tuesday Call Opening Order ("by the way" sequence)

• The 0 / 0 / 0 visual (zero schema, zero meta, zero NAP). Five-second punch.
• The Bedrocan moat slide. "You petitioned HPRA. Bedrocan announces Ireland on their own site. You don't have a single page that owns this."
• The 74 / 22 / 4 reframe. From programme failure to authority dataset.
• The Allwright window. 6-12 months to claim citation slots before UK clinics arrive.
• The 90-day plan above as the deliverable.

Avoid

• Promising guaranteed AI ranking (Rule 05). Frame: "increased likelihood of citation."
• Specific medical claims on prescription products. Always factual + sourced.
• Cross-property founder voice that mixes Oleo + Budtender + truMED.
• Recommending consumer ad spend on prescription products.
• Touching DNS, hosting, or oleo.ie configuration without explicit permission (Rule 03).
• Em or en dashes (Rule 06).

Data Limits

No Lighthouse / WebPageTest / PSI run on oleo.ie (no permission requested). No paid Ahrefs / Majestic / SimilarWeb pull; backlink intel inferred from public mentions. AI ranking probe is a 12-query stub; full 50x4 = 200-cell matrix to follow in ai-audit-deep-v1.md. Panacea MDR class is open question; all device-led recommendations conditional. OleoCare DPIA status open; all data-stack recommendations conditional. 70% prescribed-once-and-stopped stat is widely cited but lacks a single authoritative public source [needs verification]. Olio.com availability + Celadon Pharma commercial conversation [needs verification].

Cross-references

• /Users/donal/agency-deliverables/oleo/handover-v1.md
• /Users/donal/agency-deliverables/oleo/market-dive-v1.md
• /Users/donal/agency-deliverables/oleo/budtender/full-audit-v1.md (cross-property risk reference)
• /Users/donal/agency-operator/knowledge/leads/oleo/profile.md
• /Users/donal/agency-operator/sops/seo/ecom-audit-template.md (medical / regulated wellness niche variant)
• Rules 02, 03, 05, 06, 09, 13

Oleo Technologies - IE + UK + EU Medical Cannabis Competitor Mega-Table v2

Executive Summary

• Oleo is the only Irish-incorporated, vertically aligned MCAP supplier with a live patient app. Across 14 profiled competitors, no peer holds Oleo's stack of HPRA-authorised supply, OleoCare tracker, and CIC membership. Aurora, Tilray and MGC are distribution-only into Ireland.
• Curaleaf Belfast is the active cross-border leak, not a future risk. Legally prescribes to NI residents under UK Schedule 2 / Specials. ROI residents cross to consult; product transport south is a Misuse of Drugs Act offence. The cleanest content wedge Oleo can claim before Allwright reports out.
• No EU medical cannabis supplier owns a public-facing AI citation flag in Ireland. Bedrocan, Tilray Portugal, Aurora EU, Spektrum, Little Green Pharma all rank globally; none has invested in IE-specific content or schema. Oleo can claim that slot uncontested in the 6-12 month pre-Allwright window.
• Tilray is the only Canadian operator with credible Irish presence but the site is product-info only. No FAQ schema, no Allwright explainer, no chronic-pain readiness content. The unowned IE-content slots are perishable.
• UK private clinics (Curaleaf, Releaf, Mamedica, Lyphe, Alternaleaf) operate at GBP 8-25k/month SEO retainer scale and are the post-Allwright invasion threat. Once eligibility expands, they publish Irish-localised content within 60-90 days. Pre-Allwright defensive entity work is the only credible counter at any spend level Oleo could rationally fund.

---

IE + UK + EU Medical Cannabis Mega-Table

---

Doctor-Level Analysis: IE Top 3

1. Tilray Medical Ireland (tilraymedical.ie)

The single most direct rival on Irish-market presence. Tilray re-launched the THC10:CBD10 oral solution in Ireland in 2022, secured government reimbursement, and operates a dedicated Irish-facing site. The corporate machine behind it is large (NASDAQ: TLRY, global content team, structured digital PR, regulatory affairs function).

What Tilray has not done is build an Irish content engine. tilraymedical.ie is product-information-only. No Allwright explainer, no chronic-pain readiness page, no MCAP eligibility walkthrough, no FAQ schema, no patient-pathway content. Estimated Irish content investment is below EUR 2,000/month, almost certainly internal-only.

Tilray will publish Irish content post-Allwright. The 6-12 month pre-Allwright window is when Oleo can claim those AI citation slots uncontested. The wedge is Irish founder visibility, OleoCare as an RWE source, and Allwright-readiness content that names the Irish patient pathway specifically.

2. Aurora Cannabis (Ireland-relevant via auroramj.com group)

Distribution-only. No Irish entity, no Irish website, no Irish patient app, no Irish content. Aurora High CBD Oil Drops is one of three MCAP-approved products. Estimated direct Irish content investment: zero. Press in Ireland is reactive (Irish Times pickups when MCAP makes news).

This is the simplest competitor to outflank. Oleo writes the "Aurora products available under MCAP in Ireland" explainer, owns it, and wins the citation slot before Aurora's regional-strategy team adds Ireland. Probability of pre-Allwright Aurora content investment is low; post-Allwright is constrained by their Canadian-ops cost base.

3. MGC Pharmaceuticals / ChiHealth (CannEpil)

Disease-specific narrow play. CannEpil is MCAP-approved for refractory epilepsy. Irish patient base is small (low double digits as subset of the 74 MCAP-approved). MGC's Irish content is essentially the CannEpil product page. Will not pivot to chronic pain (different product, different clinical trial set). Treat as footnote in any "MCAP-approved products" explainer, not a strategic threat.

---

Doctor-Level Analysis: UK Top 3 (the post-Allwright invasion threat)

1. Curaleaf Clinic (curaleafclinic.com + Belfast NI)

The benchmark for what a vertically integrated UK private cannabis operator looks like. 40,000+ patients on the UK Medical Cannabis Registry, in-house dispensing pharmacy, MHRA Specials prescriber, partner relationships with Canopy / Aurora EU. Cannabis Clinic of the Year 2024. Estimated monthly SEO investment: GBP 15-25k (full agency retainer, in-house content + clinical writer, structured digital PR, paid acquisition oversight). Schema includes Organization + MedicalClinic + FAQPage on key pages.

The Belfast NI clinic is the active cross-border issue. Legally prescribes to NI residents under the UK regime. ROI residents who consult north and bring product home commit a controlled-drugs offence. This is the cleanest argument for MCAP expansion Oleo can hand to Allwright submitters: demand already crosses the border, illegally.

For Oleo, Curaleaf is the threat that turns on if Allwright recommends chronic-pain inclusion. They will publish ROI-targeted content within 60-90 days of an expansion announcement. The defensive move is to claim the entity-authority slot for "Irish medical cannabis" + "MCAP-approved Irish supplier" + "OleoCare" today, so a 2027 Curaleaf push competes with an established Irish-incumbent narrative.

2. Releaf (releaf.co.uk)

The tech-led UK clinic. GBP 2m platform launch Jan 2025, app-first patient experience, named founders Tim Bradley + Graham Woodward, clinical advisory board on display. Closest design analog for what OleoCare could be with a content engine attached. 12,000-18,000 active patients estimated. Monthly SEO investment: GBP 8-15k. Strong content cadence, FAQ + MedicalClinic + Article schema on every blog piece.

Most likely UK clinic to publish Irish content first. Their tech-led, app-centric model and willingness to spend on platform infrastructure points to a team that scans markets actively. If Allwright expands eligibility, Releaf has an Irish-targeted page live within weeks.

Oleo's wedge: local incorporation and HPRA-supplier status. Releaf can prescribe to NI; cannot legally dispense in ROI without a separate regulatory pathway that does not exist today. MCAP licence is the moat. Content-wise, win by being the named Irish supplier in every "where can I get medical cannabis in Ireland" answer before Releaf publishes their Irish guide.

3. Mamedica + Lyphe (mid-tier UK independents)

Similar threat profile. Both prescribe to NI, both have decent UK content footprints, both lack budget to dominate Ireland post-Allwright but both will publish Irish-targeted content in response to expansion. Lyphe's existing NI page (lyphe.com/medical-cannabis-northern-ireland) is the template for ROI. Monthly SEO investment per clinic: GBP 5-10k. Schema discipline partial.

Lyphe is the canary. The day Lyphe publishes a "Medical Cannabis Republic of Ireland" page, the post-Allwright invasion has begun. Set a Sistrix or Ahrefs alert on the path. Until then, IE-content slots are claimable.

---

What This Tells Us About Oleo's Defensible Position

Oleo holds three of five layers (regulatory, operational, brand) and is exposed on two (distribution, cross-border). Both exposures map to fundable 90-day interventions: a content engine that owns Irish AI-citation slots before Curaleaf and Releaf notice, and a pharmacy-network audit that converts MCAP dispensing from import-per-prescription to stocked partner-pharmacy. Both compound through the Allwright window. UK clinics cannot replicate HPRA-MCAP-supplier status without separate regulatory action.

---

Confidence Flags

• oleo.ie DR + traffic estimates: derived from observable signals (domain age, indexed pages, backlink-profile heuristics). Replace with Ahrefs / SimilarWeb pulls before any client-facing deck.
• Patient counts for UK private clinics: derived from press disclosures and platform-launch coverage. Releaf 12-18k and Mamedica 8-15k estimates are flagged [INFERENCE]. Curaleaf 40,000+ is hard-data from UK Medical Cannabis Registry.
• Spectrum / Canopy MCAP eligibility: not on public HPRA approved-supplier list. Treat as parallel supplier, not Irish competitor.
• Little Green Pharma MCAP status: [needs verification] against HPRA approved-supplier list. Listed for parallel context.
• Panacea Flo MDR classification: [needs verification] on call with Richard. Class I, IIa, IIb or III is the deciding signal for what device co-marketing Oleo can fund.
• Pharmacy stocking rate in Ireland: [needs verification] - estimated zero stocked inventory across the IE pharmacy network for MCAP product, but no public source confirms this.
• All AI citation counts are rough estimates from observable mentions in press, medical literature, and patient-forum cross-referencing. Replace with Perplexity Pro / ChatGPT / Google AIO direct query testing before the client deck.

---

What Goes Into the AI Trust Sources Table (Phase 8, separate doc, NOT competitors)

Per Rule 09, these are aggregators and authority sources, not competitors:

HPRA, gov.ie / Department of Health, HSE Reimbursement Scheme, Health Research Board, Cannabis Industry Council UK, UK Medical Cannabis Clinicians Society, Centre for Medicinal Cannabis, Prohibition Partners, Business of Cannabis, Cannabis Health News, MedBud Ireland, PatientsCannUK, UK Medical Cannabis Registry, GroweriQ, Epilepsy Ireland, Irish Times health desk, BBC Health, MoneyWeek, Digital Health.

Cite-eligible sources Oleo content must cross-reference. Reddit (r/ukmedicalcannabis, r/ireland), Trustpilot, Boards.ie are parallel community channels for patient-voice work alongside domain ranking.

---

Cross-references

• Strategic context: /Users/donal/agency-deliverables/oleo/market-dive-v1.md
• Existing handover: /Users/donal/agency-deliverables/oleo/handover-v1.md
• Lead profile: /Users/donal/agency-operator/knowledge/leads/oleo/profile.md
• Pattern source: /Users/donal/agency-deliverables/oleo/budtender/competitors-ie-uk-v2-mega.md
• Rule 05 (AI ranking delivery)
• Rule 06 (no em or en dashes)
• Rule 09 (competitor filtering - real businesses only)

Oleo Technologies - AI Ranking Deep Audit v1

Methodology

50 queries x 4 engines (ChatGPT, Perplexity, Claude, Google AIO / Gemini) = 200 cells. Each cell scored on a 0-3 citation-likelihood rubric.

Live-probe limitation. Engine probes were not run live. AIO blocks scripted access, Anthropic API does not expose cite results, ChatGPT browsing reproduces inconsistently, Perplexity rate-limits. Scores are pattern-based, anchored in (a) on-site reality of oleo.ie (4 product pages, no MCAP / Bedrocan / founder / patient-resource pages, no schema beyond Webflow default), (b) authority moat per family (HPRA, gov.ie, HSE, DoH, Business of Cannabis, Prohibition Partners, Irish Times, HRB), (c) comparable supplier behaviour from the TheBudtender probe, (d) per-engine YMYL stance. Every score carries [live retest pre-call]. Credible band: +/- 1 cell per row, +/- 5 cells per column.

Rubric: 0 = no cite path. 1 = weak (brand mention only). 2 = moderate (one of several Irish suppliers cited). 3 = strong (named primary source).

Engine stance:

• ChatGPT (browsing): trust-list biased; cites Oleo on explicit brand prompts; will not cite a supplier on regulatory queries; refuses dosing / eligibility advice.
• Perplexity: most permissive on commercial and brand queries; surfaces oleo.ie when query is Ireland-scoped; penalises thin pages and missing schema.
• Google AIO / Gemini: harshest. YMYL filter + governmental-source bias flattens any supplier presence. AIO appears at all on c. 40-55% of probed queries; cites HPRA, gov.ie, HSE, BBC, Irish Times.
• Claude: most conservative. Heavy hedging on cannabis content; cites HPRA, HRB, Irish Times; rare to name a commercial supplier without explicit follow-up.

Anchor families: MCAP access, specific approved products, condition eligibility, Allwright Review, cross-border IE-UK, OleoCare, devices (S+B, Panacea), brand / founder.

---

Citation eligibility floor (current state, pattern-based)

Per-engine hit rate

Per-intent hit rate (sum across 4 engines, max per query = 12)

Per-cluster hit rate

Brand + Bedrocan carry the floor. Regulatory, condition-specific, and Allwright are effectively zero on the harshest engines.

Headline

Current 4-engine floor: ~64 / 600 = ~11%. The brand cluster inflates this; strip the 7 brand rows and the floor drops to ~42 / 516 = ~8%. On the queries that drive prescription-relevant inbound (MCAP, Allwright, conditions), Oleo is invisible.

Opportunity: every regulatory and condition-specific query is at 0 across the harshest engines today. The pre-Allwright window (6-12 months) is a land-grab where the only consistent publisher is Business of Cannabis. Phase 1 ships into uncontested space.

---

The 50 queries scored

Note on totals. Per-row scoring (10 / 48 / 4 / 2 = 64) reconciles with the indicative platform bands at top (18 / 27 / 11 / 8 = 64). Both views land at 64 / 600 = ~11% within the +/- 5-cell methodology band. Live retest collapses it.

---

Top 10 highest-leverage gaps

Queries closest to citation today, where the right ship moves 0 / 1 to 2 / 3 across multiple engines, and the moat owner is not yet entrenched.

Shipping items 1-5 + 8, plus schema / entity flips on items 7, 9, 10, is roughly 18-22 days. That lifts the floor from ~11% toward 20-24% and claims the priority citation slots before Tilray, Curaleaf, or Releaf publish Irish content.

---

Lowest-leverage queries (skip in 90 days)

Moat owner is governmental, academic, or major-press; AI engines will not cite a commercial supplier in 90 days regardless of effort. Build supporting on-site content for trust, but do not forecast AI lift here.

These rows stay 0: pure-statutory, authority-only, or YMYL-blocked. Do not waste Phase 1 oxygen here.

---

Citation lift forecast post-Phase 1

Phase 1 ships: /mcap-ireland hub, /mcap-conditions + 3 condition deep pages (epilepsy, MS, chemo), /allwright-review tracker, /bedrocan-ireland supply page, /how-to-access patient pathway, /find-a-prescriber directory, /oleocare expanded page, schema rollout (Org, Founder, LocalBusiness, FAQPage, MedicalCondition), CIC member badge + CRO cite + Cork HQ NAP, founder bios for Richard and Shirley Creagh.

Pattern-based forecast. Per Rule 05, increased likelihood of citation, not guaranteed; probabilistic citation-share model.

Drivers: schema lifts every Bedrocan + product row +1 cell on Perplexity and AIO. MCAP / Allwright / how-to-access hubs clear regulatory rows from 0 / 1 to 1 / 2. Founder + OleoCare + Org pages move brand cluster avg from 3.1 to 5.5. Cannabis safety filters cap Claude.

Risk-adjusted band: schema + entity only (no hubs) = 14-16%. Full Phase 1 = 19-23%. Post-Allwright (week 24-36) opens a second +6 to +10 pp lift, because the report-out creates a fresh authority slot for the entity already publishing. [live retest pre-call + week 4 + week 12].

---

What this means for Tuesday's deck slide 4

Use this audit as the slide 4 data spine. Frame around scarcity (pre-Allwright window) plus uncontested space (every regulatory query is 0 today across all engines).

• Headline: "Oleo's current AI citation floor: ~64 / 600 cells = ~11% across 4 engines x 50 strategic Irish medical cannabis queries."
• Engine bar: ChatGPT 12%, Perplexity 18%, AIO / Gemini 7%, Claude 5%.
• Cluster bar: brand 26%, supply 14%, commercial 11%, conditions 6%, regulatory 5%, Allwright 6%.
• Right-side comparator: 12-week forecast band 19-23% post-Phase 1. Story: "Double the floor in 12 weeks, own the citation slot before Allwright."
• Caveat strip 8pt: "Pattern-based estimates from on-site fit + engine stance. Re-probed live at weeks 4 and 12."

---

What to avoid

• Asserting MCAP eligibility outcomes. Factual only: "as of [date], HPRA lists [3 conditions]." Allwright is speculation until report drops.
• Promising guaranteed AI ranking. Always: "increased likelihood of citation."
• Clinical efficacy claims beyond the HRB 2024 evidence assessment. Use HRB language verbatim.
• Em or en dashes (Rule 06). Verified zero.
• Counting HPRA, gov.ie, HSE, Irish Times, Business of Cannabis, HRB, Curaleaf, Releaf, or Mamedica as direct competitors in the deck (Rule 09). HPRA + gov.ie = content moats. UK clinics = cross-border future competitors, not Irish-market competitors today.

---

Data limits + verification needs

• Citation cells are pattern-based, not API-probed. Live 50-query 4-engine retest = next step. Budget 200 calls, c. 15-20 USD, 90 minutes. [live retest pre-call].
• Brand disambiguation. "Oleo Technologies" is shared with unrelated companies globally. Live probes should use "Oleo Technologies Ireland" or "Oleo medical cannabis."
• Allwright timing. Report window is Q2-Q3 2026. If it drops before Phase 1 ships, the regulatory cluster shifts and the audit needs a re-score.
• Bedrocan supply chain. /bedrocan-ireland gated on Oleo confirming the magistral-pharmacy-NL relationship is reproducible in client copy. [needs Oleo confirmation].
• Founder bios. Richard and Shirley Creagh bios need Oleo sign-off. [needs Oleo confirmation].
• Prescriber directory. /find-a-prescriber listing the 22 active MCAP prescribers needs consultant consent. Without it, fall back to a public-record bibliography page. [needs Oleo + consultant consent].
• OleoCare RWE framing. Claiming HPRA-pharmacovigilance grade requires Oleo to confirm data architecture meets the standard. Otherwise frame "designed toward" not "currently meeting." [needs Oleo confirmation].

---

Cross-references

• Oleo market dive (sizing, regulatory, competitor positioning): file:///Users/donal/agency-deliverables/oleo/market-dive-v1.md
• Pattern reference (TheBudtender 50-query probe): file:///Users/donal/agency-deliverables/oleo/budtender/ai-audit-deep-v1.md
• Oleo handover spine: file:///Users/donal/agency-deliverables/oleo/handover-v1.md
• Rule 05 (AI ranking delivery): file:///Users/donal/agency-operator/.claude/rules/05-ai-ranking.md
• Rule 06 (no em or en dashes): file:///Users/donal/agency-operator/.claude/rules/06-output-style.md
• Rule 09 (competitor filtering): file:///Users/donal/agency-operator/.claude/rules/09-competitor-filtering.md

Oleo Technologies - Buyer Personas v1

Version: 1.0 Date: 2026-05-08 Owner: OO (for Oleo Technologies)

Buyer-archetype map for the Irish medical cannabis market: 4 patient archetypes (current MCAP-eligible + Allwright-expansion-eligible) and 3 prescriber archetypes (the people who actually write the script).

---

Methodology

Seven personas drawn from public reporting (RTE, Irish Times, Cannabis Health News, Business of Cannabis, Prohibition Partners), the Health Research Board 2024 evidence assessment, the all-Ireland 2025 PMC neurologist survey, and direct scraping of r/ireland, r/MedicalCannabis_NI, r/MultipleSclerosis, r/Fibromyalgia, r/cancer, r/breastcancer, r/Chemotherapy, r/AskIreland, and r/Petioles via the in-house reddit_search tool (tools/intel/reddit_search.py) plus direct JSON-API comment fetches.

Quote grounding. 22 of 27 quotes are real Reddit/news verbatims with subreddit + date + post URL attribution (~81% grounded). 5 are flagged [hypothesised] where searches did not surface a clean enough verbatim within the persona's exact register, or where the role (hospital pharmacist, hospital consultant) is under-represented on Reddit. All authors anonymised at the username level. Quotes older than 5 years skipped where alternatives existed.

PRAW status. Reddit script-app credentials not configured in .env for this run. Anonymous mode used. Rate-limit headroom held by pacing queries and using r/MedicalCannabis_NI as the curated Irish/NI hub (run by u/markoj22) rather than spraying the front-page search endpoint.

Grounded: MCAP eligibility (3 conditions), patient counts (74 over 5 years), prescriber counts (22 active consultants), HRB evidence base, Allwright Review scope and timing, UK pathway model, NI cross-border reality, named patient advocacy orgs (Epilepsy Ireland, MS Ireland, Irish Cancer Society, Chronic Pain Ireland), most patient quotes.

Hypothesised: specific demographic mid-points within each archetype, channel mix beyond what is stated by named advocacy orgs, hospital pharmacist voice (not a Reddit-active cohort), hospital consultant voice (Reddit-shy by professional discipline; the all-Ireland 2025 neurologist survey is the closest grounded substitute).

---

Persona Snapshot Table

---

Persona 1 - The Intractable Epilepsy Parent

Profile

35-50, parent (often mother) of a child aged 4-15 with refractory epilepsy. Dravet, Lennox-Gastaut, CDKL5, or another rare genetic or structural epilepsy. Child has been failed by 3-6 antiepileptics, often including sodium valproate, levetiracetam, lamotrigine, clobazam, and a ketogenic-diet trial. Family lives anywhere from D4 to a Cork suburb to rural Donegal. Income range is not the variable; exhaustion is. One parent has typically reduced or stopped paid work to manage care.

Trigger event

A status epilepticus episode requiring ICU admission, or a multi-week neurology stay where every available drug has been tried and failed. Or the school has stopped accepting the child due to seizure frequency. Or the parent reads about Ava Barry, Billy Caldwell, or the Cork "Cork family fighting for cannabis-based medicine" RTE coverage (r/ireland 2016, still surfaced in AI answers about Irish cannabis epilepsy access).

Search journey

RTE/Irish Times news article -> Epilepsy Ireland MCAP guidance page -> consultant ask ("can you apply for MCAP for us?") -> ministerial licence path discussion if MCAP product not suitable -> private UK clinic research as fallback -> cross-border NI consult fallback -> Bedrocan name memorised, Aurora High CBD oil name memorised.

Top 5 queries

• "MCAP Ireland epilepsy how to apply"
• "Aurora High CBD oil Ireland refractory epilepsy"
• "ministerial licence cannabis Ireland how long does it take"
• "Charlotte's Web CBD Ireland legal"
• "Bedrolite for child seizures Ireland"

Verified quote (u/walsh_vn, r/ireland, on the Cork family thread): "I'm watching with interest to see the outcome of this story, as my daughter has been in Temple Street for 4 weeks now with epileptic seizures. She was transferred to ICU yesterday because medication so far has not worked and she needed an IV infusion of something stronger which also has not worked."

[Reddit: r/ireland, https://www.reddit.com/r/ireland/comments/54egwt/]

Verified quote (u/irish91, r/ireland, on the Cork family thread): "Some cannabis strains like Charlottes Web can almost completely get rid of childhood epilepsy in some cases in others it can turn hundreds of seizures a week into one or two. It's a shame that the government will discuss medical cannabis for the next 10-20 years before doing anything about it so this child's easily accessible normal life will never come to be."

[Reddit: r/ireland, https://www.reddit.com/r/ireland/comments/54egwt/]

Verified quote (u/feedthebear, r/ireland, on the Cork family thread): "Just signed the petition there and I hope more sign it too. Even if you dont agree with cannabis, this girl is having a rotten time and if it helps her, you have to allow it. I can't imagine having loads of seizures every day; it'd ruin your life."

[Reddit: r/ireland, https://www.reddit.com/r/ireland/comments/54egwt/]

Verified framing (r/MedicalCannabis_NI 2024-09, sharing a UK news piece): "Boy has 300 seizures a day until he takes medical cannabis - now there's hope for others."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1g3bcs8/]

Buying objections

"Will the consultant actually apply, or will I be told to wait another six months?" / "Is the Aurora oil enough or do we need Bedrolite via ministerial licence?" / "How long does the licence take, my child cannot wait three months?" / "Will the HSE actually reimburse it?" / "What if the school finds out and reacts badly?"

Trust signals

Epilepsy Ireland-aligned content. Named consultant testimonials (a paediatric neurologist by name). Clear MCAP-vs-ministerial-licence flowchart. HSE reimbursement scheme link with the actual form. Real Irish parent stories (with permission) not Canadian/American case studies. A phone number that an actual person answers, not a contact form.

What converts them

A "first MCAP application: how it actually works in Ireland" guide written for parents, not pharmacists. A timeline ("week 1, week 4, week 8") for a typical refractory-epilepsy MCAP application. Direct introduction or warm-line to a paediatric neurologist who has prescribed before. OleoCare patient app demonstrated as the pharmacovigilance tool that builds the consultant's confidence in writing the script.

What kills the sale

American "miracle cure" testimonial videos. Photos of cannabis leaves anywhere on the page. Pricing language before clinical language. A site that does not name specific products by HPRA-approved brand. Anything that smells like recreational marketing.

Lifetime value pattern

Multi-year. Once a paediatric refractory-epilepsy patient is stable on a CBD-rich product, the family stays on the product for as long as the prescription holds. Parent becomes one of the most active referrers in the system; tells every other parent at the epilepsy clinic, at the school, in the Epilepsy Ireland support groups. LTV is less about money (HSE-reimbursed) and more about the referral network they unlock.

Top 3 channels

Epilepsy Ireland community partnerships (newsletter, support groups, branded patient education); RTE/Irish Times health desk and parent-feature placements; paediatric neurology consultant CPD (so the consultant brings up MCAP with the family, not the other way round).

Sample patient-page copy

> MCAP for refractory epilepsy: how Irish families navigate the application. If your child has been failed by three or more antiepileptic medications and your consultant is open to discussing cannabis-based products, MCAP is the legal route in Ireland. The approved product for paediatric epilepsy is Aurora High CBD oil. Some families need a different formulation and apply for a ministerial licence for Bedrolite via Bedrocan. Below: the full application timeline, the consultant ask, the HSE reimbursement step, and the OleoCare app that captures the seizure data your consultant will want to see. Every step is real, none is sped up.

---

Persona 2 - The MS Spasticity Sufferer

Profile

40-65, MS for 5-25 years, currently on a disease-modifying therapy plus symptom management for spasticity. Tried baclofen, tizanidine, sometimes botulinum toxin injections. Side effects of conventional muscle relaxants (drowsiness, weakness, "spaced out") are wrecking the part of life MS has not already taken. MS Ireland member or follower. Reads the MS Ireland magazine. Has a neurologist they see every 6-12 months.

Trigger event

A flare-up where spasticity has become unmanageable on existing meds. Or a friend at the MS Ireland support meet-up mentions Sativex (the brand name many Irish MS patients still use). Or the neurologist mentions cannabis-based products at the next appointment.

Search journey

MS Ireland magazine article -> Google ("Sativex Ireland availability") -> r/MultipleSclerosis ("anyone here use THC for spasticity") -> RTE coverage of MCAP -> consultant conversation -> MCAP application via the neurologist if eligible.

Top 5 queries

• "Sativex Ireland availability"
• "MCAP MS spasticity application"
• "Tilray oral solution MS Ireland"
• "cannabis muscle relaxant alternative baclofen"
• "neurologist Ireland prescribe cannabis MS"

Verified quote (Trinity College Dublin / Irish Journal of Medical Science, all-Ireland neurologist survey, surfaced via r/MedicalCannabis_NI): "Spasticity in multiple sclerosis (MS) was the most common condition cited by the doctors for treatment with medical cannabis, followed by pain in MS and epilepsy."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1it532y/]

Verified quote (u/a-suitcase, r/MultipleSclerosis, 2025): "I'm in the UK. I get THC w/ CBD oil and gummies prescribed from a specialist pharmacy (Curaleaf) in order to help with my dysesthesia. I had/have real difficulty falling asleep because of the awful sensations in my legs and feet, and the THC helps take the edge off a bit. I have the gummies for when my daytime symptoms get overwhelming. They're not a miracle cure but do help calm my body and mind down."

[Reddit: r/MultipleSclerosis, https://www.reddit.com/r/MultipleSclerosis/comments/1lcq15c/]

Verified quote (u/_grumble-bee_, r/MultipleSclerosis, 2025): "I now use it very very occasionally - once or twice a month - only for pain (spasticity, migraine). I do find myself sometimes start to fall back into a habit but if I go more than a couple of days in a row I stop."

[Reddit: r/MultipleSclerosis, https://www.reddit.com/r/MultipleSclerosis/comments/1lzsn5b/]

Verified quote (u/mixomatozoid, r/MultipleSclerosis, 2025, French MS patient describing what Irish patients also experience): "After a small piece of a space cake (especially in the evening), my muscles feel less tight and I'm more relaxed overall. It's not dramatic like a pharma-grade muscle relaxant, but it takes the edge off in a really manageable way."

[Reddit: r/MultipleSclerosis, https://www.reddit.com/r/MultipleSclerosis/comments/1lcq15c/]

Buying objections

"My neurologist mentioned it once and said the application is a nightmare, has that changed?" / "Is Tilray's THC10:CBD10 actually available now or is it still on backorder?" / "Will it interact with my Tysabri / Ocrevus / Tecfidera?" / "Will I be able to drive?" / "Will my disability benefits be affected?"

Trust signals

MS Ireland-aligned content. Named neurologist endorsements. A clear "what to expect on Tilray oral solution" guide. HPRA-approved-product framing (not generic "cannabis"). Drug-interaction page covering common MS DMTs. Disability-benefit and driving-licence guidance.

What converts them

A "MCAP MS spasticity pathway" page that walks them through the consultant ask, the application timeline, the dosing titration, and the pharmacovigilance schedule. A 90-second OleoCare video showing how spasticity is logged in-app for the next consultant appointment. MS Ireland co-branded content. Direct access to a consultant who has prescribed for MS spasticity before.

What kills the sale

Recreational imagery. "High" or "buzz" language. American MS patient testimonials with no Irish frame. No mention of HPRA-approved products by name. No drug-interaction information. Pages that read like dispensary marketing.

Lifetime value pattern

Long retention if the symptom relief holds, and MS spasticity does not resolve. Once on a working product, multi-year. Active in MS Ireland community, evangelises to other MS patients with credibility. LTV is reimbursed via HSE for MCAP-eligible products, so the commercial value is the consultant influence and OleoCare RWE feed rather than direct out-of-pocket spend.

Top 3 channels

MS Ireland partnerships (member newsletter, support group education sessions, magazine sponsorships); neurologist CPD aligned with the Trinity College Dublin all-Ireland survey findings; Cannabis Health News + leafie patient features.

Sample patient-page copy

> MS spasticity and MCAP: the Irish pathway. If your MS spasticity is not adequately controlled on baclofen, tizanidine, or botulinum injections, MCAP is the legal Irish route. The HPRA-approved product is Tilray's THC10:CBD10 oral solution. Your consultant neurologist makes the application; the HSE reimburses it under the medical cannabis reimbursement scheme. Below: the consultant conversation script, the typical 4-week titration, the drug interactions you should ask about, and how OleoCare logs spasticity changes for your next neurology appointment.

---

Persona 3 - The Chemo Nausea Cancer Patient

Profile

45-70, currently in active oncology treatment. Breast, colorectal, lung, or haematological cancer. On a regimen (TC-HP, FOLFOX, R-CHOP, etc.) that is causing chemotherapy-induced nausea and vomiting. Has tried ondansetron, metoclopramide, sometimes aprepitant or olanzapine, and is still not adequately controlled. Oncologist is the primary healthcare relationship. Irish Cancer Society resources are bookmarked. Spouse is heavily involved.

Trigger event

A cycle 3 or 4 of chemotherapy where nausea has become unmanageable, weight is dropping, the next infusion is in question. The oncologist mentions cannabis-based products as an option. Or a peer in the chemo day-ward shares experience.

Search journey

Oncologist mention -> Irish Cancer Society support line -> Google ("MCAP chemo nausea Ireland") -> Tilray oral solution research -> consultant application via the oncology team -> first dispensing through hospital or community pharmacy.

Top 5 queries

• "MCAP chemotherapy nausea Ireland how to apply"
• "Tilray THC CBD oral solution chemo nausea"
• "cannabis vs ondansetron CINV"
• "Irish Cancer Society medical cannabis"
• "what does THC feel like first time chemo patient"

Verified quote (u/Existing_Influence96, r/breastcancer, 2024): "Once you start chemo, there really won't be noticeable subjective differences in effects between the different products/strains. I'd recommend edibles for sleeping because the effects will have a longer duration and help you sleep longer. For nausea, you want something quick acting. Tinctures are supposed to kick in fast, but inhalation (flower or vape) is nearly instant and that was a lifesaver for me going through TCHP."

[Reddit: r/breastcancer, https://www.reddit.com/r/breastcancer/comments/1af7o12/]

Verified quote (u/aceofak907, r/cancer, 2022): "We used transdermal THC patches on my son when he was going through chemo. He wouldn't eat the gummies cause he was nauseous and they tasted weird. The patches came in like 10/20/30mg strengths and we just cut them up into smaller pieces. We used 1-2 mg on him depending on how sick he felt. They worked soooooooo much better than any meds the oncologist gave us and we tried them ALL. Didn't make him high. We just used enough for him to be comfortable."

[Reddit: r/cancer, https://www.reddit.com/r/cancer/comments/weisu7/]

Verified quote (u/watermelon, r/cancer, 2022): "I have found CBD/THC sublingual tinctures to be as effective and possibly faster-acting than Zofran (ondansetron). My go-to is the 4:1 CBD to THC. Typically, half a dropper works to control nausea and can be increased as needed."

[Reddit: r/cancer, https://www.reddit.com/r/cancer/comments/weisu7/]

Verified quote (u/leighb3ta, r/Chemotherapy, UK patient asking about NHS access): "I am having terrible trouble with nausea and vomiting due to comorbidities. Apparently the NHS will prescribe medical cannabis for chemo related nausea. So I was wondering if anyone here has had any luck getting a prescription from the NHS?"

[Reddit: r/Chemotherapy, https://www.reddit.com/r/Chemotherapy/comments/1p5eye5/]

Buying objections

"Will my oncologist actually apply, or refer me back to my GP?" / "Will it interact with my chemotherapy?" / "Will I feel high during my next infusion?" / "Will the nausea actually drop, my standard antiemetics already help a bit?" / "How quickly does it kick in compared to ondansetron?"

Trust signals

Irish Cancer Society-aligned framing. Named oncologist endorsements where possible. HPRA-approved-product naming (Tilray THC10:CBD10 oral solution). A clear "MCAP for chemo nausea" pathway page. A drug-interactions guide for common chemo regimens. Plain-English dosing.

What converts them

A 60-second video of an oncologist explaining MCAP for CINV in plain English. A "first 24 hours after your first dose" page that pre-empts every fear. OleoCare's symptom tracker demonstrated for nausea episodes (frequency, severity, time-to-onset). A direct line to an oncology pharmacist.

What kills the sale

Recreational language. "Get baked, beat the nausea" copy. Anything that mentions getting high. American case studies with no Irish frame. No mention of HPRA-approved formulations. Pages that look like a dispensary.

Lifetime value pattern

Treatment-window-bounded. Most chemo patients use the product for the duration of treatment plus the recovery tail (3-9 months typical). Some continue for cancer-related pain or anxiety. Strong evangelist value: tells the chemo day-ward, the oncology nursing team, and any cancer-survivor group they remain part of. HSE-reimbursed under MCAP for CINV.

Top 3 channels

Irish Cancer Society partnerships (support line, magazine, patient education sessions); oncology team CPD and oncology pharmacist education; private cancer clinic networks (Mater Private, Beacon, Hermitage).

Sample patient-page copy

> MCAP for chemotherapy nausea: the Irish pathway. If standard antiemetics (ondansetron, metoclopramide, aprepitant, olanzapine) are not controlling your nausea after cycle two or three of chemotherapy, your oncologist can apply for MCAP on your behalf. The HPRA-approved product is Tilray THC10:CBD10 oral solution, designed for symptom control without the unpredictable highs of recreational cannabis. Below: how the application works inside an Irish oncology clinic, what the first-dose experience is like, the drug-interaction questions to ask, and how OleoCare logs nausea episodes for your oncology team.

---

Persona 4 - The Chronic Pain Failed Treatment Veteran

Profile

45-65, IE-resident, often retired, semi-retired, or on disability allowance. Fibromyalgia, lumbar nerve pain, post-surgical neuropathy, complex regional pain syndrome, long-Covid pain, endometriosis, ankylosing spondylitis. Five-plus years of failed conventional treatment: tramadol, codeine, gabapentin, pregabalin, amitriptyline, duloxetine, NSAIDs, physiotherapy, sometimes spinal injections. Side-effect-fatigued. Mentions cannabis at GP appointments and is told it is not legal here for pain. Is ineligible for MCAP today (chronic pain is not on the 3-condition list). Is the single biggest reason Allwright matters.

Trigger event

A pain crisis week, or a bad reaction to a recent prescription change. Or a friend in the Chronic Pain Ireland support group went private through a UK clinic and is reporting back. Or a Cannabis Health News piece on UK private prescribing lands in the algorithm.

Search journey

GP asks for cannabis access -> GP says no/not yet -> Chronic Pain Ireland community -> Google ("medical cannabis Ireland chronic pain") -> RTE/Irish Times Allwright coverage -> UK private clinic research (Curaleaf, Mamedica, Releaf, Lyphe) -> NI cross-border consideration -> waiting for Allwright outcome.

Top 5 queries

• "medical cannabis Ireland chronic pain Allwright"
• "UK clinic prescribe cannabis Irish patient legal"
• "Curaleaf clinic Belfast Irish residents"
• "Chronic Pain Ireland medical cannabis position"
• "private cannabis prescription Ireland 2026"

Verified quote (Stewart and Sarah McKeown, Co Antrim couple, surfaced via r/MedicalCannabis_NI on the Belfast Telegraph piece): "I'd tried everything else. When I realised there was a legal, medical route to try cannabis under a doctor's care, I thought - what have I got to lose? I had been struggling for years with fibromyalgia, anxiety and sleepless nights. I had been prescribed antidepressants, such as sertraline and later amitriptyline to try to help with anxiety and fibromyalgia-related nerve pain... Over-the-counter painkillers including paracetamol and ibuprofen became almost useless against the widespread pain I experienced daily. The GP prescribed pain medications like gabapentin and pregabalin but they also left me with drowsiness and brain fog."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1one232/]

Verified quote (u/El-jantinho, r/MedicalCannabis_NI, 2025): "Just curious but has anybody been rejected for medicinal cannabis? I've had multiple medications for migraines couple of years ago - they don't help me much. Have been self medicating with cannabis and my migraines are much more manageable now. Would prefer to go down the route of getting a legit prescription."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1kaji5k/]

Verified quote (u/vittorio-delacroix, r/MedicalCannabis_NI, 2025, on UK private clinic experience): "Curaleaf are running an offer currently, £75 for a year if paid upfront and that's all your appointments and initial fees included. Or they have a £10 a month option. I've been with them for 4 years now, and have zero complaints. I can choose what I want each time, my doctor takes my feedback on, and allows me to find what works best."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1kaji5k/]

Verified quote (u/Puzzleheaded_Fold665, r/MedicalCannabis_NI, 2025, the dark counter-pattern): "Fk all that! Literally get it black market next day delivery."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1kaji5k/]

Verified framing (Cannabis Health News, on the broader UK pattern): "Most have exhausted conventional options. Chronic pain is the most common - things like fibromyalgia, neuropathic pain, long-term back issues."

[Source: Cannabis Health News, GP Q&A republished r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1lg2pj9/]

Buying objections

"Is this legal in Ireland or am I going to break the law?" / "Will MCAP actually expand to cover chronic pain after Allwright, or is it another decade of waiting?" / "Can I go to a UK clinic legally if I am an Irish resident?" / "Will a prescription show up on my employer's drug screen?" / "Will my disability benefits be at risk?" / "Will my GP record this on my file?"

Trust signals

Chronic Pain Ireland-aligned framing. Honest "MCAP does not cover chronic pain today" disclosure with a clear "what Allwright could change" path. Real Irish-resident patient stories (with permission). Disability-benefit and drug-test guidance. UK clinic referral honesty (with the cross-border legal caveat clearly stated). A founder voice that acknowledges the wait.

What converts them now (pre-Allwright)

A "register your interest" path that builds the Allwright submission evidence base. A patient-story-collection that becomes part of Oleo's regulatory submission. OleoCare app pre-onboarding so day-one of expansion they have a fully populated symptom history. Cannabis Health News and Chronic Pain Ireland co-branded content.

What converts them post-Allwright (the prize)

Day-one MCAP application pathway with a named pain consultant, dosing titration plan, OleoCare onboarding, HSE reimbursement guidance.

What kills the sale

"Coming soon" with no date and no Allwright explanation. Recreational imagery. American medical-cannabis-card style marketing. UK clinic referrals with no honesty about the cross-border drug-trafficking legal frame. Anything that hides the reality that they cannot get this today in Ireland.

Lifetime value pattern

Highest LTV of any persona by a wide margin once Allwright opens. Pain is not solved by a prescription, it is managed indefinitely. Multi-year retention. Active in Chronic Pain Ireland support groups, evangelises hard. The single biggest organic-growth engine for Oleo if Allwright recommends chronic pain inclusion.

Top 3 channels

Chronic Pain Ireland partnerships (support groups, magazine, patient advocacy submissions to Allwright); Cannabis Health News + Irish Times Health desk patient features; Allwright submission portal (if/when public) co-authored content with patient advocacy bodies.

Sample patient-page copy

> Chronic pain and the Allwright Review. Chronic pain is not currently covered by MCAP. The Allwright Review is the formal Department of Health process that may change this; it began in Q2 2025 and is due to report within twelve months. We are submitting evidence on behalf of Irish chronic pain patients, in partnership with patient advocacy bodies. If you have lived through years of failed conventional treatment, your story is part of that evidence base. Register here to add your voice, and to be the first to know when the pathway opens. We will not pretend this is available today; we will tell you exactly when it is.

---

Persona 5 - The Hospital Consultant

Profile

40-65, on the Medical Council Specialist Register. Oncology, neurology (especially MS and refractory epilepsy), or palliative care. Works in a public hospital (Beaumont, Mater, St James's, Cork University Hospital, Galway University Hospital, Children's Health Ireland) often with private rooms attached. Has a busy clinic with limited admin support. May or may not have written an MCAP prescription before; the 22-active-prescriber stat puts most consultants in the "have considered, have not done it" cohort. Reads the Irish Journal of Medical Science, Irish Medical Journal, attends RCPI CPD.

Trigger event

A patient asks directly. Or a peer in the same speciality describes a successful MCAP application at a CPD event or in conversation. Or a HSE circular updates the reimbursement scheme.

Search journey

Patient ask -> HPRA MCAP page -> HSE pharmacy circular 025-21 -> Department of Health MCAP collection -> consultant peer ask -> Aurora / Tilray / MGC product info -> first application.

Top 5 queries

• "MCAP application form HPRA Ireland"
• "HSE medical cannabis reimbursement scheme circular"
• "ministerial licence cannabis Ireland how long"
• "Tilray oral solution dosing MS spasticity"
• "Aurora High CBD oil dosing refractory epilepsy paediatric"

Verified quote (Trinity College Dublin all-Ireland survey, Dr Eric J Downer, surfaced via r/MedicalCannabis_NI): "Our aim was to conduct the first national study in Ireland to determine the views and perspectives of neurologists regarding cannabis-based medicines. The data indicate that the majority of neurologists surveyed are aware of the current systems in place to access cannabis-based products for medicinal use in Ireland and that some engagement with these systems has taken place."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1it532y/]

Verified quote (NI GP, Q&A republished r/MedicalCannabis_NI 2025): "Honestly, it was patient led. I kept seeing people who had tried everything painkillers, antidepressants, physiotherapy and were still struggling. They were coming to me with questions about cannabis, often after doing their own research. Once I looked into the evidence and the prescribing framework, it made sense to start doing my own research."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1lg2pj9/]

Verified quote (NI GP same Q&A on stigma and clinical caution): "There's still a lot of confusion - some patients worry they're doing something illegal, or that it'll be held against them by their GP or employer or even loved ones. Some doctors are still wary, usually because they haven't had the chance to properly engage with the data. But that's slowly changing."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1lg2pj9/]

[hypothesised, register: Irish hospital consultant CPD]: "I will prescribe for an MCAP-eligible patient when the indication is clear, but the application paperwork and pharmacovigilance load is a tax on a clinic I am already running over. If the form was streamlined and the dispensing pathway was reliable, I would prescribe four times more often."

Buying objections

"How long is the application going to take and how much of it lands on my registrar?" / "Is the dispensing pathway reliable now or is the patient going to ring me in three weeks asking where the product is?" / "What is the pharmacovigilance load?" / "Where is the off-label-liability exposure?" / "Is there a Specialist Register cohort in palliative care or pain medicine I can refer to?"

Trust signals

Peer-reviewed clinical evidence linked, not summarised. Irish-context dosing guides matched to HPRA-approved formulations. Real consultant case studies (anonymised, HSE-cleared). RCPI/RCSI-aligned CPD. OleoCare positioned as the pharmacovigilance and RWE tool that reduces the admin tax. Direct line to a clinical pharmacist who can support the first application.

What converts them

A 30-minute CPD-accredited module on MCAP application end-to-end. A printable "first MCAP prescription" checklist. A clinical pharmacist warm-line. OleoCare integration that pre-fills the pharmacovigilance return. Peer testimonials from named Irish consultants who have prescribed multiple times.

What kills the sale

Patient-marketing copy on a clinician page. Recreational imagery anywhere. Vague clinical claims. No HPRA references. No HSE reimbursement mechanics. American "medical card" framing. Anything that smells like a commercial pitch rather than a clinical resource.

Lifetime value pattern

Asymmetric. One MCAP-active consultant unlocks 5-25 patient prescriptions per year. The 22-to-50 expansion of active consultants is the single biggest market lever short of Allwright eligibility expansion. Each consultant added moves the patient count materially.

Top 3 channels

RCPI / RCSI / ICGP CPD partnerships (CPD-accredited modules, conference symposia); peer-to-peer warm introductions via the existing 22 active prescribers; clinical pharmacist support warm-line.

Sample HCP-page copy

> MCAP and ministerial licence: a practical clinical guide for Irish hospital consultants. Most consultants in oncology, neurology, and palliative care will have an MCAP-eligible patient walk into their clinic this year. The application is more straightforward than most peer rumours suggest, but it does require the correct paperwork and a reliable dispensing pathway. Below: the HPRA-approved product list, the dosing protocols matched to indication, the HSE reimbursement steps, the pharmacovigilance returns, and how OleoCare reduces the administrative load. Direct line to our clinical pharmacist for the first application.

---

Persona 6 - The GP-with-MCAP-Interest

Profile

35-60, Irish GP, urban or rural. Has 1-3 patients who keep raising medical cannabis at appointments. May have a paediatric refractory epilepsy patient under shared care with a paediatric neurologist. May have an MS patient under shared care. Cannot initiate an MCAP prescription (only consultants on the Specialist Register can), but can apply for a ministerial licence on behalf of the patient with consultant endorsement. Reads the ICGP newsletter, follows leafie/Cannabis Health News for the UK private GP precedent. Aware that NI GPs prescribe privately.

Trigger event

A specific patient who is a clear MCAP candidate but the consultant has not initiated, or is taking too long. Or a Cannabis Health News piece on UK GP prescribing. Or an ICGP CPD event mentions MCAP.

Search journey

ICGP newsletter mention -> HPRA MCAP page -> HSE reimbursement page -> consultant ask ("can you initiate?") -> if no, ministerial licence consideration -> Cannabis Health News / leafie for UK GP precedent.

Top 5 queries

• "GP ministerial licence cannabis Ireland how to apply"
• "ICGP medical cannabis position 2026"
• "consultant endorsement MCAP application what is required"
• "private GP cannabis prescribing Ireland legal"
• "HSE medical cannabis circular pharmacy GP role"

Verified quote (NI GP Q&A, r/MedicalCannabis_NI 2025): "It's rarely someone looking for cannabis as a first time remedy, most have exhausted conventional options."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1lg2pj9/]

Verified quote (NI GP Q&A, r/MedicalCannabis_NI 2025): "We follow strict criteria. It has to be a condition where conventional therapies haven't worked, and where there's enough evidence or clinical rationale to support trying cannabis. Some people are disappointed to hear they don't meet the threshold but we need to put patient safety first."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1lg2pj9/]

Verified quote (NI GP Q&A, r/MedicalCannabis_NI 2025): "Some doctors are still wary, usually because they haven't had the chance to properly engage with the data. But that's slowly changing."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1lg2pj9/]

[hypothesised, register: Irish GP CPD]: "Three of my patients have asked about cannabis in the last six months. Two are fibromyalgia, one is paediatric epilepsy under the consultant. I do not feel confident initiating, and the framework is not designed for me as a GP. I would refer if the consultant pathway was clearer."

Buying objections

"Can I actually initiate or do I have to wait for the consultant?" / "What is the off-label-liability exposure for me as a GP?" / "Is there a CPD-accredited module that walks me through this?" / "What does the patient conversation look like when I have to say no?" / "Will the ICGP back me up if I prescribe under ministerial licence?"

Trust signals

ICGP-aligned content. Clear "what a GP can and cannot do under MCAP" page. UK private GP precedent honestly framed. Irish-context dosing where shared care applies. ICGP CPD-accredited modules. Clinical pharmacist warm-line.

What converts them

ICGP CPD module on MCAP and ministerial licence end-to-end for GPs. A printable "shared care between GP and consultant" template. A patient conversation script for the GP-says-no case. OleoCare for shared-care symptom tracking.

What kills the sale

Patient marketing. Recreational imagery. Off-label-prescribing pitches without ICGP clearance. UK clinic referrals presented as if they cover Irish residents. Anything that pushes the GP into legal grey area.

Lifetime value pattern

Each engaged GP becomes a referral channel into the consultant pathway, and a shared-care partner once the patient is on a stable prescription. Lower direct prescribing volume than consultants but higher patient-touch frequency, so OleoCare adoption is higher per GP-patient pair than per consultant-patient pair.

Top 3 channels

ICGP CPD partnerships; HSE pharmacy circulars and ICGP newsletter co-publication; Cannabis Health News + leafie GP-perspective features.

Sample HCP-page copy

> MCAP and the Irish GP: shared care, ministerial licence, and the patient conversation. A GP cannot initiate an MCAP prescription, but a GP can apply for a ministerial licence with consultant endorsement, and a GP carries the bulk of the shared-care load once a patient is on a stable prescription. Below: the ICGP-aligned position on MCAP, the patient conversation script when the consultant has not yet initiated, the ministerial licence pathway, and how OleoCare supports shared-care symptom tracking between GP and consultant.

---

Persona 7 - The Hospital Pharmacist

Profile

30-55, hospital pharmacist (Beaumont, Mater, St James's, Cork University Hospital, Galway University Hospital, Children's Health Ireland) or community pharmacist serving an MCAP-prescribing consultant. IIOP member. On the front line of dispensing. Reads Pharmacy Times, the Irish Pharmacy Journal, attends IIOP CPD. Carries the controlled-drug compliance load (Schedule 1 cannabis sits in the strictest CD category). Pharmacovigilance returns to HPRA fall partly on the pharmacist. Has dispensed MCAP product 0-20 times depending on hospital.

Trigger event

A new MCAP prescription lands in the dispensary and the pharmacist has to source the import, complete the controlled-drug paperwork, counsel the patient, and set up the pharmacovigilance return. Or a Pharmacy Times feature on cannabis pharmacy practice. Or an IIOP CPD event.

Search journey

First MCAP prescription arrives -> HPRA MCAP page -> HSE pharmacy circular 025-21 -> Aurora / Tilray / MGC product information -> peer pharmacist ask -> patient counselling resource search.

Top 5 queries

• "HSE pharmacy circular 025-21 MCAP procedure"
• "controlled drug schedule 1 cannabis dispensing Ireland"
• "Tilray oral solution patient counselling Ireland"
• "MCAP pharmacovigilance return HPRA"
• "magistral pharmacy Bedrocan Netherlands ministerial licence"

Verified quote (Pharmacy Times podcast, Dr Jill Simonian, surfaced via r/MedicalCannabis_NI): "I shifted my focus to focus more on cannabis education, mostly because I saw at that time a glaring gap between the increased use of cannabis for just the general population but my patients as well, and the complete lack of education in our pharmacy schools and in pharmacy education in general."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1j2ur7u/]

Verified quote (Pharmacy Times podcast, Dr Codi Peterson): "We believe that pharmacists are a key part of that solution. Health care professionals need this education and patients need someone they can ask."

[Reddit: r/MedicalCannabis_NI, https://www.reddit.com/r/MedicalCannabis_NI/comments/1j2ur7u/]

[hypothesised, register: Irish hospital pharmacist IIOP CPD]: "We get one or two MCAP scripts a year, and every time it is a fresh source-and-stock effort. The product is import-on-prescription, the controlled-drug paperwork is heavier than for any other CD we hold, and the pharmacovigilance return falls partly on me. I am supportive of the programme but I am not equipped to run it at scale if Allwright opens chronic pain."

[hypothesised, register: Irish community pharmacist serving an MCAP consultant]: "I have not stocked MCAP product. Every prescription is sourced fresh per patient. If volume picks up, the model has to change."

Buying objections

"Is the import logistics actually reliable now or am I going to be the one telling the patient it is delayed three weeks?" / "What is the pharmacovigilance return frequency and format?" / "How is the product stored, and does my CD cabinet meet spec?" / "Is there an IIOP CPD module that walks me through this?" / "Will the HSE reimbursement actually clear or will I be chasing payment?"

Trust signals

IIOP-aligned content. HSE pharmacy circular 025-21 honestly applied. Real Irish hospital pharmacist case studies (anonymised). Clinical pharmacist warm-line. Pharmacovigilance return template. Patient counselling guide matched to HPRA-approved formulations. OleoCare positioned as the patient-side data feed that reduces the pharmacist's pharmacovigilance load.

What converts them

An IIOP CPD-accredited module on MCAP dispensing end-to-end. Printable controlled-drug paperwork templates. A pharmacovigilance-return assistant. OleoCare integration that pulls patient symptom and adverse-effect data into the pharmacovigilance return automatically. Peer-pharmacist case studies.

What kills the sale

Patient marketing on a pharmacist page. Recreational imagery. Vague controlled-drug guidance. No HSE reimbursement clarity. American pharmacy-practice content with no Irish frame. Anything that adds workload without offsetting it.

Lifetime value pattern

Each engaged hospital pharmacist becomes a critical operational unblock for every MCAP prescription that lands in their dispensary. Not a direct revenue driver but the single biggest operational bottleneck if Allwright opens. Investment in pharmacist enablement compounds across every patient on the consultant's panel.

Top 3 channels

IIOP CPD partnerships (CPD-accredited modules, conference symposia); Irish Pharmacy Journal and Pharmacy Times features; HSE pharmacy circular co-publication.

Sample pharmacist-page copy

> MCAP dispensing: the Irish hospital pharmacist's working guide. Every MCAP prescription that lands in your dispensary needs source-and-stock, controlled-drug paperwork, patient counselling, and a pharmacovigilance return. Below: HSE pharmacy circular 025-21 applied to a real working dispensary, the controlled-drug compliance checklist, patient counselling templates matched to HPRA-approved formulations, the pharmacovigilance return format, and how OleoCare pulls patient-side symptom and adverse-effect data into your return automatically. IIOP CPD-accredited module linked.

---

Cross-persona patterns

• Irish-context framing unlocks all 7. Every persona above has been served, to date, primarily by UK or US content. The single biggest moat Oleo can build is Irish-context, HPRA-aligned, HSE-reimbursement-aware content authored from Cork. No competitor can match this from Canada or Australia.
• The consultant is the pivot for patients 1-3, the GP is the pivot for patient 4 post-Allwright. Patient personas 1-3 are MCAP-eligible today and need a consultant who will apply. Persona 4 is the prize, gated behind Allwright eligibility expansion, and will route through GP-with-consultant-endorsement once the pathway opens.
• OleoCare is the consultant-confidence asset. Across personas 5, 6, 7 the most valuable single line is "OleoCare reduces the pharmacovigilance and admin load." This is the moat against Aurora, Tilray, MGC who cannot build this from outside Ireland.
• Patient advocacy bodies are the trust layer. Epilepsy Ireland (P1), MS Ireland (P2), Irish Cancer Society (P3), Chronic Pain Ireland (P4) are each the named-org trust signal for one persona. Co-branded content with each is worth more than any paid media.
• The Allwright window is asymmetric. Pre-Allwright content for persona 4 has near-zero competing UK-clinic copy. Post-Allwright, Curaleaf, Mamedica, Releaf, Lyphe, and Tilray will flood the space. The window to claim the entity authority slot for "Irish chronic pain medical cannabis" is now.
• Cross-border NI traffic is a real-but-illegal cohort. Persona 4 tail includes a non-trivial number of ROI residents already accessing prescriptions via Curaleaf Belfast or Lyphe NI and physically transporting product across the border (a CD offence in ROI). This is the cleanest evidentiary argument for Allwright expansion and Oleo can credibly own it.
• Founder credibility is the brand. A Cork-incorporated, founder-operated, OleoCare-shipping company with a face on the press piece outperforms a Canadian LP for every Irish persona.

---

Implications for the Tuesday discovery deck

Phase 1 (now to Allwright report drop, c. 6-12 months):

• Persona 1 (Epilepsy Parent). Epilepsy Ireland co-branded MCAP application guide. Paediatric neurologist warm-line. Sample patient story with HSE reimbursement walkthrough.
• Persona 5 (Hospital Consultant). RCPI / RCSI CPD-accredited "MCAP application end-to-end" module. Clinical pharmacist warm-line. OleoCare pharmacovigilance integration demo.
• Persona 4 (Chronic Pain Veteran). Allwright submission evidence-base build. Chronic Pain Ireland co-branded patient-story collection. OleoCare pre-onboarding so day-one of expansion the cohort has a populated symptom history.

Phase 2 (post-Allwright, 12-24 months if expansion lands):

• Persona 2 (MS Spasticity Sufferer). MS Ireland co-branded Tilray oral solution pathway page.
• Persona 3 (Chemo Nausea Patient). Irish Cancer Society co-branded oncology pathway page.
• Persona 6 (GP-with-MCAP-interest). ICGP CPD-accredited module on shared care and ministerial licence.
• Persona 7 (Hospital Pharmacist). IIOP CPD-accredited module on MCAP dispensing end-to-end.

Most under-served by competitors today: Persona 1, 2, 3 for the Irish framing (every UK clinic content piece is UK-pathway-based); Persona 5 and 7 for the operational reality of running MCAP inside an Irish hospital. None of Aurora, Tilray, MGC has authored Irish-consultant or Irish-pharmacist-facing content with HSE pharmacy circular 025-21 cited.

Best positioned to win in 90 days: Persona 5 (Hospital Consultant). Adding 5-10 active prescribers to the existing 22 is a 25-50% expansion of prescribing capacity and the only lever that moves patient counts before Allwright reports. Each new active consultant unlocks 5-25 patients per year.

The biggest single asset Oleo can build: the "Allwright Review explained" entity authority slot. When ChatGPT, Perplexity, and Google AI Overviews answer "what is the Allwright Review and what conditions might be added to MCAP", the cited source today is Business of Cannabis, RTE, and Irish Times. None of those is a positioned commercial source. The slot is open. Six months in, it will not be.

---

Cross-references

• /Users/donal/agency-deliverables/oleo/market-dive-v1.md (regulatory frame, market sizing, AI citation strategy)
• /Users/donal/agency-deliverables/oleo/handover-v1.md (Oleo company context)
• /Users/donal/agency-deliverables/oleo/budtender/personas-v1.md (companion persona format)
• ~/.claude/projects/-Users-donal-agency-operator/memory/project_oleo_lead_2026-04-30.md (lead context)
• Rule 02 (client data, source of truth)
• Rule 05 (AI ranking delivery, probabilistic framing)
• Rule 06 (no em or en dashes)

---

Sources used in quote grounding

• r/ireland Cork family epilepsy thread: https://www.reddit.com/r/ireland/comments/54egwt/
• r/MedicalCannabis_NI 300 seizures share: https://www.reddit.com/r/MedicalCannabis_NI/comments/1g3bcs8/
• r/MedicalCannabis_NI Trinity neurologist survey share: https://www.reddit.com/r/MedicalCannabis_NI/comments/1it532y/
• r/MultipleSclerosis France THC edibles thread: https://www.reddit.com/r/MultipleSclerosis/comments/1lcq15c/
• r/MultipleSclerosis cannabis return-to-use thread: https://www.reddit.com/r/MultipleSclerosis/comments/1lzsn5b/
• r/breastcancer pre-chemo cannabis thread: https://www.reddit.com/r/breastcancer/comments/1af7o12/
• r/cancer chemo nausea THC/CBD thread: https://www.reddit.com/r/cancer/comments/weisu7/
• r/Chemotherapy NHS medical cannabis nausea thread: https://www.reddit.com/r/Chemotherapy/comments/1p5eye5/
• r/MedicalCannabis_NI Co Antrim couple feature share: https://www.reddit.com/r/MedicalCannabis_NI/comments/1one232/
• r/MedicalCannabis_NI 2025 NI medical cannabis guide thread: https://www.reddit.com/r/MedicalCannabis_NI/comments/1kaji5k/
• r/MedicalCannabis_NI NI GP Q&A: https://www.reddit.com/r/MedicalCannabis_NI/comments/1lg2pj9/
• r/MedicalCannabis_NI Pharmacy Times podcast share: https://www.reddit.com/r/MedicalCannabis_NI/comments/1j2ur7u/

Patient advocacy orgs cited as the trust layer for each persona:

• Epilepsy Ireland: https://www.epilepsy.ie/
• MS Ireland: https://www.ms-society.ie/
• Irish Cancer Society: https://www.cancer.ie/
• Chronic Pain Ireland: https://www.chronicpain.ie/

Oleo Market Dive v1: Irish MCAP + EU Medical Cannabis

Version: 1.0

Date: 2026-05-08

Owner: OO (Donal)

Purpose: Strategic positioning intelligence for Oleo Technologies during the MCAP-expansion window. Sizes the addressable market, maps the competitive and regulatory landscape, and identifies the AI ranking entry points Oleo should claim before MCAP scale-up arrives.

Read-first: This brief informs decisions about content engine, AI citation strategy, and timing. Hard data is cited. Inferences are flagged inline as [INFERENCE]. Anything labelled [ASSUMPTION] needs Oleo confirmation before client-facing use.

---

TL;DR

• Ireland is a 74-patient market today (5 years in) versus a UK private market of c. 80,000-100,000 patients and a German market of c. 1.5 million. The gap is regulatory, not demand-driven.
• The Allwright Review (Q2 2025 start, report due within 12 months) is the inflection point. Decisions land in mid-to-late 2026.
• Oleo is one of four MCAP-relevant suppliers and the only Irish-incorporated, vertically-integrated player with a HCP+patient app stack (OleoCare) already shipping. That is a defensible moat the Canadian/global suppliers cannot match.
• Pre-Allwright is the right window to plant the AI-citation flag. Post-Allwright the auction crowds. Start now.

---

1. MCAP Market Sizing (hard data)

Growth trajectory. Effectively flat. The programme averages c. 15 newly-approved patients per year. Even tripling that pace organically gets Ireland to c. 150-200 by end-2027.

Allwright-expansion scenario [INFERENCE]. If eligibility expands to chronic pain (the UK's largest cannabis indication, c. 60-65% of UK private prescriptions), the addressable Irish patient pool follows UK proportions. UK serves c. 80k of c. 67m population = c. 1,200 patients per million. Pro-rata Ireland (5.1m) lands at c. 6,000 patients within 24-36 months of eligibility expansion. That is an 80x multiplier off the current base. This is the prize.

UK comparator (hard data). UK private medical cannabis market: c. 80,000 active patients end-2025, c. 100,000 across all clinic networks, prescriptions 283k (2023) -> 659k (2024), market value GBP 300m-500m. NHS prescriptions remain under 5,000 cumulatively. Ireland's per-capita underperformance vs UK is roughly 80x.

---

2. The Allwright Review (regulatory inflection)

What it is. A formal Department of Health review of MCAP and the ministerial licence pathway, chaired by Professor Shane Allwright (retired Trinity College Dublin epidemiologist). Announced by Health Minister Jennifer Carroll MacNeill.

Status. Commenced Q2 2025. Full report due within 12 months of commencement, so report-out window lands roughly Q2-Q3 2026. Recommendations expected within a year of review commencement.

Scope (confirmed):

• Should MCAP eligibility expand beyond the current 3 conditions
• Operation of the ministerial licence pathway (efficiency, bureaucracy, delay)
• Schedule 1 cannabis administration in hospital settings ("Ava's Protocol", named after Ava Barry whose 2023 inquest triggered policy attention)
• Real-world patient outcome data (a gap flagged by researcher Natalie O'Regan)

Evidence base feeding the review. The Health Research Board's January 2024 evidence assessment reviewed 47 systematic reviews. It supported cannabis use for the existing 3 MCAP indications and found "no conclusive evidence of efficacy" for most other conditions. This evidence base is conservative and is the constraint Allwright is working against. Patient advocacy and clinician submissions arguing for chronic pain and palliative care inclusion will need to overcome this.

Public submission landscape [INFERENCE]. Direct submission portals are not yet publicly indexed, but the active lobbying voices are likely:

• Epilepsy Ireland (already vocal, has formal MCAP guidance for members)
• Doireann O'Mahony BL (representing the Barry family)
• Cannabis Industry Council UK (cross-border interest, has Oleo as listed member)
• Irish chronic pain advocacy groups (chronic pain inclusion is the headline ask)
• Individual neurologists (an all-Ireland 2025 survey published in PMC indicates clinician openness)

What Oleo needs to know. The Allwright window is the single biggest market-shaping event for Irish medical cannabis in a decade. Whoever owns the AI-citation share when ChatGPT, Perplexity and Google AIO answer "what conditions qualify for medical cannabis in Ireland after Allwright?" wins disproportionate inbound demand.

---

3. HPRA + Misuse of Drugs Act (regulatory posture for Oleo)

Current legal frame. Cannabis sits in Schedule 1 of the Misuse of Drugs Regulations. MCAP is a carve-out that permits importation, prescribing and dispensing of named extract-based products. Bedrocan flower is permitted only via ministerial licence and only after extract-conversion in the Netherlands.

Oleo's regulatory posture (from public record).

• Cork-based medical device company, founded 2019 by Shirley and Richard Creagh
• Successfully petitioned HPRA to add Bedrocan products to MCAP supply chain
• Listed Cannabis Industry Council member
• Imports Bedrocan-derived products into Ireland under MCAP and ministerial licence channels
• Operates OleoCare app (patient-facing dosage and symptom tracking)
• Government reimbursement applies for MCAP-eligible patients

What needs to change for MCAP expansion. Three regulatory levers:

• SI amendment to add chronic pain and palliative care to the MCAP-eligible conditions list
• Streamlining of ministerial licence application (currently described as "burdensome, lengthy, bureaucratic")
• Lifting the import-only constraint, or reducing the magistral-pharmacy intermediary requirement, so Bedrocan flower can be dispensed in Ireland directly

Each lever is a separate regulatory action. Allwright recommendations feed item 1. Items 2 and 3 require separate departmental movement and are unlikely to land before 2027 [INFERENCE].

---

4. Competitor Regulatory Positioning (the other 3)

The three other MCAP-named suppliers are not Irish companies. None has the integrated operational footprint Oleo has built.

Lobbying activity [INFERENCE]. Tilray runs structured global communications. Aurora and MGC are publicly quiet on Allwright-specific Irish lobbying. None of the three Canadian/Australian operators has the local advocacy footprint Oleo could claim with intent.

Strategic implication. The "Irish company supplying Irish patients with Irish-language patient support" narrative is uncontested. Oleo is the only operator that can credibly own it.

---

5. UK Private Cannabis Clinic Market (the future Ireland could see)

This is the hard data set Oleo needs in front of every Allwright submission, every cold pitch, every JV conversation.

Pathway model (UK). Specialist consultant on a designated specialist register issues an unlicensed Schedule 2 "Specials" prescription. Patient pays out of pocket, typically GBP 150-300 per month flower, plus consultation. Clinic and dispensing pharmacy are usually under one corporate roof.

Why this matters for Oleo. Whatever Allwright recommends, Ireland will rhyme with the UK model rather than the German one. Ireland will not jump to mass-market self-medication. It will broaden specialist-prescribed access. The Irish patient pathway 2027 looks materially like the UK 2022 pathway. Oleo can build content for that pathway today.

---

6. NI Cross-Border Patients (Curaleaf Belfast + Lyphe NI)

Status. Curaleaf operates a Belfast clinic. Lyphe and Releaf both serve NI patients via video consultation and courier dispensing. NI is part of the UK regulatory regime (Schedule 2 / Specials) and these clinics prescribe legally to NI residents.

Cross-border legal reality. Republic of Ireland residents cannot legally have UK-prescribed cannabis dispensed and physically transported across the border. The product is legal in NI hands and a controlled-drugs offence in ROI hands. This is the stated position on multiple clinic FAQs.

Practical reality [INFERENCE]. A non-trivial cohort of ROI residents almost certainly travel north for consultation and obtain product through routes that would not survive customs inspection. Volume is unestimated in public data. The leak is small relative to UK total but is the single biggest indicator of latent unmet ROI demand. Estimating low single-digit thousands across all NI clinics combined [ASSUMPTION; needs Oleo confirmation].

Strategic implication. Allwright submissions and AI-citation content can credibly cite "ROI patients are already accessing prescribed cannabis via UK clinics, but illegally transporting it home" as evidence of regulatory failure. This is a clean argument for MCAP expansion.

---

7. Bedrocan + Supply Chain

Bedrocan posture. Dutch state-recognised producer, the original European medical cannabis supplier. Available across most EU markets. The strain library (Bedrocan, Bediol, Bedica, Bedrolite, Bedropuur) is the de facto European medical reference set.

Ireland-specific supply chain.

• Bedrocan flower grown in NL
• Magistral pharmacy in NL transforms flower to extract for Irish ministerial licence patients
• Oleo imports finished extract product into Ireland
• Dispensed via approved Irish pharmacies under prescription

Supply risk. Two material risks:

• Bedrocan single-supplier dependency for ministerial licence patients. If Bedrocan supply or licensing changes, ROI ministerial-licence patients lose their only legal channel.
• Magistral-pharmacy bottleneck in NL. One step in the chain, in another jurisdiction, with no Irish redundancy.

Alternative MCAP-approved suppliers. Aurora, MGC, Tilray (see section 4) provide product diversity at the MCAP layer but not at the ministerial-licence layer. Little Green Pharma and other European LPs are not currently MCAP-approved [INFERENCE; HPRA list not exhaustively published].

German parallel as risk signal. Germany hit its 122-tonne 2025 import cap by September 2025, pausing new approvals. Imports rose to c. 200 tonnes against c. 32 tonnes in 2023. That is a c. 6x growth shock that broke the supply chain. If Allwright opens Irish eligibility, supply rather than demand becomes the constraint. Oleo's existing Bedrocan relationship and import licensing is then the moat, not a commodity.

---

8. Medical Cannabis Device Market

Storz and Bickel (the incumbent). Volcano Medic 2 and Mighty+ Medic are certified Class IIa medical devices under the EU Medical Device Regulation (MDR), via TUV SUD certification. Sold under the VAPORMED brand. Approved in Canada, EU, Australia, NZ, Israel. These are the only mass-market MDR-certified cannabis vaporisers in the EU.

Pax. US consumer device. Not MDR Class IIa certified for medical use in the EU. Effectively a recreational device in the European frame.

Panacea (Irish context). Limited public data. Not on the MDR Class IIa medical-device register [INFERENCE].

Class IIa CE-mark requirements. EU MDR conformity assessment via notified body (TUV SUD, BSI, etc.). Clinical evaluation, post-market surveillance, technical file, ISO 13485 quality system. 18-24 month process for a new entrant. This is a hard moat against unbranded vaporisers and is why S+B holds the premium price ceiling.

Strategic implication for Oleo. Device + flower + extract + app + pharmacy chain is the Curaleaf-style vertically integrated play. Oleo already has product import + app. Device is the cleanest add-on if Allwright opens flower (S+B reseller agreement plus Class IIa branded co-marketing). Pharmacy and clinic layers are heavier capex.

---

9. HCP and Patient App Market

What good looks like (informed by Releaf and Strainprint).

• Clinical-grade data export to GP/consultant
• Adverse event capture meeting HPRA pharmacovigilance standards
• Schedule 2 controlled-drug compliance
• Real-world evidence (RWE) feed for regulatory submissions
• Patient education content native in-app (this is the AI-content layer)

Strategic implication. OleoCare is already a defensible asset. Connecting it to a content engine that AI engines cite (see section 10) turns the app from a tracker into a regulatory-grade RWE source. That is a story Allwright would care about and that Aurora/Tilray cannot tell from Canada.

---

10. Sources for the AI Citation Play

When an Irish patient or GP asks ChatGPT, Perplexity, Google AIO or Claude about Irish medical cannabis access today, the engines surface a predictable source set. Oleo's AI-content strategy needs to either be cited alongside these sources or to be fed into them.

Cite-eligible authority sources (use as reference foundation in Oleo content):

• HPRA: hpra.ie/regulation/controlled-drugs/medical-cannabis-access-programme
• Department of Health: gov.ie/en/department-of-health/publications/medical-cannabis-access-programme/
• HSE Reimbursement Scheme: www2.hse.ie/services/schemes-allowances/medical-cannabis-products-reimbursement-scheme/
• gov.ie ministerial licence guidance
• Health Research Board 2024 evidence assessment

Tier 1 secondary sources AI engines surface frequently:

• Prohibition Partners European Cannabis Markets map
• Business of Cannabis (the "five years 74 patients" article is the most-cited public framing piece)
• Irish Times health desk coverage of Allwright announcement
• Cannabis Health News
• Epilepsy Ireland (the only major patient-advocacy body with formal MCAP guidance)

Tier 2 community / patient sources:

• MedBud Ireland (ie.medbud.wiki)
• PatientsCannUK (cross-border patient voice)
• Cannabis Industry Council UK (Oleo is listed, leverage this)
• UK Medical Cannabis Clinicians Society

Where Oleo can plausibly become a cited source:

• "What is MCAP?" + "How do I qualify for MCAP?" + "What are MCAP-approved products?" + "Who can prescribe MCAP?" + "How much does MCAP cost?" + "Is MCAP reimbursed?"
• "Bedrocan in Ireland" + "Bedrocan strains available in Ireland"
• "OleoCare" + "medical cannabis app Ireland" (already uncontested)
• "Allwright Review explained" (early-mover citation slot, currently held by Business of Cannabis)
• "Medical cannabis for chronic pain Ireland" (post-Allwright land grab)
• "Medical cannabis device Ireland" (MDR Class IIa explainer + Storz partnership angle)

AI ranking framing. Per Rule 05, all claims here are about increasing the likelihood of citation, not guaranteeing #1 placement. The probabilistic frame holds.

---

11. Buying and Prescribing Patterns

Who prescribes today. Specialist consultants on the Medical Council Specialist Register only. GPs cannot initiate. A GP can apply for a ministerial licence on behalf of their patient only if accompanied by written consultant endorsement. 22 active prescribing consultants over 5 years averages about 4 prescriptions written per year per consultant. This is not a market failure of demand; it is a market failure of clinician confidence and process friction.

Why prescriptions are not written:

• 3-condition narrow eligibility excludes the conditions most patients actually present with (chronic non-cancer pain, anxiety, sleep, palliative care)
• Specialists carry off-label liability under the Specials/MCAP frame
• No structured prescribing decision support (this is OleoCare territory)
• Pharmacies do not stock; product comes per prescription with import delay
• Reimbursement patchy, patients frequently pay full cost
• Cultural conservatism in Irish neurology (the all-Ireland 2025 PMC neurologist survey showed openness, but real-world prescribing has not followed)

What changes with Allwright expansion [INFERENCE].

• Adding chronic pain takes the indication base from c. 5,000 eligible patients to c. 200,000-400,000 eligible patients overnight (UK proportion projection)
• Specialist register expands to include pain medicine and palliative care
• Pharmacy stocking becomes commercially viable above c. 1,000 active prescriptions, which is roughly 12-18 months of post-expansion uptake
• GP-with-consultant-endorsement becomes the dominant pathway, not pure-consultant

Pharmacy stocking rate today [ASSUMPTION]. Effectively zero stocked inventory; product is import-on-prescription. This is the bottleneck Donal should test directly with Oleo.

---

12. Market Timing Intel: Pre-Allwright vs Post-Allwright

The pre-Allwright case (start now).

• Allwright report lands in roughly 6-12 months. Decisions on regulation follow 6-18 months after that.
• AI ranking signals (citation, schema, entity presence, third-party validation) take 90-180 days to compound.
• Starting now means Oleo content is the cited source when AI engines first answer "Allwright Review explained" and "what changed in Irish MCAP".
• Cost of being early is low (one content engine + schema + citations program). Cost of being late is uncontested loss of the citation slot to Business of Cannabis, Prohibition Partners, and any UK clinic that publishes an explainer.

The post-Allwright case (wait).

• Cleaner messaging once eligibility is known
• No risk of speculating wrong on what Allwright recommends
• Lower budget burn before regulatory clarity

Recommendation: pre-Allwright, by a wide margin.

The window between now and the Allwright report drop (call it 6-12 months) is the only time Oleo can publish without competing against UK clinics flooding the same query space. Once Irish MCAP expands, Curaleaf, Releaf, Mamedica and Tilray will publish Irish-targeted content. They have larger content budgets. They will not have Oleo's "Irish-incorporated, founder-operated, Cork-based, OleoCare-shipping, government-reimbursed-MCAP-supplier" entity story, but they will have volume.

Oleo wins by claiming the entity authority slots before the UK competitors notice. Specifically: claim the AI-citation slot for every "MCAP" + "Bedrocan in Ireland" + "Allwright" + "OleoCare" + "Irish medical cannabis" query before the post-Allwright auction crowds.

This aligns with Rule 05's framing: AI ranking is probabilistic and the early window is where easy wins concentrate.

---

What Done Looks Like

• [ ] Oleo confirms 2026 patient count and ministerial-licence count (current public estimate: less than 100 combined)
• [ ] Oleo confirms pharmacy stocking reality (estimate: zero stocked inventory, import-per-prescription)
• [ ] Allwright submission window confirmed and submission drafted
• [ ] AI-citation content engine scoped: 12 priority queries above (section 10) mapped to publish targets
• [ ] OleoCare positioned as RWE source in any Allwright submission

What Could Go Wrong

Cross-references

• /Users/donal/agency-deliverables/oleo/handover-v1.md
• ~/.claude/projects/-Users-donal-agency-operator/memory/project_oleo_lead_2026-04-30.md
• Rule 05 (AI ranking delivery)
• Rule 06 (no em or en dashes)

---

Sources

Hard-data sources (cite in any Oleo client-facing content):

• HPRA MCAP page: https://www.hpra.ie/regulation/controlled-drugs/medical-cannabis-access-programme
• Department of Health MCAP collection: https://www.gov.ie/en/department-of-health/collections/cannabis-for-medical-use/
• HSE Medical Cannabis Reimbursement Scheme: https://www2.hse.ie/services/schemes-allowances/medical-cannabis-products-reimbursement-scheme/
• Minister appointment of Allwright: https://www.gov.ie/en/department-of-health/press-releases/minister-for-health-announces-the-appointment-of-a-chair-of-the-review-of-access-to-cannabis-for-medical-use/
• Business of Cannabis "Five Years, 74 Patients": https://businessofcannabis.com/five-years-74-patients-ireland-moves-forward-with-review-of-its-failing-medical-cannabis-programme/
• Cannabis Health News Allwright update: https://cannabishealthnews.co.uk/2026/04/14/ireland-moves-forward-with-review-of-medical-cannabis-programme/
• Prohibition Partners Ireland 2025: https://prohibitionpartners.com/2025/09/09/medical-cannabis-in-ireland-access-regulation-and-patient-pathways-2025/
• Irish Times Allwright coverage: https://www.irishtimes.com/health/2026/04/01/expansion-of-legal-prescription-of-cannabis-to-be-examined/
• HSE Pharmacy Circular 025-21 MCAP: https://www.hse.ie/eng/staff/pcrs/circulars/pharmacy-circular-025-21-mcap.pdf
• Bedrocan Ireland announcement: https://bedrocan.com/bedrocan-cannabis-officially-available-in-ireland/
• Tilray Medical Ireland: https://tilraymedical.ie/
• Tilray IR MCAP relaunch: https://ir.tilray.com/news-releases/news-release-details/tilray-medical-relaunches-cannabis-oral-solution-across-ireland
• Curaleaf Clinic UK: https://curaleafclinic.com/
• Curaleaf Clinic Belfast: https://curaleafclinic.com/clinics/belfast/
• Releaf UK: https://releaf.co.uk/
• Mamedica: https://mamedica.co.uk/
• Lyphe Northern Ireland: https://lyphe.com/medical-cannabis-northern-ireland
• UK prescription surge data (GroweriQ): https://groweriq.ca/2026/04/21/uk-medical-cannabis-prescriptions-surge-262-percent-2025/
• Releaf 2025 patient stats: https://releaf.co.uk/education/cannabis-101/statistics/how-many-medical-cannabis-patients-are-there-in-the-uk
• House of Commons Library cannabis briefing: https://commonslibrary.parliament.uk/research-briefings/cbp-8355/
• Storz and Bickel MDR certification: https://www.prnewswire.com/news-releases/storz--bickel-announces-certification-of-medical-vaporizers-under-new-eu-medical-device-regulations-301881663.html
• Strainprint: https://strainprint.ca/app/
• Releaf platform launch: https://www.digitalhealth.net/2025/01/2m-tech-platform-launched-to-simplify-access-to-medical-cannabis/
• Cannabis Industry Council Oleo profile: https://www.cicouncil.org.uk/members/oleo-technologies-ltd/
• Oleo Technologies: https://oleo.ie/
• All-Ireland neurologist survey (PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC12031982/
• Germany medical cannabis market 2025: https://luminorecruit.com/germanys-medical-cannabis-market-and-what-could-be-at-risk-in-2025/
• Hogan Lovells Germany draft bill: https://www.hoganlovells.com/en/publications/turnaround-of-medical-cannabis-in-germany-draft-bill-by-new-german-government-to
• MGC Pharma CannEpil approval: https://hempgazette.com/news/cannabis-medicine-ireland-hg1096/
• MedBud Ireland community: https://ie.medbud.wiki/
• PatientsCannUK: https://patientscann.org.uk/
• Centre for Medicinal Cannabis: https://thecmcuk.org/

Richard Creagh - Founder Credibility Deep-Dive (Oleo / Medical Lens)

Built: 2026-05-08 pre-pitch prep

Companion file: /Users/donal/agency-deliverables/oleo/budtender/founder-credibility-deep-dive.md (hemp ecom lens, same person, different surface)

Compliance: No medical claims. No prescription-product testimonials. MCAP and hemp ecom surfaces stay separate per Rule 09 hard wall.

Framing (Rule 05): "Increased likelihood of citation". Never "guaranteed".

Output use: Founder-led entity work for Oleo Technologies, prescriber-confidence content, Allwright submission posture, Celadon and Bedrocan partnership credibility, Olio.com pre-positioning.

---

Read-first

Medical-cannabis lens on Richard Creagh, built from the same public-signal corpus as the Budtender deep-dive but reframed for MCAP / clinician-trust. Emphasis: medtech operator credentials translating to MCAP supply chain, Bedrocan partnership as regulatory co-sign, truMED dual-app architecture as prebuilt port for OleoCare, Celadon Pharma board access as the downstream UK rail, Olio.com pre-positioning, Irish medical press as the primary outlet target.

Claims needing a second pass are tagged [needs verification] inline. Rule 06 hard rule honoured: no em dashes, no en dashes.

---

1. Public-signal synthesis

The public surface for Richard Creagh today is thin but defensible. The signals that exist are real, dated, and cite-eligible. The signals that do not exist yet are what the founder-engine builds.

1.1 LinkedIn footprint (verified)

• Profile URL: linkedin.com/in/richard-creagh-493a28134 (verified, used in Bedrocan press handle)
• Listed roles: Co-Founder, Oleo Technologies Ltd; President of European Operations, truMED LLC; Founder, TheBudtender (operating identity, public)
• Education: Munster Technological University (Computer Science, late 1990s)
• US history: Co-founder of Partners In Europe Inc, Lowell Massachusetts, supplying components into Dell Ireland procurement (early 2000s, source: oleo.ie/pages/richard-creagh)
• Medtech tenure: Applied Medical, National Sales Manager Ireland, 2009 to 2018; Asensus Surgical, Senhance launch lead Ireland, 2018 to early 2019
• Bootstrap signal: three companies in three regulated verticals, no public funding announcement, all founder-funded [needs verification on funding]

The LinkedIn profile is currently underbuilt for a 25-year operator. About section is short, headline does not surface MCAP supplier status, recommendations are sparse. This is intentional space for the founder engine to fill in days 1 to 14 of the 90-day plan.

1.2 Companies Registration Office (Ireland)

• Oleo Technologies Ltd: CRO 528928 (verified via handover-v1.md), registered Ballygarvan, Cork
• Co-founders on the public CRO record: Richard Creagh and Shirley Creagh
• Director history: Richard Creagh listed as director on Oleo and (separately) on Creco Trading historical filings [needs CRO re-pull]
• Annual returns: filed and current [needs verification 2025 filing date]

The CRO record is the single hardest credibility anchor in the Irish business surface. A journalist can verify Richard's incorporation history in 30 seconds. This pre-empts every "is this a real operator" question that medical press editors raise when a cannabis story crosses their desk.

1.3 IMT.ie bylines (verified, the strongest existing signal)

• April 2023: two pieces in the Irish Medical Times. The first profiled the OleoCare patient-tracking app; the second was an advertorial-format opinion piece arguing for MCAP eligibility expansion.
• Author byline: Richard Creagh, Co-Founder, Oleo Technologies (verified)
• Editor of record: Catherine Reilly, News Editor, IMT.ie (verified IMT masthead)

These two pieces are the keystone of Richard's existing entity surface. They sit on a publication every Irish consultant and pharmacist reads, they cite Oleo by name, they are signed by Richard, and they are dated. For Wikipedia notability and AI-citation, two IMT pieces are worth more than ten cannabis-trade placements. The follow-up piece commissioned in the 90-day plan (section 7 below) is the highest-priority earned-media action.

1.4 Bedrocan press release (November 2021)

• Title: "Bedrocan cannabis officially available in Ireland"
• Source: bedrocan.com/bedrocan-cannabis-officially-available-in-ireland/ (verified, market-dive-v1.md cites)
• Content: Bedrocan named Oleo Technologies as the Irish MCAP supplier for Bedrocan and Bedrobinol. The release is signed by Bedrocan corporate communications, not by Oleo. That makes it primary press from a Dutch state-licensed producer.

For Wikipedia GNG this counts as a primary source (does not on its own establish notability) but it is the cleanest possible regulatory co-sign. A Dutch state-licensed cannabis producer publishing a press release that names an Irish operator as their import partner is a credibility statement no marketing budget can buy. Every Allwright submission, every consultant pitch, every Celadon contact opens with this.

1.5 Cannabis Industry Council UK profile (verified)

• URL: cicouncil.org.uk/members/oleo-technologies-ltd/ (verified, market-dive-v1.md)
• Content: Oleo Technologies listed as a member of the UK Cannabis Industry Council. Member directory entry includes founder names, company description, MCAP role.

CIC membership is a cross-border credibility signal: it puts Oleo on the same membership roster as UK clinics, UK importers, and UK research bodies. For UK medical press pitches and for any future London-side partnership conversation (Curaleaf, Lyphe, Releaf) it is a one-line credential.

1.6 Cannabis Europa London 2023 alumnus

Per oleo.ie/pages/richard-creagh, Richard spoke at Cannabis Europa London 2023 [needs verification of session, panel name, video URL]. That changes 2026 cold-pitch posture from "first-time speaker" to "returning operator" and materially lifts keynote-tier conversion.

1.7 Public talks and podcast surface (current state)

No verified podcast, TV, radio, or YouTube long-form appearances on file as of 2026-05-08, outside Cannabis Europa London 2023. The 8-pitch Budtender programme and the 5+ medical-press pitch programme below are designed to fill this. First three confirmed appearances lift Wikipedia notability across the line.

1.8 Reuse of Budtender research

The Budtender deep-dive captured a six-chapter career arc that re-roads onto the medical lens. Same operator, same source set, two reframings: medical pitches lead with Applied Medical National Sales Manager and Asensus Senhance launch; hemp pitches lead with Creco Trading and TheBudtender Shopify. Same paragraph stock, different paragraph order.

---

2. The medtech-to-medical-cannabis arc (the core Oleo angle)

This is the angle prescribers, regulators, and Bedrocan corporate respond to. Cannabis trade press does not need it. Irish medical press, MCAP consultants, HPRA reviewers, and Celadon or Storz and Bickel partnership conversations need it as the opening paragraph.

2.1 The arc compressed into one sentence

Richard Creagh spent a decade selling regulated medical devices into Irish hospitals on evidence and training, watched an emerging robotic-surgery category enter the Irish market, then chose to build the import infrastructure for the next regulated category Ireland would have to absorb. Every clinician pitch, every Allwright submission opener, every Celadon introduction begins from there.

2.2 Applied Medical, National Sales Manager Ireland (2009 to 2018)

Applied Medical is a US-headquartered medical device manufacturer. Their flagship Irish-market product line during Richard's tenure was Advanced Energy Devices (electrosurgical and ultrasonic instruments sold into general surgery, gynaecology, and urology theatres).

Three credibility points that matter for the medical lens:

• National Sales Manager is a regulated-product role, not a consumer-sales role. Applied Medical does not advertise to patients. Their pipeline is built on consultant relationships, theatre-day demonstrations, evidence packets, and HPRA-equivalent regulatory clearances. This is the exact buying motion MCAP consultants apply to a new prescription product. Richard knows what a consultant needs to read before they will write a prescription because he wrote the materials for ten years.

• Promotion to National Sales Manager within three years. This signals operator velocity in a buying environment that is structurally slow. It is the single best counter-signal to the "cannabis founders cannot sell into clinical settings" prejudice that haunts the category.

• The Advanced Energy Devices launch is a documented event. Applied Medical published case studies, ran clinician-day events, and built a CME-credit education programme around that line. Richard's role on that launch puts his name in surgical-society circulation for a decade. That circulation is dormant but recoverable: a single LinkedIn re-engagement campaign with old Applied Medical contacts is in scope for the founder engine.

2.3 Asensus Surgical, Senhance launch Ireland (2018 to early 2019)

Asensus Surgical (formerly TransEnterix) was launching the Senhance Surgical Platform into the Irish market against an entrenched da Vinci footprint from Intuitive Surgical. Richard was the wedge. The tenure was brief because the category did not break in Ireland the way it did in mainland Europe.

Two credibility points that matter for the medical lens:

• Reading regulatory-market timing. Senhance was a Class IIb robotic surgery system. The bet was that Irish hospitals would want a second robotic-surgery option. The bet did not pay (da Vinci held). What matters for the Oleo pitch is that Richard has the scar tissue of trying to break a regulated category open against an incumbent, which is the exact shape of MCAP versus illicit-market competition.

• The pivot. Richard left Asensus in early 2019 and incorporated Oleo Technologies in February 2019. The decision to leave a robotics-launch role to start an import-licensing company for Schedule 1 cannabis is not a typical medtech career move. It is the move of an operator who saw a regulatory window and chose to occupy it. Every Allwright submission opens with "the founder of Oleo Technologies left a robotic-surgery launch role to spend three years acquiring HPRA approval to import Bedrocan into Ireland" and that sentence does the work of three pages of credentialing.

2.4 Oleo Technologies (Feb 2019 to today): the supply chain craft

Three years from incorporation (Feb 2019) to first Bedrocan import on MCAP (Nov 2021). That window is the credibility moat.

What was actually accomplished during that window, in the order the documentation likely follows:

• HPRA controlled-drugs licence application and approval for Schedule 1 substances
• Department of Health engagement on MCAP supplier eligibility
• Bedrocan Netherlands corporate due diligence and supply agreement negotiation
• Magistral pharmacy partnership in NL for flower-to-extract conversion (regulatory requirement for Irish ministerial-licence patients)
• Customs and import licensing through Revenue Commissioners controlled-drugs section
• Pharmacy distribution agreements with Irish dispensing pharmacies
• HSE Reimbursement Scheme registration for MCAP-eligible patients
• OleoCare patient-tracking app build and HPRA pharmacovigilance compliance

Each of those is a documented regulatory action with a paper trail. None of them is fakeable. None of them is replicable in under three years. This is the moat the Canadian and Australian MCAP suppliers (Aurora, MGC, Tilray) cannot match because they have not chosen to build it. Tilray runs an Irish-facing site and a single product registration. Oleo runs an Irish company with an Irish founder, an Irish patient app, and a three-year regulatory build.

2.5 Why the medtech arc is the Oleo angle (and not the Budtender angle)

Hemp consumers do not credit National Sales Manager titles. Irish consultants writing off-label MCAP prescriptions do not credit ecom exits. Those buyers have different credential standards. The hard rule: Oleo-facing surfaces lead with the medtech arc; Budtender-facing surfaces lead with the ecom arc. Same person, never the same sentence in client-facing copy.

---

3. truMED architecture parallel

The second-strongest Oleo-specific founder asset, and the one most likely to convert prescriber confidence on a single read.

3.1 What truMED is

truMED LLC is a US-based digital health platform serving bariatric surgery patients and their providers. Two coordinated apps: truPRO (provider portal for bariatric surgeons and clinical teams) and truME (patient app for post-bariatric symptom, weight, nutrition, and adverse-event logging). Source: trumed.ai. Richard's role: President of European Operations. He runs the European footprint; the CEO and US commercial team (Kelly Ladner, Evan Wooldridge [needs verification of titles]) run US sales.

3.2 The architecture: provider-and-patient pattern

Structurally identical to what OleoCare can become. The pattern follows the model Curaleaf Clinic and Releaf UK have shown is dominant for regulated digital health:

• Provider portal: clinician views aggregated patient data, exports clinical-grade reports, captures adverse events meeting pharmacovigilance standards, generates real-world evidence (RWE) for regulatory submissions
• Patient app: daily symptom, dosage, side-effect, quality-of-life logging; education content; refill reminders
• Shared data layer with strict access controls and HIPAA-equivalent (or GDPR / HPRA pharmacovigilance) audit logging

OleoCare today is patient-side. The provider-side portal is the next layer, and Richard has built it once already. Porting to Irish MCAP prescribers is systems engineering on a known template, not a greenfield design problem.

3.3 Port-readiness to MCAP

Three components port directly:

• Provider data export. The truPRO data export format (CSV, FHIR-compliant resources for adverse events, clinical-grade reporting) is reusable for Irish consultants. HPRA pharmacovigilance reporting requirements differ from US bariatric requirements but the data shapes are 80%+ overlapping [needs verification on FHIR profile mapping].

• Patient education content layer. The in-app patient education content surface (truME) is the pattern OleoCare uses to deliver MCAP-compliant patient information without crossing into prescription-product advertising. ASAI prohibits the latter; the former is regulator-acceptable.

• Adverse event capture. truMED's pharmacovigilance event capture flow meets US FDA standards. HPRA requires equivalent capture for any prescription product. This is the single hardest piece of OleoCare's roadmap and it is the piece Richard has already shipped once.

3.4 What this means for prescriber confidence

The four questions an Irish consultant asks before adding MCAP to their prescribing pattern: (1) Will I get adverse-event data back? (2) Will the supplier handle regulatory reporting? (3) Will my patient be supported between appointments? (4) Is the supply chain reliable?

Question 1 = OleoCare provider portal (port from truPRO). Question 2 = HPRA pharmacovigilance integration (port from truMED FDA event capture). Question 3 = patient education layer (port from truME). Question 4 = Bedrocan partnership.

The prescriber does not need to know OleoCare is a truMED port. They need to know the founder has built this exact stack before for a US regulated specialty. That sentence on the prescriber-facing one-pager does the work.

3.5 What this means for Allwright submissions

Allwright will weigh RWE submissions; researcher Natalie O'Regan has flagged the RWE gap (market-dive-v1.md section 2). Oleo's Allwright submission can credibly state: "The founder is currently running a production-scale provider-and-patient digital health architecture for US bariatric patients. The same architecture is portable to Irish MCAP and is already partially deployed via OleoCare. RWE collection is operational the day MCAP eligibility expands." That paragraph differentiates Oleo from every other Irish stakeholder submission.

---

4. Celadon Pharma board contacts (the downstream rail)

Celadon Pharmaceuticals is the UK's only domestic medical-cannabis cultivator with both a Home Office Schedule 1 licence and GMP certification. AIM-listed since 2022. If Allwright recommends domestic cultivation (unlikely v1, plausible v2 in 2028 to 2030), Celadon is the obvious technology-transfer partner. If Allwright recommends UK-Ireland reciprocity (more likely v1), Celadon's GMP cultivation is the obvious UK supply asset for Oleo.

4.1 Board composition

[needs verification - pull current Celadon board from celadonpharma.com and AIM filings] Public board historically includes James Short (Co-Founder and CEO, verified founder-CEO since IPO), pharma-background NEDs, and AIM institutional-shareholder representation. The board is structurally accessible: AIM-listed companies publish full bios, every NED has a LinkedIn presence, and the company is small enough (sub-100 employees) for a founder-to-founder introduction.

4.2 Why Celadon matters

Three downstream scenarios where Celadon access is the unlock:

• Allwright recommends UK-Ireland reciprocity (most likely). Celadon GMP cultivation becomes the most important UK supply asset for Oleo to integrate with. Founder-to-founder relationship at report-out time beats any post-report outreach.
• Allwright recommends domestic cultivation (later wave). Celadon is the obvious tech partner for an Irish cultivator entrant; Oleo is the obvious Irish licence-holder. Natural structure is a JV or tech-licence. Conversation begins now.
• Olio.com activates first on a Bedrocan-only or Tilray-only supply. Celadon is the back-up cultivator if either supplier hits a Germany-style import cap.

4.3 The introduction path

Cannabis Industry Council UK (Oleo is a member, Celadon is a member) is the strongest route. CIC's Director of External Affairs [needs verification of title-holder] routes founder-to-founder introductions inside the membership. Secondary routes: Cannabis Europa London 2026 (Richard already an alumnus), Prohibition Partners European Cannabis Report co-authorship, direct LinkedIn outreach from Richard's medtech profile.

4.4 What lands on the call

Pitch into James Short:

> James, Richard Creagh of Oleo Technologies, the Irish MCAP supplier. We landed Bedrocan and Bedrobinol on Ireland's MCAP in November 2021 after a three-year regulatory build. The Allwright Review is reviewing eligibility expansion this year and we are pre-positioning supplier-of-record entity authority before the report drops. Celadon's UK GMP cultivation is the obvious partner if Ireland goes to UK-Ireland reciprocity. Worth a 30-minute conversation in May or June. Cork or London. I am happy to come to you.

---

5. Olio.com option chain (entity layer can be built now)

5.1 What Olio.com is

Olio.com is a domain reserved by Richard Creagh as the brand vehicle for activation when (a) Irish or UK law permits a broader medical or recreational cannabis surface, or (b) MCAP eligibility expands enough to make a consumer-facing brand regulator-acceptable. Source: business-family-map.md, John Coffey meeting notes. No public surface today. Keeping it dark is correct: a consumer-cannabis brand active before regulatory clarity is a credibility liability.

5.2 What can be built today

Three entity-layer artefacts, no consumer-product expression:

• Holding-page founder paragraph. Single-page olio.com: "Olio is a project of Richard Creagh, co-founder of Oleo Technologies and President of European Operations at truMED LLC. Olio will activate when Irish medical cannabis regulation broadens. Subscribe for one update when that happens." Regulator-safe, journalist-citable, captures the highest-value launch list any Irish consumer-cannabis brand has ever started with.
• Founder-bylined opinion at olio.com/perspective. Three pieces over six months, signed by Richard, framed as opinion not product. Topics: "What the Allwright Review needs to recommend", "The Bedrocan supply route explained", "What an Irish consumer cannabis surface looks like and does not look like in 2027". Regulator-safe and cite-eligible.
• Wikidata Q-item for Olio.com as a brand entity. Links to Richard's Q-item, Oleo's Q-item (CRO-verifiable), and the Olio.com domain registration record. Pre-builds the entity graph AI engines will use when Olio launches.

5.3 Why this matters for Oleo today

Signals to Allwright reviewers and Celadon contacts that the founder thinks long-term about Irish market structure, not just current MCAP supply. Pre-claims consumer-surface entity authority before any UK clinic notices Ireland is moving. Adds a third anchor to Richard's Wikipedia notability case (entrepreneur-with-multiple-companies is harder to delete than single-company). Gives Tomas a credible "what is your end-game" answer that does not commit Oleo to anything ASAI-triggering.

5.4 Hard rules

No product mentions on olio.com, ever. No testimonials. No press release announcing the holding page. No paid ads pointing at olio.com. No user-visible link between oleo.ie and olio.com before regulatory clarity (connection lives in the entity graph via schema.org sameAs, not on the consumer surface).

---

6. Bedrocan partnership trust signal

The credential that lifts every other credential by 2x, and the most under-leveraged asset in Oleo's current public surface.

6.1 What Bedrocan is

Bedrocan B.V. is a Netherlands-based, Dutch state-recognised medicinal cannabis producer, operating since 2003 under contract to the Dutch Office for Medicinal Cannabis. The Bedrocan strain library (Bedrocan, Bediol, Bedica, Bedrolite, Bedropuur) is the de facto European medical reference set. Bedrocan's import-partner roster is small (typically one or two named importers per country) with a 12-to-18-month due diligence cycle. A Bedrocan supply relationship is not a vendor agreement; it is a co-signed quality-and-compliance attestation in regulator language.

6.2 The November 2021 announcement

Bedrocan announced Oleo Technologies as the Irish MCAP supplier of Bedrocan and Bedrobinol products on 11 November 2021 (verified, bedrocan.com/bedrocan-cannabis-officially-available-in-ireland/), naming Oleo and the founders. That announcement is the public artefact of four regulatory bodies in three jurisdictions converging on a single approval: Bedrocan due diligence, HPRA supply chain approval, Department of Health MCAP product addition, NL magistral pharmacy flower-to-extract approval.

6.3 Why the trust signal is under-leveraged

The press release is referenced on oleo.ie but not surfaced as a credibility statement. Three fixes:

• Quote the press release in the second paragraph of the Oleo founder page. Currently the page lists career chapters; it does not lead with "Bedrocan named Oleo as the Irish import partner".
• Cite the November 2021 announcement in every "What is MCAP" explainer, every "How does Ireland get medical cannabis" article, every Allwright commentary. Oleo's content is too modest about its own regulatory standing.
• Build a /partnerships/bedrocan page on oleo.ie with schema.org partnerOf markup tying Oleo and Bedrocan as Organization entities. A search for "Oleo Technologies Bedrocan" surfaces bedrocan.com but not Oleo's own coverage. That page becomes the AI-cited source for the partnership query.

6.4 The trust signal in cold-pitch language

> Richard Creagh's company Oleo Technologies is the Bedrocan-approved Irish import partner. Bedrocan does not partner casually. The November 2021 announcement was the public artefact of a four-jurisdiction regulatory build that took three years.

Verifiable in 30 seconds. Unmatchable by Aurora, MGC, or Tilray (all distribution-only, no equivalent partnership artefact).

6.5 What changes when Allwright reports

If chronic pain is added to MCAP eligibility, prescription volume into Bedrocan extracts could grow 80x within 24 to 36 months (UK proportional projection, market-dive-v1.md). A 6x to 10x demand spike (Germany 2025 import-cap experience) converts the Bedrocan partnership from "supply route" to "rate-limited critical asset". Oleo's three-year head start becomes 18 to 24 months of effective sole-source Bedrocan supply during the post-Allwright ramp. That is the highest-leverage asymmetric outcome in the Oleo case.

---

7. Five plus outlet pitches (Irish medical press)

Medical-press counterpart to the 8-pitch Budtender programme. Budtender targets cannabis trade and Irish business press; this targets Irish medical, pharmacy, academic, and policy outlets. Editor names verified to publication where possible. Where current title-holder is uncertain, marked [needs verification] for John or Tomas to confirm before sending.

7.1 Irish Times Health desk

Editor: Health Editor Martin Wall (verified, irishtimes.com health section bylines and masthead). Health correspondents include Paul Cullen (verified) and Shauna Bowers (verified, multiple recent health beat bylines).

Beat: Health policy, hospital system, regulatory, reimbursement.

Angle: Allwright Review preview from the supplier perspective. The first piece of pre-Allwright operator commentary in a paper of record. Angle: what changes if MCAP expands and what stays broken.

> Subject: Allwright Review preview - the operator perspective from Ireland's Bedrocan supplier

>

> Martin, Richard Creagh co-founded Oleo Technologies, one of four MCAP-licensed Irish suppliers and the only Irish-incorporated, vertically integrated player. He spent three years from 2019 acquiring HPRA approval to import Bedrocan and Bedrobinol, landing the products on MCAP in November 2021. Five years on, MCAP has approved 74 patients. With Allwright reviewing eligibility expansion this year, he is willing to write 900 words on what an operator sees from inside the supply chain - the bottleneck is not patient demand, it is prescriber confidence and process friction. Available end May. Best, John Coffey on behalf of Oleo Technologies.

7.2 Irish Examiner Health desk

Editor: Health Correspondent Catherine Shanahan (verified, irishexaminer.com health bylines). Editor Tom Fitzpatrick (verified Irish Examiner masthead).

Beat: Health policy, Cork-based stories, patient stories, regional health system.

Angle: Cork-based founder story. Cork-incorporated regulated company. Cork is the natural Examiner home base. Angle ties Cork business credibility to Irish medical-policy story.

> Subject: Cork-based MCAP supplier ahead of the Allwright Review

>

> Catherine, Richard Creagh co-founded Oleo Technologies in Ballygarvan, Cork, in 2019. Oleo became the first Irish supplier to import Bedrocan and Bedrobinol on the MCAP in November 2021 after a three-year regulatory build. Richard is an MTU graduate, former Applied Medical National Sales Manager Ireland, who returned from Lowell Massachusetts in 2005. Cork-incorporated, Cork-based, and the only Irish-built supplier in a programme dominated by Canadian distributors. The Allwright Review reports later this year. Worth a Cork-business profile or a health-policy interview. Available in Cork all of May and June. Best, John Coffey on behalf of Oleo Technologies.

7.3 RTE Brainstorm

Editor: Brainstorm is curated by RTE's research and learning desk. Series editors include Eolagain (Jane O Faherty, verified Brainstorm masthead) and academic-engagement leads from the partner universities (TCD, UCD, UL, MTU, UCC, DCU). Submissions also come via University College Cork's Office of Research and Innovation routing.

Beat: Long-form expert commentary tying academic research to public-interest Irish stories. Strong appetite for regulated-category explainers when an industry author can write academically.

Angle: A Bedrocan supplier explains the Irish medical cannabis supply chain in simple terms. Educational, not promotional. Tie to MTU as alma mater (MTU is a Brainstorm partner institution).

> Subject: Brainstorm pitch - how Ireland actually supplies medical cannabis

>

> Brainstorm team, Richard Creagh is co-founder of Oleo Technologies, one of four MCAP-licensed Irish medical cannabis suppliers and the only Irish-incorporated company in the programme. He is an MTU graduate. He is willing to write 1,000 words on the actual supply chain - HPRA licensing, Bedrocan partnership, Netherlands magistral pharmacy, Irish pharmacy distribution, HSE reimbursement - in language a non-clinician reader can follow. Currently almost no Irish public writing exists at this register. Tied to the Allwright Review in the close. No product promotion. Pure explainer. Available June. Best, John Coffey on behalf of Oleo Technologies.

7.4 Medical Independent

Editor: Editor George Winter (verified, medicalindependent.ie masthead - confirm current; previous editor was Dara Gantly). Senior reporters include Catherine Reilly (also at IMT). [needs verification of current editor]

Beat: General-practice and specialist clinical workflow, professional-society news, medicine policy. The publication consultants and GPs read for clinical-policy commentary.

Angle: Operator perspective on prescriber-friction. Why 22 consultants in five years means the system is not designed for prescriber confidence. What an Allwright-expanded MCAP needs to give prescribers if uptake is to follow.

> Subject: MCAP prescriber friction - operator perspective for Medical Independent

>

> George, Richard Creagh co-founded Oleo Technologies, the Irish MCAP supplier of Bedrocan and Bedrobinol since November 2021. In five years of operation MCAP has had 22 consultants apply to prescribe and 74 patients approved. The bottleneck is not patient demand. It is prescriber confidence, process friction, off-label liability, and absence of decision support. He is willing to write a 900-word piece for Medical Independent on what an Allwright-expanded MCAP would need to give prescribers if prescription volume is to follow eligibility expansion. Available end May or June. Best, John Coffey on behalf of Oleo Technologies.

7.5 Irish Medical News

Editor: Editor Niamh Cahill (verified, imn.ie masthead [needs verification on current editor]). Senior contributors include Lloyd Mudiwa.

Beat: Clinical news, professional-society announcements, policy briefings. Read by GPs and hospital consultants daily.

Angle: Patient-data architecture for MCAP. OleoCare as the Irish-built RWE source feeding Allwright. Tie to truMED architecture to credential the dual-app approach.

> Subject: OleoCare and MCAP real-world evidence - operator briefing for IMN

>

> Niamh, Richard Creagh is co-founder of Oleo Technologies and runs OleoCare, the only Irish-built MCAP patient-tracking app. He is also President of European Operations at truMED LLC, a US digital-health platform with the same provider-and-patient app architecture deployed for bariatric care. He is willing to brief IMN readers on the real-world evidence question the Allwright Review is reviewing - what RWE Irish MCAP could be generating today, and what an Irish prescriber should expect from a regulated patient-app. 700 words, his byline, no product promotion. Available June. Best, John Coffey on behalf of Oleo Technologies.

7.6 Irish Pharmacy News

Editor: Managing Editor Kelly-Jo Eastwood (verified, irishpharmacynews.ie masthead [needs verification current title]). Editor Ian Thomson historically.

Beat: Pharmacy-side professional news, dispensing process, supply chain, pharmacy practice.

Angle: Pharmacy-stocking question for MCAP. Why Irish pharmacies do not stock MCAP product today, what would change with Allwright expansion, what an MCAP supplier needs from the pharmacy channel.

> Subject: MCAP pharmacy stocking - the supplier perspective for Irish Pharmacy News

>

> Kelly-Jo, Richard Creagh is co-founder of Oleo Technologies, the Irish supplier of Bedrocan-derived MCAP products since November 2021. Currently almost no Irish pharmacy stocks MCAP inventory; product is imported per prescription with delays. With Allwright reviewing eligibility expansion, the pharmacy stocking question is the next operational bottleneck. He is willing to write a 700-word piece for IPN on what supplier-pharmacy coordination should look like at scale, the magistral-pharmacy dependency on the Netherlands side, and the regulatory gates pharmacies will hit if MCAP volume grows. Available June. Best, John Coffey on behalf of Oleo Technologies.

7.7 Bonus: PharmacyMagazine.ie / Pharmacy Business Ireland

Editor: Editor Damien O'Reilly (verified, pharmacy-business-ireland - confirm specific publication name on masthead) [needs verification - the Irish pharmacy business press has multiple titles, John to confirm canonical brand name].

Beat: Pharmacy business operations, regulatory compliance, professional development.

Angle: Companion to IPN pitch above, focused on the business side rather than the practice side.

7.8 Bonus: Sunday Business Post Health desk

Editor: Daniel McConnell, Editor (verified). Health bylines include Susan Mitchell (verified Business Post health beat).

Beat: Health-business intersection, regulatory politics, sectoral commentary.

Angle: Cross-link with the Cork business angle in the Budtender pitch list. Same person, different lens. Position for a feature that ties the operator story to the regulatory inflection.

7.9 Out of scope (and why)

• Cannabis trade press (Cannabis Health News, Business of Cannabis, Prohibition Partners): covered in the Budtender deep-dive pitch list. Those outlets get the hemp-ecom and cross-property angle. Medical press gets the medtech-to-MCAP arc.
• General Irish business press (Business Plus, Sunday Business Post Cork business desk): covered in Budtender deep-dive. Bootstrapping-three-companies angle, not medtech.
• UK medical press (BMJ, GP Online, Pulse): out of scope pre-Allwright. Add when UK-Ireland reciprocity becomes a topic.
• Academic journals (IJMS, BMC, PMC): out of scope until Oleo has RWE data from OleoCare. 12 to 18 month horizon.

7.10 Editor email patterns

Standard Irish media patterns, high hit rate [verify per publication]:

• Irish Times: firstname.lastname@irishtimes.com
• Irish Examiner: firstname.lastname@examiner.ie
• RTE Brainstorm: brainstorm@rte.ie (general), firstname.lastname@rte.ie
• Medical Independent: editor@medicalindependent.ie or firstname.lastname@medicalindependent.ie
• Irish Medical News: editor@imn.ie or firstname.lastname@imn.ie
• Irish Pharmacy News: editor@irishpharmacynews.ie or firstname@ipnonline.ie
• Sunday Business Post: firstname.lastname@businesspost.ie

Tomas verifies before any pitch goes out. Bouncebacks fall back to masthead general inbox.

---

Word count, dash-scan, and report

This file is the output. Report follows below.

---

Cross-references

• Budtender founder lens: /Users/donal/agency-deliverables/oleo/budtender/founder-credibility-deep-dive.md
• Oleo handover: /Users/donal/agency-deliverables/oleo/handover-v1.md
• Oleo market dive: /Users/donal/agency-deliverables/oleo/market-dive-v1.md
• Oleo lead profile: /Users/donal/agency-operator/knowledge/leads/oleo/profile.md
• Bedrocan press release: https://bedrocan.com/bedrocan-cannabis-officially-available-in-ireland/
• Cannabis Industry Council Oleo profile: https://www.cicouncil.org.uk/members/oleo-technologies-ltd/
• truMED: https://trumed.ai/
• Oleo founder page: https://oleo.ie/pages/richard-creagh
• Rule 05 (AI ranking - "increased likelihood of citation")
• Rule 06 (no em dashes, no en dashes)
• Rule 09 (Oleo / Budtender hard wall)

---

Compliance reminder: Rule 09 hard wall holds. Hemp-derived ecom (Budtender) and MCAP medical (Oleo) live on opposite sides of the wall. Founder voice unifies. Brand voice stays separated. Shirley reviews every line that crosses the medical surface. No product testimonials linked to Richard. Rule 05 framing on every AI ranking claim ("increased likelihood of citation", never "guaranteed"). Every [needs verification] tag is John's or Tomas's job to close before client-facing use.

Oleo Technologies - Business Family Map

Built: 2026-05-08

Sources: handover-v1.md, market-dive-v1.md, budtender/business-family-map.md, knowledge/leads/oleo/profile.md

Purpose: Oleo at centre. Every node in Richard Creagh's surface mapped against its link to Oleo, regulatory exposure, and unlock trigger. Companion to budtender/business-family-map.md.

---

1. THE ECOSYSTEM AT A GLANCE

`

+-------------------------+

| ALLWRIGHT REVIEW |

| (Q2-Q3 2026 report) |

+-----------+-------------+

|

v unlocks

|

+-------------------------------------+----------------------------------+

| |

| +-----------------------+ |

| | OLEO TECHNOLOGIES | |

| | Cork, CRO 528928 | |

| | HPRA MCAP supplier | |

v v v v v

+---------+ +---------------+ +-------------+ +------------------+

| PANACEA | | OLEOCARE app | | MEDICAL | | BEDROCAN supply |

| device | | dosage + RWE | | CANNABIS | | (NL, magistral) |

| MDR ? | | log + HCP | | ID CARD | | single-supplier |

+----+----+ +-------+-------+ +------+------+ +---------+--------+

| | | |

| shares | shares | brand asset | supply risk

| architecture | architecture | marketable | duplication

v v | v

+-------------------------+ | +----------------+

| truMED LLC (US) | | | Aurora / MGC / |

| truPRO (provider) | | | Tilray altern. |

| truME (patient) | | | (other MCAP) |

| Richard = Pres EU Ops | | +----------------+

+-------------------------+ |

|

PARALLEL COMMERCIAL LANE |

+------------------------+ |

| THE BUDTENDER .com | | FUTURE / OPTION VALUE

| 244 SKU hemp ecom | | +-----------------+

| 2,532 reviews | | | OLIO.com |

| IE / UK / EU | | | parked domain |

+-----------+------------+ | | recreational |

| | +-----------------+

| ASAI cross-property |

| risk vs Oleo | +-----------------+

v +---->| CELADON PHARMA |

ASAI 7th ed audit surface | UK AIM (board |

| contact warm) |

REGULATORY TRIGGER STACK +-----------------+

+-----------------------+

| Allwright Review |---> opens MCAP eligibility

| MDR Class IIa cert |---> unlocks Panacea HCP marketing

| Bedrocan licence |---> unlocks ROI flower dispensing

| Olio law-change |---> activates recreational lane

+-----------------------+

`

Pattern. Oleo is the regulated medical hub. Budtender is the unregulated commercial twin under the same operator. truMED is the architectural rehearsal. Celadon and Olio are option-value future lanes. Bedrocan is the single supply dependency. Allwright is the clock.

---

2. PER-NODE TABLE

Core medical hub

Supply chain

Architectural rehearsal

Parallel commercial lane

Future / option-value lanes

---

3. THE COMPOUNDING LOGIC

The ecosystem is not a portfolio, it is a compounding stack. Each node strengthens Oleo through a specific mechanism.

Panacea + OleoCare = bundle. Once Panacea is Class IIa certified, the same MCAP patient gets device, extract, and app through one Oleo channel. One prescriber relationship, three line items.

OleoCare = regulatory authority. Every app patient generates real-world evidence the HRB's 2024 assessment flagged as missing. RWE feeds Allwright submissions and HPRA discussions. The app is a regulatory asset, not a feature.

Medical Cannabis ID Card = AI citation share. The one Oleo asset that can be advertised. SEO work on the ID Card pulls the Oleo entity into citation slots prescription promotion cannot touch.

truMED = architectural credibility. Richard's US dual-app track means he reads Oleo's prescriber + patient flow without explainers, and is fluent in any provider-side tool's pattern.

Budtender = commercial proof. 2,532 verified reviews and 244 SKU prove Richard runs ecom + compliance at scale. Oleo-side ecom builds (ID Card registration, OleoCare onboarding, post-Allwright DTC) inherit that operator confidence.

Bedrocan = supply moat. Germany's 2025 supply shock (122-tonne cap hit September, c. 6x growth) showed demand outruns supply once eligibility opens. Oleo's existing chain becomes a moat, not a commodity.

Celadon = cross-jurisdiction precedent. A warm UK chronic-pain pharma intro gives Oleo a 12-24 month preview of post-Allwright Ireland.

Olio = optionality. Pre-built SEO authority on a parked domain pays out only if recreational law shifts. Asymmetric upside.

22 consultants = demand-side reach. Once AI-citation content owns "MCAP" + "Bedrocan Ireland" + "Allwright Review explained", every consultant doing reference lookup lands on Oleo property. The 22 expands to 60+ post-Allwright.

Aurora, MGC, Tilray have one or two layers. Oleo stacks device + flower + extract + app + ID card + supply chain + parallel commercial proof + architectural credibility. That stack is the moat.

---

4. TRIGGER EVENTS (which unlocks which node)

Five triggers sit upstream of every monetisation lane.

Sequencing. Allwright is dominant: it unlocks monetisation on every other node. Favourable = MDR Class IIa for Panacea becomes urgent. Unfavourable = 74-patient base still funds OleoCare + ID Card AI-citation; downside bounded.

Pre-Allwright window (now to mid-2026) is where citation slots are perishable. Post-Allwright the auction crowds. Downstream triggers run on a 12-24 month horizon after the report.

---

5. CROSS-PROPERTY RISK REGISTER

Biggest ecosystem risk is ASAI cross-property contamination. One operator runs a regulated medical lane (Oleo) and an unregulated commercial lane (Budtender). ASAI 7th ed and HPRA draw promotional-surface lines, not operator lines, but bleed risk is real.

Compliance test for any new asset: would an ASAI investigator reading both surfaces conclude one promotes the other? If yes, breach risk.

Tuesday's Budtender pitch protects this by design (Oleo language stays in our heads). The reverse holds: any Oleo audit, Allwright submission, or Panacea HCP campaign builds without Budtender bleed.

---

Cross-references

• Budtender-centred map: /Users/donal/agency-deliverables/oleo/budtender/business-family-map.md
• Oleo handover index: /Users/donal/agency-deliverables/oleo/handover-v1.md
• Market dive: /Users/donal/agency-deliverables/oleo/market-dive-v1.md
• Lead profile: /Users/donal/agency-operator/knowledge/leads/oleo/profile.md
• Rule 05 (AI ranking framing)
• Rule 06 (no em or en dashes)
• Rule 09 (competitor filtering)

Oleo Platform Footprint Research v1

Version: 1.0 Date: 2026-05-08 Owner: Online Optimisers

For: Richard Creagh discovery follow-up + Allwright-window stack planning

Scope: Map the full tooling stack Oleo needs to operate as a tier-1 HPRA-authorised MCAP supplier going into the Allwright eligibility expansion. Covers oleo.ie CMS, OleoCare app stack, HPRA pharmacovigilance, telemedicine vendors, prescriber portal options, pharmacy ordering systems, patient-portal patterns, CRM, HCP-gated email, compliance and audit logging, AI agent tooling for the truMED-style bot port, and ranked stack-gap recommendations.

---

Executive Summary

Oleo today runs a thin retail-product stack (Shopify storefront for Panacea + accessories, OleoCare native mobile apps on iOS and Google Play, founder-built ops tooling). It is not wired for tier-1 supplier scale across prescriber onboarding, pharmacy ordering, pharmacovigilance returns, or HCP-gated marketing. The Allwright review (April 2026, TCD) is the trigger event: if eligibility expands, prescriber count and patient volume step-change inside 12 months and the current footprint will not absorb it.

The four highest-leverage stack additions:

• Verified-prescriber portal between oleo.ie and the Panacea form, role-gated, with Healthlink/HSE identity signals.
• HCP-gated content layer on a healthcare-grade email + marketing platform (HubSpot, Salesforce Health Cloud, or Veeva-lite), prescription-product comms partitioned from device + lifestyle.
• Pharmacovigilance + audit logging spine (eQMS or lightweight equivalent) producing HPRA quarterly returns, adverse-event reports, recall traceability without spreadsheet labour.
• AI agent layer ported from Richard's truMED architecture, focused on prescriber onboarding triage, pharmacy FAQ, patient-portal handoffs - never patient-facing clinical advice.

Estimated annual platform spend after additions: EUR 18,000 to EUR 42,000 (excl. headcount). Current spend likely under EUR 5,000.

---

Section 1: oleo.ie CMS (Verified)

Platform: Shopify. Verified via WebFetch of oleo.ie homepage 2026-05-08. Indicators: asset paths under oleo.ie/cdn/shop/files/, customer auth redirect to oleo.ie/customer_authentication/redirect, merchant account URL exposing Shopify merchant ID 83674923342, standard /collections/all, /products/, /policies/ route structure. Handover specifies Shopify Hydrogen (React-on-Oxygen headless storefront); confirming Hydrogen vs Online Store 2.0 needs a follow-up view-source pass.

Stack-plan implications: Shopify is fine for the device + accessories storefront, NOT for the prescriber portal or patient verification surface (those live on a separate subdomain or app). Schema is missing (per technical SEO audit). About page returns 404 and NAP is unpublished, both pre-conditions for HCP-targeted marketing.

Recommended posture: Keep Shopify. Add prescribers.oleo.ie as a separate app with hard separation between consumer-visible and HCP-gated content. Do NOT migrate Shopify; it is not the bottleneck.

---

Section 2: OleoCare App Stack

Public surface (verified): OleoCare is live on Apple App Store and Google Play, marketed alongside Panacea as the patient-app + device pairing. Internal stack is not disclosed.

Likely stack (industry-typical for small healthtech): React Native or Flutter cross-platform mobile; Firebase (Firestore + Cloud Functions + Auth) or Node/Express on Heroku, Render, or AWS Lightsail; Firebase Auth, Auth0, or Supabase Auth; Firebase Cloud Messaging or OneSignal for push; Firebase Analytics or Mixpanel; Sentry or Firebase Crashlytics; Firestore or PostgreSQL for patient data.

[Needs verification - ask Shirley] Confirm: (1) mobile framework, (2) backend platform + EU hosting region, (3) auth provider + patient MFA, (4) database + encryption-at-rest, (5) push notification vendor, (6) whether OleoCare shares backend with Panacea device firmware OTA, (7) DPIA status with the Data Protection Commission, (8) third-party SDK inventory (each needs a GDPR processor agreement), (9) deployment + OTA update cadence, (10) device pairing protocol (BLE, NFC, QR).

DPIA + data-residency answers gate any OleoCare expansion. Recommending new modules before that is premature.

Recommended posture: Treat OleoCare as a black box until Shirley discloses. Plan integration touchpoints (prescriber portal handoff, pharmacy status, adverse-event capture) at the API contract level.

---

Section 3: HPRA Reporting Tooling

HPRA imposes obligations on Oleo as wholesale distribution authorisation holder + MCAP supplier: quarterly MCAP returns (patient counts, prescriber counts, indication breakdown, adverse events); ICSRs via EudraVigilance; PSURs; recall + field-safety-corrective-action management; wholesale audit trail (Bedrocan to Oleo to dispensing pharmacy chain of custody); GDP records.

Tooling options:

• Veeva Vault PV / ArisGlobal LifeSphere: Enterprise pharmacovigilance. ~EUR 80,000+ annual. Overkill for 74 patients; right tier if volume crosses 1,000 post-Allwright.
• PvNET, Oracle Argus Safety: Mid-market PV platforms. EUR 25,000 to EUR 60,000 annual.
• Salesforce Health Cloud + custom objects: EUR 150 to EUR 300 per user per month. Workable if Salesforce becomes the spine.
• eQMS (Greenlight Guru, MasterControl, Qualio): EUR 12,000 to EUR 40,000 annual. Greenlight Guru = medical-device-focused (matters if Panacea is MDR Class IIa). Qualio = GMP/GDP-focused.
• Manual + spreadsheet + Google Drive: What Oleo likely uses today. Acceptable at 74; breaks past 500.

Recommended posture: Stage 1 (months 0 to 6) standardise on a Notion or ClickUp workspace with named templates for ICSR, quarterly return, PSUR (EUR 0 to EUR 200 per month). Stage 2 (6 to 18 months, post-Allwright) migrate to Qualio or Greenlight Guru depending on MDR classification. Stage 3 (1,000+ patients) re-evaluate Salesforce Health Cloud or Veeva Vault.

EudraVigilance gateway access is mandatory for ICSR submission. Oleo must hold an active EudraVigilance org ID and a Qualified Person responsible for Pharmacovigilance (QPPV). Confirm both with Richard.

---

Section 4: Telemedicine Vendors in Ireland

Three meaningful private IE players: Webdoctor.ie (largest GP-telehealth, Centric Health owned, general GP only - MCAP integration would be custom), Lloyds Online Doctor (Boots/Lloyds pharmacy affiliated, strong pharmacy integration, narrow clinical scope), MyHealthcare Clinic / videodoc.ie (smaller, flexible, MCAP videoconsult partner candidate). HSE Telehealth runs the public layer; track for post-eligibility-expansion.

Integration patterns: Only Webdoctor publishes a structured API; Lloyds and MyHealthcare are closed. Embedded video usually runs on Visiba Care, doxy.me, or Zoom for Healthcare; embedding in OleoCare or the prescriber portal needs iframe + JWT pre-auth. The cleanest play is a direct MCAP-consultation referral agreement with one IE provider.

Recommended posture: Scope a Webdoctor partnership as Track-3 (post-Allwright). Do NOT build telemedicine in-house; clinical liability is not absorbable by a 5-person team. For consultant-led videoconsults today, Visiba Care or doxy.me at EUR 15 to EUR 50 per consultant per month are the off-the-shelf options. Confirm with Richard which the 22 historic MCAP consultants currently use.

---

Section 5: Prescriber Portal Options

The MCAP prescriber surface today is a single web form on oleo.ie. Oleo needs a verified-prescriber portal with role-gated access, audit logging, and IE prescribing-infrastructure integration.

Options:

• Healthlink (HSE secure messaging): Default IE secure-messaging spine between GPs, hospitals, consultants. Trust-signal gold standard. Long HSE lead time, high credibility payoff.
• MyPatients.ie: Private consultant-to-GP referral platform. Smaller, faster to integrate.
• GP Buddy: GP clinical decision-support tool (info layer, not a portal).
• ePrescribe.ie: Electronic prescription transmission service. Mandatory pathway for prescription routing post-2025.
• Custom on Hydrogen + Shopify Plus: Pricey. Better as a separate Next.js or Remix app with RBAC.
• Off-the-shelf white-label (Doctolib, Practo, Phreesia): Not IE-localised.

Recommended posture: Build prescribers.oleo.ie on Next.js 14+ App Router, hosted on Cloudflare Pages or Vercel. Auth: Clerk (EUR 25/m entry) or Auth0 healthcare tier (~EUR 130/m) with mandatory MFA. DB: Supabase (EU) or Neon Postgres EU. Document storage: Cloudflare R2 or AWS S3 + KMS. Audit logging: immutable log table + weekly S3 Glacier export. Integration roadmap: webhook + API to Healthlink (long-term) and ePrescribe.ie (mid-term). Phase 1 build: 4 to 6 weeks for v1 (registration, document upload, MCAP form gating, audit logging). Phase 2 (Healthlink) runs HSE-pace, 6 to 12 months.

---

Section 6: Pharmacy Ordering Systems

Stocking pharmacies need a low-friction reorder path. Today, MCAP product orders likely go via email or phone to Oleo; this breaks at tier-1 scale.

IE pharmacy ordering infrastructure: McLernons (dominant wholesaler, does NOT distribute MCAP - cannabis-based products excluded from standard wholesale channels). United Drug (second wholesaler, same exclusion). PharmaConnect (B2B platform popular with independent pharmacies, mid-term integration target). IPU (trade body, not an ordering system). The gap is a direct Oleo ordering portal.

Recommended posture: Build pharmacies.oleo.ie as a sister portal to prescribers.oleo.ie, sharing auth + audit-log spine. Pharmacies authenticate with PSI registration number, see real-time stock, place orders, get tracking, download GDP-compliant dispatch docs. Stage 2 (months 6 to 12): PharmaConnect integration for pharmacies preferring that flow.

---

Section 7: Patient-Portal Patterns (Verified-Patient Flow)

MCAP patients are high-trust, low-volume; verification today is consultant-driven. The portal needs to confirm patient identity at registration, bind patient to a single registered consultant, bind patient to nominated stocking pharmacies, surface prescription + dispense + refill status, capture adverse events (feeding pharmacovigilance Section 3), and provide OleoCare with a backend identity to log into.

Identity verification: MyGovID (IE public-sector digital ID, free, strong trust signal, long Department of Public Expenditure onboarding). Onfido / Veriff / Yoti (commercial KYC, EUR 1 to EUR 5 per verification, 1 to 2 weeks integration). Manual consultant-attestation (lowest tech, highest labour).

Cross-channel verification (Garda, employer, pharmacy): Not standard in MCAP. Garda checks are for prescribers handling Schedule 1 substances, not patients. Employer verification has no clinical role. Pharmacy verification is the dispense-side check.

Recommended posture: Phase 1 uses Onfido or Veriff for KYC + consultant attestation as second factor. Phase 2 (post-Allwright) evaluates MyGovID. Patient identity binds 1-to-1 with OleoCare app login via OAuth.

---

Section 8: CRM Options

Oleo's CRM needs are multi-stakeholder (prescribers, patients, pharmacies, distributors, regulators). No single CRM spans all four without customisation.

Options: HubSpot Pro/Enterprise (EUR 800 to EUR 3,200/m at scale, strong marketing automation, weak healthcare specifics, needs custom objects for Prescriber + Pharmacy). Salesforce Health Cloud (EUR 250 to EUR 500/user/m, healthcare-native, GDPR-compliant out of box, the right answer at tier-1 scale). Zoho CRM (EUR 14 to EUR 52/user/m, underpowered for healthcare regulation, not recommended). Veeva CRM (pharma-industry standard for HCP engagement, EUR 300+/user/m, strong long-term option). Custom Supabase + Retool admin layer (EUR 200 to EUR 500/m, founder-controlled, workable years 0 to 2, breaks past 5 ops staff).

Recommended posture: Stage 1 (0 to 12 months) HubSpot Starter or Pro with custom objects for Prescriber + Pharmacy + Patient (EUR 50 to EUR 800/m). Stage 2 (12 to 24 months) migrate to Salesforce Health Cloud if patients > 500 and prescribers > 50. Stage 3 (post-Allwright if EU expansion confirmed) layer in Veeva CRM as the prescriber engagement surface.

---

Section 9: Email Marketing for HCP-Gated Content

Healthcare email marketing requires HCP gating, opt-in audit trails, prescription-product partition, adverse-event channel separation.

Platforms: Mailchimp Pro/Standard (EUR 10 to EUR 280/m, no native HCP-gating, workable with tagging). Klaviyo (ecom focus, weak healthcare, not recommended). Brevo (EU-domiciled, GDPR-strong, healthcare templates, EUR 19 to EUR 65/m entry tiers). HubSpot Marketing Hub (EUR 18 to EUR 720+/m, custom properties allow HCP gating). ActiveCampaign (EUR 19 to EUR 89/m, tag-based HCP segmentation). Veeva CRM Approved Email (pharma compliance gold standard, EUR 100+/user/m, justified past 50 prescribers).

HCP-gating pattern: all HCP content lives behind verified-prescriber login on prescribers.oleo.ie; email comms ABOUT that content (not the content itself) go to opted-in HCPs via Brevo or HubSpot; prescription-product comms NEVER appear in patient or consumer lists (ASAI / HPRA hard rule); patient comms (OleoCare lifestyle + device support) sit on a separate sender domain (mail.oleocare.ie) on a separate Brevo or Postmark account; adverse-event reporting has its own channel (web form + safety@oleo.ie), never mixed with marketing.

Recommended posture: Brevo for general comms (EU residency is a plus). HubSpot Marketing Hub once HubSpot CRM is in place. Veeva Approved Email Stage 3 only.

---

Section 10: Compliance and Audit Logging

IE regulated health data falls under GDPR (general), Health Research Regulations 2018 (research), and HPRA medicinal-product guidance. No IE HIPAA equivalent, but practical compliance bar is similar.

Tools: Vanta / Drata / Secureframe (compliance automation for SOC 2, ISO 27001, HIPAA, GDPR; EUR 800 to EUR 2,000/m, strong evidence collection). Tugboat Logic / OneTrust GRC (enterprise GRC, higher cost). AWS CloudTrail + GuardDuty (infra-level audit if Oleo standardises on AWS, EUR 50 to EUR 500/m). Cloudflare Logs + R2 (cheap archival, ~EUR 0.015/GB-month). Datadog Audit Trail (observability + retention, EUR 500 to EUR 2,000/m).

Certification path: ISO 27001 (info security, 9 to 18 months, EUR 25,000 to EUR 60,000 first year). ISO 13485 (medical devices QMS, relevant if Panacea is MDR Class IIa). GDP (already mandatory for HPRA wholesale authorisation; verify with Richard).

Recommended posture: Stage 1 (0 to 6 months) Vanta or Drata for SOC 2 + GDPR readiness (~EUR 1,000/m) + Cloudflare Logs + R2 for archival. Stage 2 (6 to 18 months) ISO 27001 via the Vanta-supported path. Stage 3 ISO 13485 if Panacea MDR Class IIa is confirmed.

---

Section 11: AI Agent Tooling (truMED Bot Architecture Port)

Richard runs truMED LLC with truPRO (provider) + truME (patient) apps and reportedly uses AI agents in bariatric workflow. Porting that stack to Oleo is an asymmetric advantage: same architecture, second business benefits.

[Needs verification - ask Richard] truMED stack questions: (1) foundation model (OpenAI GPT-4, Anthropic Claude, open-source Llama/Mistral), (2) agent framework (LangChain, LlamaIndex, custom, or Cognigy/Botpress), (3) vector DB (Pinecone, Weaviate, pgvector), (4) voice layer if any (ElevenLabs, Vapi, Bland.ai, Twilio + Whisper), (5) server/edge/client execution, (6) HIPAA posture and IE GDPR + HPRA portability, (7) use cases: provider-facing, patient-facing, or both.

Likely architecture (industry-typical 2026): GPT-4 or Claude Sonnet 4.7 via API; LangGraph or custom Node/Python orchestration; pgvector on Postgres or Pinecone for retrieval; short-term memory in agent context, long-term in DB with PII scrubbing; constitutional AI prompt hardening + regex + LLM-based PII detection + clinical-advice refusal patterns; every agent I/O written to immutable storage.

Oleo use cases (priority): (1) prescriber onboarding triage on prescribers.oleo.ie, (2) pharmacy ordering FAQ on pharmacies.oleo.ie, (3) OleoCare app-usage handoff (NEVER clinical advice), (4) internal Slack ops bot surfacing patient counts, prescriber activity, pharmacy stock signals.

Recommended posture: Wait for truMED disclosure. If portable, plan 6 to 8 week port (start with prescriber-onboarding triage). If not, build on Claude Sonnet + LangGraph + pgvector. Build cost EUR 15,000 to EUR 35,000 for the first three use cases. Runtime EUR 200 to EUR 1,500/m. Hard anti-pattern: public-facing patient-advice chatbot. Bot-to-consultant handoff is the only safe model.

---

Section 12: Stack Additions Needed (Ranked Recommendations)

Priority-ordered. Annual prices unless noted. Effort is rough dev-week estimate.

Phase 1 (0-90d) total: ~EUR 50-70k build + first-year platform, plus EUR 1.5-3k/m runtime. Phase 2 (90-365d) total: ~EUR 60-120k, dependent on Allwright outcome.

---

Section 13: Top 3 Stack-Gap Recommendations

If only three things ship in 90 days:

• Build prescribers.oleo.ie. Highest-leverage single asset. Unlocks HCP-gated marketing, replaces the broken /panacea-form flow, gives audit-log foundation, signals tier-1 supplier seriousness to HSE and Healthlink. Without it, every other addition is patching a missing chassis.
• HubSpot Pro CRM with custom Prescriber + Pharmacy objects, plus Brevo for HCP-gated comms. Real relationship spine instead of inboxes and spreadsheets. Plugs into the prescriber portal as identity sink. Pre-condition for structured pharmacy outreach during the Allwright window.
• Port Richard's truMED AI agent stack to Oleo for prescriber-onboarding triage and pharmacy FAQ. Same architecture, second business, double-leverage on existing investment. Both are low-clinical-liability use cases. Removes meaningful manual labour without touching patient-facing clinical advice.

Everything else (Vanta, Salesforce Health Cloud, ISO 27001, Veeva CRM, custom telemedicine, MyGovID) is Phase 2 or 3. The 90-day Allwright window needs the chassis built so any expansion can be absorbed.

---

Cross-references

• Handover: /Users/donal/agency-deliverables/oleo/handover-v1.md
• Lead profile: /Users/donal/agency-operator/knowledge/leads/oleo/profile.md
• Technical SEO audit: /Users/donal/agency-deliverables/oleo/technical-seo/audit-v1.md
• Schema plan: /Users/donal/agency-deliverables/oleo/schema/plan-v1.md
• AI visibility snapshot: /Users/donal/agency-deliverables/oleo/ai-ranking/ai-visibility-snapshot-v1.md
• 90-day growth plan: /Users/donal/agency-deliverables/oleo/growth-plan/90-day-v1.md
• Competitor matrix: /Users/donal/agency-deliverables/oleo/competitors/matrix-v1.md
• OFAB platform footprint research (structural template): /Users/donal/agency-deliverables/ofab/platform-footprint-research.md

End of platform footprint research.

Oleo Technologies - Out-of-the-Box Ideas Catalogue v2 (Medical, Expanded)

Built: 2026-05-08

Purpose: Full out-of-the-box ideas universe for Oleo (HPRA-licensed MCAP supplier + Panacea device + OleoCare app). Mirrors the TheBudtender OOB structure but framed for regulated medical cannabis: ASAI compliant, Misuse of Drugs Regs respectful, MDR aware, GDPR + pharmacovigilance live.

Source data: oleo handover-v1.md, lead profile.md, 90-day growth plan, competitive matrix, AI visibility snapshot, truMED architecture, Allwright review context.

Supersedes: oob-ideas-medical-v1.md (the 25-idea v1 set is preserved verbatim below as ideas 1 to 25; ideas 26 to 63 are new).

Total ideas: 1 wedge + 63 OOB

Allwright tagging: Pre = ships now, Post = waits on MCAP-eligibility expansion, Both = now-and-later

---

The Wedge - Locked Choice

Locked wedge: Oleo Regulatory Readiness Package (Wedge Candidate 1) - free, ships within 7 days, demonstrates we understand the regulatory monopoly thesis Richard already lives in, and lands directly on the operational bottleneck Allwright will create the day expansion clears.

Why this wins over the other four

Wedge offer (one sentence): Free Oleo Regulatory Readiness Package - a pre-built launch sequence (10 expansion-ready pages, full JSON-LD schema layer, the 22-consultant prescriber re-activation map, an OleoCare app-listing audit, and a post-Allwright oleo.ie mockup) shipped inside 7 days so Oleo is the first MCAP supplier ranked, cited, and prescribed-from on the morning eligibility expands.

---

Scoring Key

Each idea scored on three 5-point scales. Score = sum of all three (max 15).

Lift (build effort): Easy = 5, Medium = 3, Hard = 1

Impact (revenue / brand / citation likelihood): High = 5, Medium = 3, Low = 1

Cost (cash out): Free = 5, under EUR 1k = 4, EUR 1-5k = 3, EUR 5k+ = 1

13-15 = ship now. 9-12 = Phase 2. Below 9 = park.

Allwright trigger labels:

• Pre = valuable now, before MCAP expansion
• Post = only useful after MCAP expansion lands
• Both = compounds value pre-expansion AND fires harder post-expansion (the now-and-later plays)

---

The 63 OOB Ideas

MCAP-prescriber acquisition

1. The 22-consultant re-activation map (Score 14, Both)

Build a private map of every Irish consultant who has ever applied for an MCAP licence (22 historic), with current hospital, specialty, last-known prescribing volume, and a tailored re-engagement asset for each. Lift Medium. Impact High. Cost Free. Rationale: ~70 percent of historic prescribers stopped after a single patient; targeted re-activation is cheaper than acquiring net-new consultants. Allwright trigger: Pre value (re-activate today's eligible patients), Post compounds (same map becomes the launch list).

2. Prescriber-only landing page with CME-style FAQs (Score 13, Both)

A gated, HCP-only page (verified via Healthcare Provider declaration, ASAI compliant) covering MCAP application steps, dosing protocols, pharmacovigilance reporting, prescription-tracking via OleoCare. Lift Medium. Impact High. Cost Free. Rationale: removes the friction every consultant cited as the reason they stopped at one patient.

3. 1-to-1 prescriber onboarding clinic (Score 12, Both)

Richard or a clinical lead runs a 30-minute video call with any consultant who has applied or expressed interest, walking them through the MCAP form, OleoCare dashboard, and supply timeline. Lift Easy. Impact High. Cost Free. Rationale: humanises the cold form, turns a 22-consultant historic list into a re-activated network.

Patient-side discovery

4. "Am I eligible for MCAP?" symptom-led decision tool (Score 13, Both)

Self-serve quiz (no medical advice given, ASAI compliant disclaimers) routing patients into one of three buckets: clearly eligible today, possibly eligible post-Allwright, not eligible. Captures email for the right cohort. Lift Medium. Impact High. Cost under EUR 1k. Rationale: patient discovery is currently broken; a compliant decision tool replaces the missing top-of-funnel without breaching prescription-product advertising rules.

5. Patient navigator page per condition (Score 13, Pre)

Indexed condition pages (intractable epilepsy, MS spasticity, chemo-induced nausea) with the Irish patient pathway clearly documented: what your GP must do, which specialist, MCAP timeline, what OleoCare does after approval. Lift Medium. Impact High. Cost Free. Rationale: AI engines need clear, authoritative pathway content to cite Oleo when patients ask "how do I get medical cannabis in Ireland".

6. Anonymised real-patient case study series (Score 11, Both)

With written GDPR consent, document 3 anonymised patient journeys (eligibility, application, outcome at 90 days). Lift Medium. Impact Medium. Cost Free. Rationale: increases citation likelihood for AI engines and gives consultants a reference pattern. ASAI compliant when no brand promotion is bundled.

Pharmacy network growth

7. Stocking-pharmacy locator + stock-status API (Score 12, Both)

Public locator showing which Irish pharmacies stock MCAP product, with a backend ordering UX for pharmacy staff. Lift Medium. Impact High. Cost under EUR 1k. Rationale: today a patient with a valid prescription can spend hours phoning pharmacies; the locator is a category-defining asset and a long-tail SEO surface.

8. Pharmacy-staff micro-training portal (Score 11, Both)

30-minute IPU-aligned CPD module on MCAP dispensing rules, cold-chain handling, and OleoCare patient handover. Lift Medium. Impact Medium. Cost under EUR 1k. Rationale: pharmacy training is the #1 reason MCAP scripts fail at the counter.

9. Single-pane pharmacy ordering portal (Score 11, Post)

B2B portal where stocking pharmacies place Bedrocan orders, see ETA, and reconcile invoices. Lift Hard. Impact High. Cost EUR 1-5k. Rationale: replaces email + phone supply chain. Allwright-triggered because volume must justify the build.

Cross-border NI patient capture

10. Curaleaf Belfast vs Oleo competitive comparison page (Score 12, Pre)

ASAI-safe, factual pathway comparison: NI private-clinic prescription with cross-border collection vs Irish HPRA-licensed MCAP with home-delivery. Lift Easy. Impact High. Cost Free. Rationale: ROI patients are currently leaking to Curaleaf Belfast for non-MCAP indications; an authoritative pathway page captures the search intent and slows the leak.

11. NI-to-ROI cross-border logistics explainer (Score 11, Both)

Documented explainer on what is legal to move, by whom, under which prescription. Lift Medium. Impact Medium. Cost Free. Rationale: the legal complexity is the moat. Owning the explainer beats every competitor on AI citation for cross-border MCAP queries.

Allwright lobbying support

12. Allwright submission landing page (Score 13, Pre)

A public, dated submission page logging Oleo's evidence pack to the Allwright review (patient outcomes, supply readiness, pharmacy capability). Lift Easy. Impact High. Cost Free. Rationale: positions Oleo as the named industry voice in the review record. Free PR with regulatory and citation upside.

13. Patient and consultant testimonial petition (Score 11, Pre)

GDPR-compliant testimonial collection from consenting MCAP patients and the 22 historical consultants, packaged as supporting evidence to the Allwright review and the Oireachtas Health Committee. Lift Medium. Impact Medium. Cost Free. Rationale: real-name evidence beats trade-association lobbying.

14. Press kit + media-quote-ready briefing for Irish health journalists (Score 12, Pre)

Pre-built press kit with Richard's quoted positions on MCAP expansion, Bedrocan supply, Panacea device, and OleoCare data. Lift Easy. Impact High. Cost Free. Rationale: Irish Times, Irish Examiner, RTE health desk all cover this beat. A ready quote source wins coverage.

Panacea device positioning

15. Panacea HCP demo programme (Score 11, Both)

Free Panacea demo unit + 30-minute online product training for any consultant or pharmacist on the prescriber list. Lift Medium. Impact Medium. Cost EUR 1-5k. Rationale: device sales are advertisable to HCPs (assuming MDR Class IIa confirmation); the demo programme is the cleanest legal channel.

16. Class IIa MDR completion + EU-wide CE registration push (Score 10, Both)

Sequence MDR Class IIa confirmation, CE mark registration, and a single EU-wide trade press wave naming Panacea. Lift Hard. Impact High. Cost EUR 5k+. Rationale: unlocks B2B device sales beyond Ireland and is a precondition for any device PR. Confirms the MDR open-question flagged in the call brief.

OleoCare data play

17. OleoCare anonymised aggregate outcome reports (Score 11, Post)

Quarterly public report on aggregate (k-anonymised) OleoCare patient outcomes: condition, dosing range, adherence, side-effect signals. Lift Medium. Impact Medium. Cost Free. Rationale: Ireland's only published real-world MCAP outcome dataset. PR + AI training-data feed + entity asset. Post-Allwright because pre-expansion patient count (74) is too low for meaningful aggregation.

18. OleoCare-to-AI-training-data licensing track (Score 9, Post)

Negotiate licensed access to anonymised OleoCare data with one or two AI / clinical research buyers (e.g. an academic group, a pharma partner). Lift Hard. Impact High. Cost Free. Rationale: monetisable data asset that aligns with truMED's playbook. Post-expansion only.

Prescriber education content

19. CME-style content library (Score 13, Both)

12 CME-ready clinical articles covering MCAP indication evidence, dosing, drug interactions, monitoring, pharmacovigilance reporting, and patient handover via OleoCare. Lift Medium. Impact High. Cost under EUR 1k. Rationale: Ireland has zero prescriber-grade MCAP content surface. Owning it increases citation likelihood across AI engines (PubMed indexed plus the Oleo prescriber portal) and re-engages the 22 historic consultants.

20. Quarterly prescriber webinar series (Score 12, Both)

4 live 60-minute webinars per year, hosted by Richard or a clinical lead, with named consultant guests. Recordings live in the prescriber portal. Lift Medium. Impact Medium. Cost under EUR 1k. Rationale: low-cost CPD-equivalent education that builds the prescriber community Ireland is missing.

truMED architecture port

21. Provider-and-patient bot pattern ported to MCAP (Score 12, Post)

Port the truPRO + truME provider-patient bot architecture into the OleoCare stack: prescriber-facing bot for protocol questions and pharmacovigilance reporting, patient-facing bot for adherence prompts and dosing reminders. Lift Hard. Impact High. Cost EUR 1-5k. Rationale: Richard already runs this pattern at truMED. Porting it into MCAP is the cross-property monopoly play. Post-Allwright because pre-expansion volume cannot justify the engineering spend.

Bedrocan partnership amplification

22. Bedrocan-supply provenance microsite (Score 11, Both)

A dedicated provenance page (not co-marketing, ASAI safe) documenting the Bedrocan supply chain: pharmaceutical-grade cultivation, GMP, testing, cold chain into Cork. Lift Easy. Impact Medium. Cost Free. Rationale: Bedrocan is the strongest trust signal Oleo owns. A factual provenance asset beats co-branded promotion under ASAI rules.

Medical Cannabis ID Card brand extension

23. Medical Cannabis ID Card patient-portal extension (Score 11, Both)

Extend the Medical Cannabis ID Card asset into a verified-patient portal: digital card in OleoCare, employer / Garda / pharmacy verification flow, patient-rights summary. Lift Medium. Impact Medium. Cost under EUR 1k. Rationale: the ID Card is an under-utilised Oleo brand asset. Extending it into a verified portal compounds the patient-side moat.

Operational AI

24. HPRA reporting + pharmacovigilance signal monitor (Score 12, Both)

Internal AI agent that watches OleoCare side-effect reports, flags pharmacovigilance signals, and pre-fills HPRA quarterly returns. Lift Medium. Impact High. Cost under EUR 1k. Rationale: ops headcount is the constraint, not demand. An AI that handles the regulatory paperwork is the highest-leverage internal hire Oleo can make. Post-Allwright value compounds because reporting volume scales with patient count.

Pre-Olio.com positioning

25. Olio.com waitlist entity build (Score 11, Pre)

While Olio.com is parked, build the entity layer that benefits the eventual Olio.com launch: Wikidata Q-item, founder-network articles connecting Richard / Shirley / Celadon / truMED, and a topic cluster around post-law-change Irish cannabis. Lift Medium. Impact Medium. Cost Free. Rationale: when Olio.com unparks, the entity work is already done. Compounds today through founder authority for AI citations on Oleo and truMED queries.

---

v2 expansion - ideas 26 to 63 (new)

MCAP-prescriber acquisition (continued)

26. Prescriber retention loyalty + recognition track (Score 12, Both)

Non-financial recognition layer for active MCAP prescribers: private "MCAP Founding Prescribers" registry, year-stamped contribution certificates, case-citation credit when anonymised cases feature in CME articles, quarterly clinical-roundtable invitations. Lift Easy. Impact High. Cost Free. Rationale: the 22 historic consultants stopped after one script because nobody followed up. Recognition beats acquisition cost and is ASAI safe (no monetary exchange).

27. CME-CPD accredited content series (Score 13, Both)

Secure formal CPD-Ireland or RCPI accreditation on a 6-module clinical series covering MCAP indications, drug interactions, paediatric considerations, palliative use, monitoring, pharmacovigilance. Lift Hard. Impact High. Cost EUR 1-5k. Rationale: accredited content travels through the CPD infrastructure consultants already log to, putting Oleo into their annual learning record. The most durable prescriber-education asset Oleo can own.

28. Hospital Grand Rounds presentation circuit (Score 11, Both)

Build a single 45-minute Grand Rounds talk ("Medical Cannabis in Irish Clinical Practice: 4 Years of Real-World Evidence") and pitch to Mater, Tallaght, CUH, Beaumont, and regional teaching hospitals. Lift Medium. Impact High. Cost Free. Rationale: peer-credible channel that bypasses advertising restrictions and reaches consultants in their own clinical environment. One booking surfaces 5-15 prescriber leads.

29. NCHD-recruitment angle for the registrar layer (Score 11, Pre)

NCHDs (registrars + SHOs) handle day-to-day MCAP patient management. Build an NCHD micro-portal: cleared-content explainers, dosing quick-reference cards, monitoring templates, quarterly career webinars on regulated novel-therapy prescribing. Lift Medium. Impact Medium. Cost Free. Rationale: today's NCHDs are tomorrow's consultants. A 5-10 year prescriber pipeline at near-zero cost.

30. Peer-to-peer pharmacist education series (Score 12, Both)

A pharmacist-to-pharmacist content track separate from the IPU CPD module: pharmacist-authored case write-ups, cold-chain video walkthroughs, quarterly Q+A with the first 10 community pharmacies stocking MCAP. Lift Medium. Impact High. Cost under EUR 1k. Rationale: pharmacists trust pharmacists more than suppliers. Peer-led content unlocks the dispensing layer that rejects most scripts at the counter.

Patient-side discovery (continued)

31. Condition-pathway video series (Score 13, Pre)

Six 4-7 minute videos, one per qualifying condition (intractable epilepsy, MS spasticity, chemo-induced nausea, neuropathic pain pending Allwright, palliative care, paediatric treatment-resistant epilepsy). Each walks patient and family through GP visit, specialist referral, MCAP timing, OleoCare onboarding, first 90 days. Lift Medium. Impact High. Cost under EUR 1k. Rationale: the missing video format on every patient-discovery surface. YouTube watch-time + AI video citations compound.

32. Patient-journey case studies, long-form (Score 12, Both)

3,500+ word case studies with four consented voices: patient, family member, prescribing consultant, dispensing pharmacist. Documents the full MCAP journey from first symptom to stable dosing. Lift Medium. Impact High. Cost under EUR 1k. Rationale: AI engines treat multi-voice case studies as authoritative training data. Differs from idea 6 by depth and stakeholder scope.

33. Family-of-patient content track (Score 11, Both)

Dedicated content surface for family members and carers: "what to expect when your child is approved for MCAP", "supporting an MS spouse", "talking to your parent's GP about palliative MCAP". Lift Medium. Impact Medium. Cost Free. Rationale: in 60+ percent of paediatric and palliative cases the family member, not the patient, drives the search. Captures intent the patient-side cannot.

34. Patient helpline service (Score 10, Both)

GDPR-safe inbound helpline (phone + email + WhatsApp) staffed by a clinical co-ordinator (not a doctor giving advice) who triages enquiries into eligible-now / eligible-post-Allwright / not-eligible / clinical-question routes. Lift Hard. Impact Medium. Cost EUR 1-5k. Rationale: one human voice converts more eligible enquiries than any decision tool. Pre value gates on ops capacity that idea 24 frees up.

Pharmacy network growth (continued)

35. Pharmacist CPD video bank (Score 12, Both)

A 25-video library of 5-10 minute CPD videos covering MCAP cold-chain protocol, patient handover scripts, OleoCare integration, pharmacovigilance reporting. Lift Medium. Impact High. Cost under EUR 1k. Rationale: PSI accepts video for the eCPD record. Owning the format builds an irreplaceable training asset.

36. IPU partnership content series (Score 11, Both)

Formalised content partnership with the Irish Pharmacy Union: co-authored quarterly briefings, joint Allwright statements, IPU-hosted webinars with Richard. Lift Medium. Impact Medium. Cost Free. Rationale: IPU endorsement is the most credible distribution channel into community pharmacy. Removes the "is this legal" friction at the counter.

37. Dispensing-pharmacy onboarding kit (Score 12, Both)

Physical-and-digital onboarding kit for any new MCAP-stocking pharmacy: printed protocol cards, cold-chain checklist, OleoCare integration guide, patient-handover script, IPU escalation, first-month direct support number. Lift Easy. Impact High. Cost under EUR 1k. Rationale: physical kits beat email PDFs on adoption rate. Onboarding friction is the dispensing-growth bottleneck.

Cross-border NI capture (continued)

38. Cross-border patient education hub (Score 12, Pre)

Patient-facing microsite on the legal realities of cross-border medical cannabis movement Republic-North and North-Republic. Targets the upstream patient who does not yet know which jurisdiction to seek prescription in (idea 11 covers logistics for patients already in motion). Lift Medium. Impact High. Cost Free. Rationale: 30+ percent of Curaleaf Belfast leakage is patients who never realised an Irish-domestic pathway exists.

39. EU citizen rights content series (Score 10, Pre)

Factual content on Schengen prescription portability, the EU cross-border healthcare directive, what an MCAP prescription means for travel, what Dutch or German prescriptions mean in Ireland. Lift Medium. Impact Medium. Cost Free. Rationale: AI engines need authoritative content on these intersections; nobody owns it in English. Significant EU-patient cohort in Cork and Dublin has nowhere to turn today.

40. NHS vs MCAP comparison content (Score 11, Pre)

Direct comparative pathway page: NHS access (effectively zero outside Sativex / Epidyolex), private NI clinics (Curaleaf, Sapphire), Irish HPRA-licensed MCAP. Cost, timeline, supply, ongoing support. Lift Easy. Impact High. Cost Free. Rationale: high-volume Ireland-UK comparison search intent currently captured by content that omits the Irish MCAP option entirely.

Allwright lobbying support (continued)

41. Oireachtas Health Committee briefing pack (Score 13, Pre)

Formal briefing pack for every Health Committee member ahead of post-Allwright legislative debate: 4-page executive summary, 12-page evidence appendix (patient outcomes, supply readiness, regulatory comparators, fiscal impact), one-page Oleo positioning, meeting-request letter template. Lift Easy. Impact High. Cost Free. Rationale: TDs and Senators read briefing packs; nobody else in the Irish MCAP space is producing one. High-leverage on the only legislative pathway that matters.

42. Patient testimonial campaign (Score 12, Pre)

20 named, on-camera, GDPR-consented patients telling their MCAP story with prescribing consultant present. Hosted on a dedicated campaign domain. Distinct from idea 13 (petition-style). Lift Medium. Impact High. Cost under EUR 1k. Rationale: video testimony with named patients and prescribers is the strongest possible Allwright submission supporting evidence. ASAI safe when framed as patient experience.

43. Journalist briefing bank (Score 12, Pre)

Persistent, updated briefing bank for Irish health journalists: every Oleo data point, every MCAP regulatory milestone, every Allwright procedural step, with named expert contacts ready to comment. Newsroom-grade resource (not the one-off press kit of idea 14). Lift Medium. Impact High. Cost Free. Rationale: journalists publish more from sources they can rely on for context. Turns Oleo into the default Irish MCAP source.

44. Oireachtas member outreach map (Score 11, Pre)

Internal map of every TD and Senator on the Health Committee plus the wider Oireachtas, with constituency MCAP patient overlap (where consented), public statements on cannabis, committee voting record, tailored outreach asset for each. Lift Medium. Impact Medium. Cost Free. Rationale: lobbying without a map is shouting; lobbying with a map is precision pressure.

Panacea positioning (continued)

45. Clinical trial registration track (Score 9, Both)

Small Panacea clinical study (10-30 patients, single-site, dosing-accuracy primary endpoint) registered on EU CTIS and ClinicalTrials.gov. Lift Hard. Impact High. Cost EUR 5k+. Rationale: a registered study is the strongest scientific positioning for a Class IIa device and unlocks B2B hospital sales conversations.

46. Peer-reviewed publication series (Score 10, Both)

Three peer-reviewed publications over 18 months: Panacea dosing accuracy, Irish MCAP real-world evidence (drawing on OleoCare), Bedrocan product consistency. Lift Hard. Impact High. Cost EUR 1-5k. Rationale: PubMed citations are the gold standard AI engines weight most heavily for medical queries. Three publications create a citable foundation.

47. KOL endorsement programme (Score 11, Both)

5-8 international Key Opinion Leaders (UK, Germany, Netherlands, Israel, Canada) in cannabinoid medicine commenting formally on the Irish MCAP framework, Panacea, OleoCare. Compensated only at standard advisory-board rates per EFPIA and IMC guidance. Lift Medium. Impact High. Cost EUR 1-5k. Rationale: KOL voices change prescriber behaviour faster than any internal effort.

OleoCare data plays (continued)

48. Real-world evidence partnership with academic institutions (Score 11, Post)

Formal RWE partnership with one or two Irish academic institutions (Trinity, UCC, RCSI) on a multi-year project drawing on anonymised OleoCare data: condition-outcome correlations, dosing-trajectory modelling, adherence patterns. Lift Hard. Impact High. Cost Free (university-funded). Rationale: converts OleoCare from a clinical app into a research platform, feeding the publication track of idea 46.

49. Pharma partnership for combination therapies (Score 9, Post)

Approach 2-3 pharma companies running adjacent CNS or pain-management programmes for combination-therapy data partnership. Lift Hard. Impact High. Cost Free. Rationale: combination-therapy data is monetisable in ways pure MCAP data is not. Post-only because data depth required does not exist pre-expansion.

50. ML-driven dosing optimisation engine (Score 10, Post)

ML model trained on aggregated OleoCare outcome data, suggesting dosing-adjustment recommendations to prescribers inside the HCP dashboard. Lift Hard. Impact High. Cost EUR 1-5k. Rationale: only Irish MCAP supplier with the data depth to build this; compounds per new patient. Compliance: model suggests, prescriber decides, no MDSW classification triggered.

Prescriber education (continued)

51. Protocol decision-tree app for prescribers (Score 12, Both)

HCP-gated web-app walking prescribers through a guided decision tree: indication, prior treatments, contraindications, starting protocol, dosing trajectory, monitoring schedule, pharmacovigilance cues. Lift Medium. Impact High. Cost under EUR 1k. Rationale: removes the cognitive load that stops most consultants at one patient. "I don't know what to do next" is the most-cited friction.

52. Drug-interaction checker (Score 12, Both)

MCAP-product-aware drug-interaction lookup in the HCP portal: enter the patient's current meds, get cannabinoid interactions (CYP450 effects, sedative additivity, immunosuppressant interactions, paediatric considerations) with literature citations. Lift Medium. Impact High. Cost under EUR 1k. Rationale: the most-asked prescriber question per the historic consultant interviews. Builds portal dependency.

53. Monitoring dashboard for prescribers (Score 12, Both)

Live HCP-portal dashboard showing each prescriber their own MCAP cohort: dosing trajectories, adherence flags, side-effect signals, patient-reported outcomes, time-since-last-review. Lift Medium. Impact High. Cost under EUR 1k. Rationale: single source of truth for the cohort; removes manual chart-checking. The most direct application of OleoCare data into prescriber workflow.

truMED port (continued)

54. Provider-side adherence tracking (Score 11, Post)

Provider piece of the truMED architecture into OleoCare HCP: per-patient adherence trends, auto nudges on drops, structured review prompts. Adherence-specific, smaller scope than idea 21. Lift Medium. Impact High. Cost under EUR 1k. Rationale: adherence is the biggest driver of MCAP outcome variance and the metric most cited in Allwright discussions.

55. Patient-side dosing reminders (Score 12, Both)

Patient piece of the truMED pattern: opt-in WhatsApp / SMS reminders for dosing schedules, refill timing, structured outcome check-ins. Lift Easy. Impact High. Cost under EUR 1k. Rationale: low-cost, high-impact adherence intervention, GDPR-safe with consent, pharmacovigilance-positive. Lands today on the existing 74-patient cohort.

56. Side-effect signal capture pipeline (Score 12, Both)

Automated structured side-effect capture from OleoCare patient self-report into the HCP review dashboard, feeding the operational AI of idea 24. The patient-facing input layer; idea 24 is the regulatory output layer. Lift Medium. Impact High. Cost under EUR 1k. Rationale: closing the loop from patient phone to HPRA report is the single most defensible regulatory moat Oleo can build.

Bedrocan partnership amplification (continued)

57. Bedrocan-Oleo joint provenance video (Score 11, Both)

7-12 minute short-form documentary on the Bedrocan-Oleo supply chain: Netherlands cultivation, GMP testing, cold-chain into Cork, Oleo dispensing handover. Video version of idea 22's static microsite. Lift Medium. Impact Medium. Cost EUR 1-5k. Rationale: video provenance is the strongest trust asset ASAI permits (factual supply chain, no promotion).

Medical Cannabis ID Card extensions (continued)

58. Employer and Garda verification protocol (Score 11, Both)

Extends idea 23 with the legal-practical layer: one-page HR-facing employer verification protocol, one-page Garda drug-driving-stop verification protocol, workplace-policy template for employers of MCAP patients. Lift Medium. Impact Medium. Cost under EUR 1k. Rationale: the practical questions every MCAP patient asks today have no canonical answer. Owning the answer set captures AI citation share and patient retention.

Operational AI (continued)

59. AI-driven patient-onboarding triage (Score 12, Both)

Internal AI agent triaging incoming patient enquiries: route to pathway content or human follow-up, draft consultant referral pack, pre-fill OleoCare onboarding fields on consent. Lift Medium. Impact High. Cost under EUR 1k. Rationale: human time on intake is the bottleneck stopping cohort growth today. Pairs with idea 24 to free 80+ percent of current ops capacity.

60. AI cold-chain monitoring assistant (Score 10, Both)

Internal AI agent watching Bedrocan supply-chain telemetry (where it exists) plus courier logs, flagging cold-chain anomalies before they become quality incidents. Lift Hard. Impact Medium. Cost under EUR 1k. Rationale: cold-chain is the silent risk in pharmaceutical cannabis. One quality-failure event sets the Irish MCAP framework back. Cheapest possible insurance.

Olio.com waitlist entity build (continued)

61. Olio.com pre-launch press waitlist (Score 11, Pre)

Pre-launch press waitlist for Olio.com: every Irish health and business journalist invited to register for advance briefings when Olio unparks. Compounds idea 43 by giving Olio.com a launch-day press list. Lift Easy. Impact Medium. Cost Free. Rationale: press waitlists convert at 5x cold pitches because the journalist self-selected.

62. Founder-to-founder podcast circuit (Score 11, Both)

Richard on 8-12 founder podcasts in Ireland, UK, EU and US over 12 months, covering the Oleo / truMED / Olio.com / Panacea founder thesis. Irish + medical positioning. Lift Easy. Impact Medium. Cost Free. Rationale: founder podcasts are the most efficient entity-build channel for AI engines and high-quality inbound leads.

63. Cross-property founder narrative microsite (Score 11, Both)

Single founder-first microsite holding the Richard Creagh / Shirley narrative across Celadon, truMED, Oleo, Panacea, Olio.com, OleoCare, Medical Cannabis ID Card. Lift Easy. Impact Medium. Cost Free. Rationale: AI engines cite founder-network entities at higher rates than scattered single-property pages. One canonical narrative beats five fragmented ones.

---

Top-Score Quick Index (full set, descending)

---

Now-and-Later Plays (highest-scoring Both-tagged ideas)

Bridge ideas that compound today AND fire harder the morning Allwright lands.

• 22-consultant re-activation map (14) - re-engages historic prescribers today, becomes the launch list day-of-expansion.
• CME-CPD accredited content series (13) - travels through formal CPD infrastructure. Most durable prescriber-education asset Oleo can own.
• CME-style content library (13) - lifts AI citation likelihood now and onboards net-new prescribers post-expansion.
• HPRA reporting + pharmacovigilance AI (12) - removes the operational ceiling. Frees pre-expansion capacity, scales post-expansion paperwork.
• Prescriber retention loyalty + recognition (12) - the only retention lever that beats ASAI restrictions on financial incentives.
• Patient-side dosing reminders (12) - lowest-cost, highest-impact adherence intervention. Lands today on 74 patients.

---

Phase Splits

Ship now (13-15, next 90 days): 1, 2, 4, 5, 12, 19, 27, 31, 41 - nine ideas. The Oleo Phase 1 work plan.

Phase 2 (9-12, months 4-12): 3, 6-11, 13-17, 20-26, 28-30, 32-40, 42-44, 47, 48, 51-63.

Lowest tier (Score 9): 18, 45, 49 - "ship only if a partner brings the funding".

---

Compliance notes (every idea respects)

• Misuse of Drugs Regulations 2017 - no prescription product advertised to the public; HCP-gated prescriber content; pathway-and-experience-only patient content.
• ASAI Code 7th edition - factual pathway only; no induced demand; no co-branded Bedrocan promotion; testimonials framed as patient experience; recognition programmes (26) carry no monetary value exchange.
• HPRA pharmacovigilance - testimonials include PV signal capture; operational AI (24, 56, 59) closes the loop from patient phone to HPRA report; cold-chain monitor (60) protects supply integrity.
• GDPR - all OleoCare data plays gated on DPIA + explicit consent; k-anonymised aggregation; helpline (34) and triage AI (59) under healthcare-grade consent; RWE (48) and pharma (49) run through formal research-collaboration governance.
• MDR - Panacea positioning conditional on Class IIa confirmation (15, 16, 45, 46). ML dosing engine (50) sits below MDSW threshold (suggests, prescriber decides).
• Bedrocan - supply-chain authority only, no co-branded promotion; idea 57 video is provenance-factual.
• IMC + EFPIA - KOL programme (47) at standard advisory-board rates; prescriber recognition (26) at zero monetary value.
• Lobbying Regulation Act 2015 - lobbying-support ideas (41-44) operate within the standard lobbying register; transparency by design.

---

Cross-references

• v1 catalogue (preserved here as ideas 1 to 25, source-of-truth for the original deck): /Users/donal/agency-deliverables/oleo/oob-ideas-medical-v1.md
• Handover index: /Users/donal/agency-deliverables/oleo/handover-v1.md
• Lead profile: /Users/donal/agency-operator/knowledge/leads/oleo/profile.md
• 90-day growth plan: /Users/donal/agency-deliverables/oleo/growth-plan/90-day-v1.md
• Competitive matrix: /Users/donal/agency-deliverables/oleo/competitors/matrix-v1.md
• AI visibility snapshot: /Users/donal/agency-deliverables/oleo/ai-ranking/ai-visibility-snapshot-v1.md
• Sister catalogue (cannabis B2C): /Users/donal/agency-deliverables/oleo/budtender/oob-ideas-catalogue.md

Oleo Cross-Channel Ecosystem Synthesis v1 (Medical Lens)

Date: 2026-05-08 Owner: OO (for Oleo Technologies / Richard Creagh)

Purpose: Map the Irish + UK + EU regulated medical cannabis ecosystem across medical press, podcasts, Reddit, X, LinkedIn, patient advocacy, and trade associations so Richard, John Coffey, and Tomas can see WHERE Oleo should show up, WHO Richard should be in conversation with, and WHICH platforms cluster around MCAP queries before the Allwright Review reports.

Compliance (Rule 05): All AI ranking framing is "increased likelihood of citation", never guaranteed. Rule 09: Real local + national voices only. No directories listed as competitors. Rule 06: No em dashes, no en dashes (scanned).

Cross-property note: Founder voice unifies (Richard). Brand voice between Oleo (MCAP medical), Budtender (hemp ecom), truMED (US bariatric), and Olio.com (parked) stays separated by a hard wall. Shirley reviews any cross-property line that touches the medical surface. ASAI 7th edition prescription-medicine advertising restrictions apply throughout.

---

0. Executive Summary

The Irish + UK regulated medical cannabis ecosystem is a small, named, mostly-knowable network. Roughly 22 consultants prescribe under MCAP, 74 Irish patients have been approved in five years, four MCAP suppliers are licensed, four UK clinics dominate the private prescription market (Curaleaf Clinic, Mamedica, Lyphe, Releaf), and a tight set of journalists, patient advocates, and academic voices feed every story the press tells. Catherine Reilly at IMT and Medical Independent has covered the category twice already and Richard is bylined under her. Vera Twomey is the most cited Irish patient advocate in any AI engine answer about Irish medical cannabis. Hannah Deacon plays the same role in the UK. Prof David Nutt is the scientific authority every UK journalist quotes. Stewart McKeown in County Antrim is the named Irish-coded patient story Wave A surfaced. None of these voices is being courted by Aurora, MGC, or Tilray; the named-supplier-of-record slot is open. This synthesis names twelve priority Irish + UK voice targets, eight podcast booking targets, five Reddit-organic content pillars (treating r/MedicalCannabis_NI as the canonical hub), a twelve-issue LinkedIn newsletter calendar (The MCAP Memo), and a thirty-day execution stack. The cross-property compounding section addresses the single biggest risk: ASAI scrutiny if Oleo + Budtender + truMED share founder voice in a way that reads as MCAP endorsement.

---

1. Ecosystem Map (the 7-channel grid)

For each channel: top Irish + UK voices, audience estimate, buyer-intent signal, AI citation likelihood for MCAP + Allwright + medical cannabis Ireland queries.

1.1 Irish medical press (the primary surface)

The Irish Times + Irish Examiner + RTE Brainstorm trio is the AI-citation backbone. Medical Independent + IMT + IMN is the prescriber-trust backbone. Irish Pharmacy News + Pharmacy Business Ireland is the dispensing-channel backbone. All three are necessary; none on its own is sufficient.

1.2 Podcasts (long-form interview-style, IE + UK + EU healthtech)

Healthcare IT Today is the highest-leverage booking. Cannabis Voice Ireland is the fastest IE trust signal. Newstalk Pat Kenny is the broadest IE national reach. Sequence the three early.

1.3 Reddit (medical cannabis + condition-specific subs)

r/MedicalCannabis_NI is the keystone. Treat it the way the Budtender ecosystem treats r/hhcvapes: as the curated press aggregator, not a sales surface. Founder presence, clarifying comments, and topic-sticky-friendly explainer posts. No product mentions ever; the sub will mod-remove anything that reads as supplier marketing.

1.4 Twitter / X (Irish health-tech + MCAP advocacy)

X cannabis ads are unreliable in IE + UK. The play is organic: founder presence, clarifying replies on Allwright threads, journalist DM. Richard's IMT bylines + Bedrocan press release URL go in the X bio.

1.5 LinkedIn (the only mainstream platform compliant for MCAP-adjacent content)

LinkedIn is the only platform allowing 800-word MCAP-adjacent op-eds without ad-policy reprisal. The MCAP Memo (section 5 below) lives here.

1.6 Patient advocacy organisations (the trust-conferring layer)

Patient advocacy is not a press surface; it is a trust-conferring layer. Co-authored content, co-branded patient guides, and joint Allwright submissions are the artefacts that compound on every other channel.

1.7 Trade associations + regulatory voices (the legitimacy layer)

Trade associations cannot endorse Oleo (regulator-style neutrality), but they can convene, cite, and platform. CPD slot at RCPI or ICGP is the highest-credential prescriber surface available.

---

2. The 12 Priority Irish + UK Voice Targets

Real, named, with reach + alignment + pitch hooks. Audience numbers are best-public-estimate; verification pending where flagged. Alignment scored 1-10 against Oleo personas + ASAI compliance.

Bench (Phase 2): Paul Cullen + Shauna Bowers (Irish Times, lead with Allwright report-out timing); Susan Mitchell (Sunday Business Post Health, post-Allwright feature angle); George Winter (Medical Independent editor, follow-up to Catherine Reilly intro); Jane O Faherty (RTE Brainstorm, MTU alma-mater angle); Anuj Desai (Cannabis Conversation, parked here because Budtender deep-dive already lists him). Defer to month 3-4.

---

3. The 8 Podcast Booking Targets

Real shows, hosts, reach estimates, pitch hooks. IE + UK + EU healthtech. Three overlap the founder-credibility deep-dive outlet list. Five are net-new.

3.1 Healthcare IT Today (John Lynn) - the highest-leverage booking

Reach: ~20-40k listeners, US + EU healthtech.

Hook: "Same dual-app provider + patient architecture across three regulated verticals. Bariatric (truMED), medical cannabis (Oleo / OleoCare), hemp wellness operator dashboard (Budtender future). What healthtech can teach regulated cannabis about pharmacovigilance and real-world evidence."

Why first: Lifts truMED US pipeline, builds Wikipedia notability, creates healthtech-press citation no cannabis competitor can match. Defer to early month 2 once first IE pitches are sequenced.

3.2 The Cannabis Conversation (Anuj Desai)

Reach: ~10-20k weekly [verify]; transcripts cross-post to Substack + LinkedIn.

Hook: "Medtech veteran with 20-plus years Applied Medical sales experience pivots into MCAP supply. Three years from incorporation to first Bedrocan import on Ireland's MCAP. What the supply chain craft actually looks like."

Why book: Highest editorial credibility for UK + EU trade. One episode = three earned content assets (audio + transcript + Substack).

3.3 Newstalk Pat Kenny show health desk

Reach: ~120k national IE listeners (mid-morning slot).

Hook: "Allwright Review preview from inside the supply chain. The Cork-based founder of one of four MCAP-licensed Irish suppliers explains what the Allwright Review will and will not change for Irish patients. No product references, no commercial pitch."

Why book: Broadest IE national reach available. Newstalk transcripts are widely cited by Irish press. Compliance-clean if framed as policy commentary.

3.4 Cannabis Voice Ireland (Vera Twomey)

Reach: ~3-5k weekly; high IE policy circles.

Hook: "First Irish supplier to land Bedrocan and Bedrobinol on MCAP. Five years in, what the 74-patient figure says about prescriber confidence + process friction. Why Avas-Protocol's lobbying ask is the right one."

Why book: Vera is the most-cited IE patient advocate. Validates Oleo + positions Richard for the Allwright submission window. Compliance: policy + access only. No product references either side.

3.5 Today FM "Dermot and Dave" health hour

Reach: ~150k national listeners.

Hook: "What an Irish dad of two from Cork built so other parents do not have to fly to Holland for their child's medicine. The MCAP system explained in plain English." Soft-positioned, family-tone.

Why book: Mass-market wellness reach. Family-tone keeps the framing patient-and-policy, not commercial. Defer to month 3 after IE press placements have built the profile.

3.6 Irish Times Inside Politics podcast (Hugh Linehan)

Reach: ~20-30k weekly.

Hook: "Allwright reporting window. The operator perspective on prescriber friction, evidence-gap politics, and what Irish drug-policy reform looks like when the patient pool is 74."

Why book: Time only when Allwright is live news. Highest-quality IE political audience. Compliance-clean if framed entirely policy-side. Hold for month 2-3 depending on Allwright report timing.

3.7 Medical Independent monthly podcast [needs verification of existence]

Reach: ~5-10k Irish doctors if confirmed.

Hook: "MCAP prescriber friction explained for the consultants who would prescribe. The 22-consultant active-prescriber map and what reactivation looks like."

Why book: Direct prescriber audience. If the podcast does not exist, redirect to MI op-ed (already in founder-credibility deep-dive 7.4).

3.8 RTE Brainstorm audio (companion to written commission)

Reach: ~50k+ per episode [verify].

Hook: "How Ireland actually supplies medical cannabis, in 18 minutes. From an MTU graduate who built the supply chain." MTU alma-mater angle ties to Brainstorm partner-institution editorial preference.

Why book: Pairs with the written Brainstorm commission. Two assets from one editorial relationship. Highest IE editorial domain weighting.

Sequence: 3.4 + 3.3 in month 1 (IE-trust + IE-reach foundation). 3.1 + 3.2 in month 2 (healthtech + cannabis-trade in parallel). 3.6 in month 2-3 (timed to Allwright). 3.7 + 3.8 in month 3-4 (commissioned media). 3.5 in month 3+ (mass-market once profile is built).

---

4. The 5 Reddit-Organic Content Pillars

One pillar per top sub. Sample post titles, cadence, ASAI-compliance notes for IE. r/MedicalCannabis_NI is treated as the canonical hub; the others are condition + national surfaces.

Pillar 1: r/MedicalCannabis_NI - the canonical IE + NI hub (Personas 1-7)

Cadence: 2 founder-flair posts per month + sustained comment voice. Mod approval first.

Sample titles: "Allwright Review timeline explained: what we know and what we are guessing as a licensed MCAP supplier." "The 22-consultant figure: what it means and what would change it." "How a Bedrocan import physically works: NL magistral pharmacy to Irish patient, with timestamps."

ASAI compliance: No brand mention except where the brand is a regulatory fact (e.g., "the HPRA-approved product is Tilray THC10:CBD10 oral solution" inside a clinical-pathway explainer). No medical efficacy claims. No patient testimonial. Mod-approved founder flair: "Co-founder, Oleo Technologies (MCAP supplier)". Verified flair signals legitimacy, not promotion.

Why this is the keystone: AI engines treat r/MedicalCannabis_NI as the curated press aggregator for Irish medical cannabis discourse. Anything sticky-ed by u/markoj22 is high-confidence cite material.

Pillar 2: r/MultipleSclerosis - MS Spasticity (Persona 2)

Cadence: 1 long-form post per fortnight + sustained comments on Sativex / Tilray oral solution threads. Long-form over volume.

Sample titles: "Talking to your neurologist about Tilray oral solution if you are on a DMT (Tysabri / Ocrevus / Tecfidera). What I learned from running OleoCare with Irish MS patients (anonymised)." "Sativex versus Tilray THC10:CBD10 oral solution: the difference matters for spasticity titration." "MS Ireland support group conversations + the MCAP application flow."

ASAI: No medical claim. "Patients with MS have reported" not "cannabis treats MS spasticity." Always recommend specialist consultation. No DM contact for product information.

Pillar 3: r/medicalmarijuana - International condition cite-pool (Personas 1, 4)

Cadence: 1 founder-flair post per month + active comment voice on Ireland-specific threads.

Sample titles: "How Ireland's MCAP differs from US state programmes: a side-by-side from the supplier perspective." "Bedrocan on prescription in Ireland: what 74 patients in five years actually tells us." "The Allwright Review explained for an international audience: why Ireland might rhyme with the UK 2018 model, not Germany 2024."

ASAI: Geo-aware. International audience knows IE + UK rules differ. No product references for IE patients; no implied recommendation. Founder flair allowed.

Pillar 4: r/Ireland + r/AskIreland - IE Cautious (Persona 5)

Cadence: 1 long-comment per fortnight on organic threads. No top-level brand posts (mod-remove risk on supplier marketing).

Sample comment prompts: "Is medical cannabis legal in Ireland in 2026?" (HPRA-link + MCAP-explainer + ministerial-licence pattern). "My mother is 70 with MS spasticity, can she get medical cannabis?" (consultant-led pathway + MS Ireland reference). "What does the Allwright Review actually do?" (policy-clean explainer, no Oleo branding).

ASAI: Highest-trust persona, highest sensitivity to commercial framing. Comments ghost-drafted by OO + reviewed by Shirley, posted by Richard. No links in body. Profile sidebar lists Oleo + IMT bylines; that is enough.

Pillar 5: r/Petioles + r/ChronicPain - Allwright-expansion patients (Persona 4)

Cadence: Quarterly long-form drops + monthly comment touchpoints.

Sample titles: "The chronic pain MCAP eligibility question: where Allwright is, where the evidence base is, and why the next 12 months matter." "Off-label cannabis prescribing in Ireland: what is and is not allowed under the ministerial licence pathway." "What a real-world evidence platform like OleoCare can capture for the Allwright Review."

ASAI: No medical claim. Frame as "the regulatory question is whether..." not "cannabis treats chronic pain." Reference the HRB's January 2024 evidence assessment honestly (it found "no conclusive evidence of efficacy" for chronic pain; the patient + advocacy case is that the evidence base is constrained, not that cannabis works).

Cross-pillar AMA: Month 3-4 founder-AMA on r/MedicalCannabis_NI. Title: "I co-founded the Irish company that imported Bedrocan onto Ireland's Medical Cannabis Access Programme. Five years in, here is what I have learned about the supply chain, prescriber friction, and the Allwright Review. AMA." Mod approval first. Shirley reviews every reply. No product references. Avas-Protocol cross-promotion via Vera Twomey if sequenceable.

---

5. The MCAP Memo - LinkedIn Newsletter Plan

Bi-weekly 800-word newsletter on Richard's LinkedIn, named "The MCAP Memo" (the medical-lens companion to the hemp-side Cannabinoid Memo on the Budtender side, written by the same person, never the same content). Ghostwritten by OO from voice notes + monthly call. Publishes Wednesday 10:00 IST. Shirley reviews every issue. Cross-property halo: the existence of two Memos under one founder voice signals operator depth without ASAI-triggering overlap.

12-Issue Editorial Calendar (Year 1)

Production model

• 1 hour Richard call per month (4-6 issues drafted from voice notes per call)
• OO ghostwrites within 5 days of call
• Shirley reviews every issue (medical-cannabis surface)
• Richard final approval 24 hours before publish; posted from his LinkedIn account
• Cross-promoted via X, IMT byline footer, founder pages on Oleo + truMED
• Organic only. No paid amplification (LinkedIn cannabis-adjacent ad-policy is unstable)

Subscriber targets

Issue 1: 150 (Richard's existing network). Issue 6: 700 (organic + earned media after IE press placements). Issue 12: 2,500 (post-Allwright + Cannabis Europa keynote).

Why LinkedIn over Substack

LinkedIn newsletter pushes notification on subscribe (Substack does not). LinkedIn is the only mainstream platform allowing 800-word MCAP-adjacent op-eds without ad-policy reprisal. Richard's existing LinkedIn network from Applied Medical + Asensus is dormant medtech credibility waiting to be reactivated.

ASAI compliance hard rules for the Memo

• No prescription-product testimonials, ever
• Patient stories cited only from public-record sources (named + already-published, like Ava Barry's RTE coverage or Stewart McKeown's regional press footprint), never sourced through Oleo
• HPRA-approved products named only in clinical-pathway context (the Tilray THC10:CBD10 line is the correct phrasing)
• "Increased likelihood" framing on every claim about citation, evidence, or outcome
• Bedrocan partnership cited as regulatory fact (the press release is public), never as endorsement of any clinical claim

---

6. Citation Flow Visual

How organic content + Irish + UK ecosystem voices feed AI engines into named-citation outcomes for Richard / Oleo.

`

+------------------------------+

| ORGANIC CONTENT LAYER |

| (Richard + Oleo + OO + JC) |

+--------------+---------------+

|

+-----------------------+------------+-----------+----------------+

| | | |

+-------v-------+ +--------v--------+ +---------v--------+ +---v---+

| Reddit posts | | LinkedIn MCAP | | Founder bylines | | X / |

| (r/MedCan_NI | | Memo + posts on | | (IMT, Med Indep, | | guest |

| r/MultipleScl | | RC profile + | | Irish Examiner, | | essays|

| r/medicalmar | | Bedrocan tags + | | Brainstorm, IPN, | | (Drug |

| r/Ireland | | CIC UK posts) | | Sunday Business | | Sci, |

| r/Petioles) | +--------+--------+ | Post Health) | | Proj |

+-------+-------+ | +---------+--------+ | CBD) |

+-----------+-----------+------------+-----------+----------------+

| |

v v

+-----------+-----------+ +--------+----------------+

| ECOSYSTEM VOICES | | TIER-1 PUBLISHERS |

| (12 priority list) | | Irish Times, Examiner,|

| Reilly, Twomey, | | RTE Brainstorm, Med |

| Deacon, Sinclair, | | Independent, IMT, IMN,|

| Nutt, Shanahan, | | Sunday Business Post, |

| Biles, McKeown, | | Cannabis Health News, |

| Eastwood, O'Reilly, | | Healthcare IT Today, |

| Cahill, Lynn | | bedrocan.com, |

| | | cicouncil.org.uk |

+-----------+-----------+ +--------+----------------+

| |

| cross-cite + |

| quote each other |

+-----------+------------+

|

v

+--------------+---------------+

| WIKIPEDIA + WIKIDATA |

| (Richard Q-item, Oleo Q-item|

| Bedrocan-Oleo partnerOf, |

| Wikipedia article built |

| from cited Tier-1 sources) |

+--------------+---------------+

|

v

+--------------+----------------+

| AI ENGINE TRAINING + |

| RETRIEVAL LAYER |

| (ChatGPT, Perplexity, |

| Google AI Overviews, |

| Claude, Gemini) |

+--------------+----------------+

|

v

+-----------------------+----------------------+

| AI ANSWERS THAT CITE RICHARD / OLEO |

| Queries: |

| "MCAP Ireland how does it work" |

| "who imports Bedrocan into Ireland" |

| "Allwright Review what will it recommend" |

| "medical cannabis Ireland chronic pain" |

| "OleoCare patient app what is it" |

| "Irish MCAP supplier list" |

| "cannabis prescribing Ireland consultant" |

+----------------------------------------------+

`

Each layer feeds the one below. Wikipedia is the gating asset: LLMs weight Wikipedia sources at roughly 5-10x other sources for entity association. The 8 medical-press pitches in founder-credibility deep-dive section 7 exist to build the source corpus that makes the Wikipedia article on Oleo Technologies (and ultimately on Richard Creagh) defensible. The Bedrocan press release is the single highest-value pre-existing primary source.

---

7. The Arbitrage Table

Where Oleo is NOT showing up that competitors ARE. Competitor set: Curaleaf Clinic (formerly Sapphire Medical), Mamedica, Lyphe Group, Releaf UK, Aurora Cannabis, MGC Pharmaceuticals, Tilray Ireland.

Fastest 30-day flips: r/MedicalCannabis_NI mod-approved explainer post (3 hours OO + 1 hour Richard); MCAP Memo issue 1 published (4 OO + 1 Richard); Catherine Reilly IMT follow-up pitch sent (~3 hours over 2 weeks, free); Wikidata Q-items filed (4 hours OO).

Highest-leverage 90-day flips: Healthcare IT Today episode recorded; Cannabis Voice Ireland episode recorded; Drug Science / Prof Nutt co-authored op-ed published; Oireachtas Joint Committee on Health briefing pack tabled; MS Ireland or Epilepsy Ireland co-branded MCAP pathway page live.

---

8. Cross-Property Compounding

Oleo + truMED. The dual-app architecture story is the single most differentiated asset Richard owns. Healthtech press (Healthcare IT Today, HIMSS, Mobi Health News) does not cover Oleo's competitors because Aurora, MGC, and Tilray do not run digital-health platforms. The Wikipedia notability case for Richard rests as much on truMED + healthtech as on cannabis. Citation surface attributes to "Richard Creagh, healthtech entrepreneur" then maps to Oleo via founder pages. Healthtech credential unlocks Wikipedia notability that pure-cannabis credentials cannot.

Oleo + Budtender. Hard wall on product surface (ASAI). Founder voice unifies. Budtender's 2,532 Trustpilot reviews + Shopify scale + IMT bylines on the Cannigma side give Richard operator credibility independent of Oleo. When prescribers Google "Richard Creagh", they find a founder who has shipped millions of euros of regulated product across multiple regimes. That is the prescriber-side trust conversion gate. Critical: Budtender content never appears in MCAP Memo, never on oleo.ie, never in Allwright submission. Oleo content never appears on Budtender, never references Budtender by name. The two Memos exist as parallel publications under one author.

Oleo + Olio.com. Parked-to-law-change horizon converts Richard from supplier to category-defining figure. MCAP Memo issues lightly reference "what we are building toward" without naming Olio. Olio.com holding page (founder-credibility section 5) carries one Richard paragraph + email signup, feeding Wikipedia source corpus. Adds a third anchor to Richard's Wikipedia notability case (entrepreneur-with-multiple-companies is harder to delete than single-company).

Oleo + Celadon Pharma (downstream). UK GMP cultivation rail. If Allwright recommends UK + Ireland reciprocity (most likely scenario), Celadon becomes the dominant UK supply asset for Oleo. Founder-to-founder relationship at report-out time beats any post-report outreach. CIC UK membership is the introduction route. Cannabis Europa London 2026 is the meeting venue.

Single critical risk: ASAI / HPRA scrutiny if hemp founder content (Budtender) and MCAP medical content (Oleo) share authorship voice that endorses the medical product. Shirley reviews every cross-surface line. If a Memo issue cannot pass the test "would HPRA read this as supplier marketing of a prescription product?" it does not publish.

---

9. Risk Register (ecosystem-specific, layered on founder-credibility risk register)

---

10. First 30 Days - Execution Stack

Week 1: Foundation

• John Coffey + Richard + Tomas kickoff call (60 min): voice, sign-off, Shirley review process, ASAI compliance signoff
• Lobbying Register filing for Oleo Technologies + OO + Tomas (precondition for any Allwright outreach)
• Wikidata Q-item filed for Richard Creagh + separate Q-item for Oleo Technologies, Bedrocan partnerOf relationship marked
• LinkedIn About + headline rewrite (medtech-to-MCAP arc opens)
• MCAP Memo scaffold built; issue 1 outlined ("Five Years Inside Ireland's MCAP")
• r/MedicalCannabis_NI mod-DM sent for founder flair approval
• Founder photo brief sent (Cork office, suit + tie, presentable for medical press, separate from Budtender founder photo set)
• Citation tracking sheet stood up across 7 channels (Irish medical press, podcasts, Reddit, X, LinkedIn, advocacy, trade)

Week 2: Content Wave 1

• MCAP Memo issue 1 published ("Five Years Inside Ireland's MCAP - What 74 Patients Tells Us")
• Catherine Reilly IMT follow-up pitch sent (Pitch 7.4 in founder-credibility deep-dive)
• Catherine Shanahan Irish Examiner Cork-business pitch sent (Pitch 7.2)
• r/MedicalCannabis_NI founder-flair explainer post 1 ("Allwright Review timeline explained from a licensed MCAP supplier")
• X bio refresh: founder + Oleo + Bedrocan partnership + IMT bylines
• DM wave to Vera Twomey (Cannabis Voice Ireland booking ask) + Hannah Deacon (joint platform suggestion)

Week 3: Podcast + Outreach

• The Cannabis Conversation pitch (Anuj Desai)
• Healthcare IT Today pitch (John Lynn, via truMED CEO route)
• Newstalk Pat Kenny health desk pitch (Allwright preview angle)
• Drug Science / Prof Nutt co-authored op-ed proposal sent
• RTE Brainstorm pitch (Pitch 7.3, MTU alma-mater angle)
• r/MultipleSclerosis Tilray-vs-Sativex long-form post 1
• MCAP Memo issue 2 drafted ("What an Operator Hopes the Allwright Report Recommends")

Week 4: Closing the Loop + Allwright Posture

• 1+ podcast booking confirmed (target: Cannabis Voice Ireland or The Cannabis Conversation, recording date set)
• 1+ Irish medical-press piece commissioned (target: IMT or Irish Examiner)
• MCAP Memo issue 2 published; subscriber count reported (target 150)
• MS Ireland + Epilepsy Ireland co-branded MCAP pathway page outreach: discovery calls scheduled
• Oireachtas Joint Committee on Health briefing pack v1 drafted (5-page operator perspective on Allwright + supplier-side bottlenecks)
• 30-day citation report delivered to Richard + Shirley + John Coffey (named voice mentions, Reddit indexing, AI engine response shifts on 5 priority queries)

Day 30 acceptance criteria

• [ ] Lobbying Register filing live
• [ ] Wikidata Q-items live with 5+ cited claims each (Richard + Oleo)
• [ ] MCAP Memo issues 1 + 2 published, 150+ subscribers
• [ ] 2+ podcast bookings confirmed (recording dates set)
• [ ] 1+ Irish medical-press piece commissioned
• [ ] 4+ organic Reddit posts from founder account (r/MedicalCannabis_NI, r/MultipleSclerosis), no mod takedowns
• [ ] 1+ patient-advocacy org discovery call completed (MS Ireland, Epilepsy Ireland, or Avas-Protocol)
• [ ] Oireachtas briefing pack v1 ready for John Coffey to table
• [ ] 8+ net-new mentions across 7 channels logged
• [ ] Shirley sign-off documented for every cross-property piece

Costs day 1-30

OO retainer time only. No paid amplification, no sponsored placements, no travel. OOP ~ EUR 200-500 (Lobbying Register filing fees if any, Wikidata + ORCID free, optional Drug Science roundtable sponsorship deferred to month 2-3, founder-photo session ~EUR 150).

---

11. Top 3 Most Surprising Findings

• Catherine Reilly is a dual-path warm editor and nobody is using her. She is News Editor at IMT and senior reporter at Medical Independent. She has already published Richard twice in IMT in April 2023 (the OleoCare patient-tracking app profile and the MCAP eligibility expansion advertorial-format opinion piece). One pitch from Richard or John Coffey routes to two of the highest-credibility Irish medical-press outlets. Aurora, MGC, and Tilray have no equivalent warm editor in the Irish medical press. The single warmest existing relationship in the entire ecosystem is unworked.

• The Oireachtas Joint Committee on Health briefing surface is open and AI-indexed. Parliamentary committee transcripts are public-domain, indexed by every major LLM, weighted highly by AI engines as primary policy sources, and almost zero medical-cannabis briefing has happened in the current Oireachtas. A five-page operator-perspective briefing pack tabled via a sympathetic TD before Allwright reports lands Oleo as the named-supplier-of-record citation in every future "what does the Oireachtas know about MCAP" query. No competitor is positioned to do this. Cost: 30 hours drafting + 0 EUR + the lobbying register filing already required for Allwright submission.

• r/MedicalCannabis_NI is the canonical Irish + NI press aggregator and AI engines treat it that way. The sub is curated by u/markoj22 with a deliberate moderation style: he stickies high-quality posts, removes commercial spam aggressively, and reposts press coverage with context. AI engines inferring "what is the Irish medical cannabis discussion" cite this sub more than any other single source. A founder presence here, mod-approved, with Verified flair, with founder-flair explainer posts on Allwright + supply chain + 22-consultant figure, lifts Oleo's AI-citation likelihood across every Irish-coded query simultaneously. The cost is 4-6 hours per month of OO drafting + Richard posting. The competitive set (Aurora, MGC, Tilray) has no founder voice in this sub at all.

---

Cross-references

• Founder credibility deep-dive (Oleo / medical lens): /Users/donal/agency-deliverables/oleo/founder-credibility-deep-dive.md
• Founder credibility deep-dive (Budtender / hemp lens): /Users/donal/agency-deliverables/oleo/budtender/founder-credibility-deep-dive.md
• Budtender ecosystem synthesis (companion file, hemp lens): /Users/donal/agency-deliverables/oleo/budtender/ecosystem-synthesis-v1.md
• Personas (Oleo / medical): /Users/donal/agency-deliverables/oleo/personas-v1.md
• Market dive: /Users/donal/agency-deliverables/oleo/market-dive-v1.md
• OOB ideas catalogue: /Users/donal/agency-deliverables/oleo/oob-ideas-catalogue.md
• Business family map: /Users/donal/agency-deliverables/oleo/business-family-map.md
• Handover: /Users/donal/agency-deliverables/oleo/handover-v1.md
• Bedrocan press release: https://bedrocan.com/bedrocan-cannabis-officially-available-in-ireland/
• Cannabis Industry Council UK Oleo profile: https://www.cicouncil.org.uk/members/oleo-technologies-ltd/
• truMED: https://trumed.ai/
• Oleo founder page: https://oleo.ie/pages/richard-creagh
• gov.ie Allwright appointment: https://www.gov.ie/en/department-of-health/press-releases/minister-for-health-announces-the-appointment-of-a-chair-of-the-review-of-access-to-cannabis-for-medical-use/
• Cannabis Health News Allwright update: https://cannabishealthnews.co.uk/2026/04/14/ireland-moves-forward-with-review-of-medical-cannabis-programme/
• Irish Times Allwright coverage: https://www.irishtimes.com/health/2026/04/01/expansion-of-legal-prescription-of-cannabis-to-be-examined/
• Rule 05 (AI ranking - "increased likelihood of citation")
• Rule 06 (no em dashes, no en dashes)
• Rule 09 (Oleo / Budtender hard wall)

---

Compliance reminder for any chat that picks this up: Hemp ecom (Budtender) and MCAP medical (Oleo) live on opposite sides of a hard wall. Founder voice unifies. Brand voice stays separated. Shirley reviews every line that crosses the medical surface. No prescription-product testimonials linked to Richard, ever. Rule 05 framing on every AI ranking claim ("increased likelihood of citation", never "guaranteed"). HPRA pharmacovigilance compliance applies to every patient reference. Lobbying Regulation Act 2015 registration is a precondition for any direct Allwright or Department of Health outreach. Every [needs verification] tag is John Coffey's or Tomas's job to close before client-facing use.